WO2016130444A1 - Inhibitors of the renal outer medullary potassium channel - Google Patents
Inhibitors of the renal outer medullary potassium channel Download PDFInfo
- Publication number
- WO2016130444A1 WO2016130444A1 PCT/US2016/016918 US2016016918W WO2016130444A1 WO 2016130444 A1 WO2016130444 A1 WO 2016130444A1 US 2016016918 W US2016016918 W US 2016016918W WO 2016130444 A1 WO2016130444 A1 WO 2016130444A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- oxo
- dihydrofuran
- ethyl
- piperidin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 26
- 102000004257 Potassium Channel Human genes 0.000 title description 10
- 108020001213 potassium channel Proteins 0.000 title description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 247
- 150000003839 salts Chemical class 0.000 claims abstract description 76
- 206010020772 Hypertension Diseases 0.000 claims abstract description 19
- 206010019280 Heart failures Diseases 0.000 claims abstract description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims abstract description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 5
- -1 4-methyl - 5 -oxo-2, 5 -dihydrofuran-3 -yl Chemical group 0.000 claims description 67
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 41
- 125000000217 alkyl group Chemical group 0.000 claims description 38
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 28
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 23
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229940002612 prodrug Drugs 0.000 claims description 14
- 239000000651 prodrug Substances 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 5
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 4
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 4
- 230000002497 edematous effect Effects 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010048962 Brain oedema Diseases 0.000 claims description 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 3
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 3
- 208000024940 Dent disease Diseases 0.000 claims description 3
- 206010052337 Diastolic dysfunction Diseases 0.000 claims description 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 3
- 208000037147 Hypercalcaemia Diseases 0.000 claims description 3
- 206010020852 Hypertonia Diseases 0.000 claims description 3
- 208000027530 Meniere disease Diseases 0.000 claims description 3
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 3
- 208000007718 Stable Angina Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 229960002576 amiloride Drugs 0.000 claims description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims description 3
- 208000006752 brain edema Diseases 0.000 claims description 3
- 229960000932 candesartan Drugs 0.000 claims description 3
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 230000008694 endothelial dysfunction Effects 0.000 claims description 3
- 230000000148 hypercalcaemia Effects 0.000 claims description 3
- 208000030915 hypercalcemia disease Diseases 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- QIJLJZOGPPQCOG-NFAWXSAZSA-N (2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylic acid Chemical compound N([C@H](C)C(=O)SC[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)C1CCCCC1 QIJLJZOGPPQCOG-NFAWXSAZSA-N 0.000 claims description 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
- MZRJMEZXNRSVII-UHFFFAOYSA-N 1-[1-[1-hydroxy-1-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)propan-2-yl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound OC(C(C)N1CCC(CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C MZRJMEZXNRSVII-UHFFFAOYSA-N 0.000 claims description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
- IFYLTXNCFVRALQ-OALUTQOASA-N Ceronapril Chemical compound O([C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)P(O)(=O)CCCCC1=CC=CC=C1 IFYLTXNCFVRALQ-OALUTQOASA-N 0.000 claims description 2
- 108010061435 Enalapril Proteins 0.000 claims description 2
- 108010066671 Enalaprilat Proteins 0.000 claims description 2
- 108010007859 Lisinopril Proteins 0.000 claims description 2
- 239000005480 Olmesartan Substances 0.000 claims description 2
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 229960004530 benazepril Drugs 0.000 claims description 2
- 229960000830 captopril Drugs 0.000 claims description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
- 229950005749 ceronapril Drugs 0.000 claims description 2
- 229960005025 cilazapril Drugs 0.000 claims description 2
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 claims description 2
- 229960005227 delapril Drugs 0.000 claims description 2
- WOUOLAUOZXOLJQ-MBSDFSHPSA-N delapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 WOUOLAUOZXOLJQ-MBSDFSHPSA-N 0.000 claims description 2
- 229960000873 enalapril Drugs 0.000 claims description 2
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
- 229960002680 enalaprilat Drugs 0.000 claims description 2
- 229960004563 eprosartan Drugs 0.000 claims description 2
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
- 229960002490 fosinopril Drugs 0.000 claims description 2
- 229960001195 imidapril Drugs 0.000 claims description 2
- KLZWOWYOHUKJIG-BPUTZDHNSA-N imidapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1C(N(C)C[C@H]1C(O)=O)=O)CC1=CC=CC=C1 KLZWOWYOHUKJIG-BPUTZDHNSA-N 0.000 claims description 2
- 229960002198 irbesartan Drugs 0.000 claims description 2
- 229960002394 lisinopril Drugs 0.000 claims description 2
- 229960004773 losartan Drugs 0.000 claims description 2
- 229950006549 moveltipril Drugs 0.000 claims description 2
- 229960005117 olmesartan Drugs 0.000 claims description 2
- 229960002582 perindopril Drugs 0.000 claims description 2
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
- 201000011461 pre-eclampsia Diseases 0.000 claims description 2
- 229960001455 quinapril Drugs 0.000 claims description 2
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 2
- 229960003401 ramipril Drugs 0.000 claims description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000529 riociguat Drugs 0.000 claims description 2
- 229960002909 spirapril Drugs 0.000 claims description 2
- HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 claims description 2
- 108700035424 spirapril Proteins 0.000 claims description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 2
- 229960002256 spironolactone Drugs 0.000 claims description 2
- 229960004084 temocapril Drugs 0.000 claims description 2
- FIQOFIRCTOWDOW-BJLQDIEVSA-N temocapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C[C@H](SC1)C=1SC=CC=1)=O)CC1=CC=CC=C1 FIQOFIRCTOWDOW-BJLQDIEVSA-N 0.000 claims description 2
- 229960002051 trandolapril Drugs 0.000 claims description 2
- 229960001288 triamterene Drugs 0.000 claims description 2
- 229960004699 valsartan Drugs 0.000 claims description 2
- 229950005018 vericiguat Drugs 0.000 claims description 2
- QZFHIXARHDBPBY-UHFFFAOYSA-N vericiguat Chemical compound N1=C(N)C(NC(=O)OC)=C(N)N=C1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F QZFHIXARHDBPBY-UHFFFAOYSA-N 0.000 claims description 2
- VMAFFLQXROHJCG-NNBQYGFHSA-N 3-[1-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC(CC1)C1C(N(CC1)C=1COC(C=1C)=O)=O)O VMAFFLQXROHJCG-NNBQYGFHSA-N 0.000 claims 2
- SRJOCJYGOFTFLH-UHFFFAOYSA-M piperidine-4-carboxylate Chemical compound [O-]C(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-M 0.000 claims 2
- MZRJMEZXNRSVII-ZHRRBRCNSA-N 1-[1-[(1R,2R)-1-hydroxy-1-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)propan-2-yl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound O[C@@H]([C@@H](C)N1CCC(CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C MZRJMEZXNRSVII-ZHRRBRCNSA-N 0.000 claims 1
- MZRJMEZXNRSVII-KSFYIVLOSA-N 1-[1-[(1S,2S)-1-hydroxy-1-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)propan-2-yl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound O[C@H]([C@H](C)N1CCC(CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C MZRJMEZXNRSVII-KSFYIVLOSA-N 0.000 claims 1
- JYTPWXOOLKCMGS-JDMGRSRBSA-N 1-[1-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperidin-4-yl]-4-methyl-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound O[C@@H](CN1CCC(CC1)N1C(N(C(C1)C)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C JYTPWXOOLKCMGS-JDMGRSRBSA-N 0.000 claims 1
- WBGXLQQZKOJSRW-IBGZPJMESA-N 1-[1-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)-1,3-diazinan-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC(CC1)N1C(N(CCC1)C=1COC(C=1C)=O)=O)O WBGXLQQZKOJSRW-IBGZPJMESA-N 0.000 claims 1
- CQLYCAWMWVFUGK-PKDNWHCCSA-N 1-[1-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-4-methyl-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC(CC1)N1C(N(C(C1)C)C=1COC(C=1C)=O)=O)O CQLYCAWMWVFUGK-PKDNWHCCSA-N 0.000 claims 1
- FGKCFDNDCABZQS-QFIPXVFZSA-N 1-[1-[(2R)-2-methoxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound CO[C@@H](CN1CCC(CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C FGKCFDNDCABZQS-QFIPXVFZSA-N 0.000 claims 1
- QFDBQNMOFUINQC-IBGZPJMESA-N 1-[1-[(2R)-2-methoxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC(CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)OC QFDBQNMOFUINQC-IBGZPJMESA-N 0.000 claims 1
- WBGXLQQZKOJSRW-LJQANCHMSA-N 1-[1-[(2S)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)-1,3-diazinan-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@@H](CN1CCC(CC1)N1C(N(CCC1)C=1COC(C=1C)=O)=O)O WBGXLQQZKOJSRW-LJQANCHMSA-N 0.000 claims 1
- XNMXTWWQZAYJRU-UHFFFAOYSA-N 1-[1-[2-hydroxy-2-[2-methyl-6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)-1,3-diazinan-2-one Chemical compound OC(CN1CCC(CC1)N1C(N(CCC1)C=1COC(C=1C)=O)=O)C=1C(=NC(=CC=1)N1N=NN=C1)C XNMXTWWQZAYJRU-UHFFFAOYSA-N 0.000 claims 1
- VUZSTZPHGZDIAK-UHFFFAOYSA-N 1-[1-[2-hydroxy-2-[2-methyl-6-(tetrazol-1-yl)pyridin-3-yl]ethyl]pyrrolidin-3-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound OC(CN1CC(CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=NC(=CC=1)N1N=NN=C1)C VUZSTZPHGZDIAK-UHFFFAOYSA-N 0.000 claims 1
- SSZRTZKXZOVGQD-GXMUVECYSA-N 1-[3-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CC2C(C2C1)N1C(N(CC1)C=1COC(C=1C)=O)=O)O SSZRTZKXZOVGQD-GXMUVECYSA-N 0.000 claims 1
- UJNVVGQQOGLQEQ-UHFFFAOYSA-N 1-ethyl-3-(5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound C(C)N1C(N(CC1)C=1COC(C=1)=O)=O UJNVVGQQOGLQEQ-UHFFFAOYSA-N 0.000 claims 1
- UKUKYMBAIBXTHL-UHFFFAOYSA-N 1-methyl-3-(5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound CN1C(N(CC1)C=1COC(C=1)=O)=O UKUKYMBAIBXTHL-UHFFFAOYSA-N 0.000 claims 1
- NQEMSWOXKMDWHD-BVHINDKJSA-N 3-[1-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperidin-4-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)piperidin-2-one Chemical compound O[C@@H](CN1CCC(CC1)C1C(N(CCC1)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C NQEMSWOXKMDWHD-BVHINDKJSA-N 0.000 claims 1
- LDBSDKRCFVIZLO-HSTJUUNISA-N 3-[1-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-3-methyl-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC(CC1)C1(C(N(CC1)C=1COC(C=1C)=O)=O)C)O LDBSDKRCFVIZLO-HSTJUUNISA-N 0.000 claims 1
- VMAFFLQXROHJCG-WHCXFUJUSA-N 3-[1-[(2S)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@@H](CN1CCC(CC1)C1C(N(CC1)C=1COC(C=1C)=O)=O)O VMAFFLQXROHJCG-WHCXFUJUSA-N 0.000 claims 1
- QWFZHFXGNHFFLV-UHFFFAOYSA-N 3-[1-[2-hydroxy-2-[5-(tetrazol-1-yl)pyridin-2-yl]ethyl]piperidin-4-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound N1(N=NN=C1)C=1C=CC(=NC=1)C(CN1CCC(CC1)C1C(N(CC1)C=1COC(C=1C)=O)=O)O QWFZHFXGNHFFLV-UHFFFAOYSA-N 0.000 claims 1
- LSKIJALBPSKDJV-QWAKEFERSA-N 3-[4-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperazin-1-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound O[C@@H](CN1CCN(CC1)C1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=C2COC(C2=CC=1)=O)C LSKIJALBPSKDJV-QWAKEFERSA-N 0.000 claims 1
- FVKPREGXSOCWTJ-UHFFFAOYSA-N 3-[4-[2-hydroxy-2-[2-methyl-6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperazin-1-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound OC(CN1CCN(CC1)C1C(N(CC1)C=1COC(C=1C)=O)=O)C=1C(=NC(=CC=1)N1N=NN=C1)C FVKPREGXSOCWTJ-UHFFFAOYSA-N 0.000 claims 1
- BUOOXZGJQZNAEM-QWAKEFERSA-N 3-[4-hydroxy-1-[(2R)-2-hydroxy-2-(4-methyl-1-oxo-3H-2-benzofuran-5-yl)ethyl]piperidin-4-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound OC1(CCN(CC1)C[C@@H](C=1C(=C2COC(C2=CC=1)=O)C)O)C1C(N(CC1)C=1COC(C=1C)=O)=O BUOOXZGJQZNAEM-QWAKEFERSA-N 0.000 claims 1
- OPTALOXSVQJOSA-DAFXYXGESA-N 3-[4-hydroxy-1-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CCC(CC1)(O)C1C(N(CC1)C=1COC(C=1C)=O)=O)O OPTALOXSVQJOSA-DAFXYXGESA-N 0.000 claims 1
- XETYLXDQSRUIJT-CARYKQCGSA-N 4-[3-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]-3-azabicyclo[3.1.0]hexan-6-yl]-1-(4-methyl-5-oxo-2H-furan-3-yl)pyrrolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1CC2C(C2C1)C1CC(N(C1)C=1COC(C=1C)=O)=O)O XETYLXDQSRUIJT-CARYKQCGSA-N 0.000 claims 1
- LPIFCRYBHQXTIH-NRFANRHFSA-N 5-[(1R)-1-hydroxy-2-[4-[4-methoxy-5-(4-methyl-5-oxo-2H-furan-3-yl)pyrimidin-2-yl]piperazin-1-yl]ethyl]-4-methyl-3H-2-benzofuran-1-one Chemical compound O[C@@H](CN1CCN(CC1)C1=NC=C(C(=N1)OC)C=1COC(C=1C)=O)C=1C(=C2COC(C2=CC=1)=O)C LPIFCRYBHQXTIH-NRFANRHFSA-N 0.000 claims 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 claims 1
- 241001184731 Eira Species 0.000 claims 1
- 229950007884 alacepril Drugs 0.000 claims 1
- 229960000528 amlodipine Drugs 0.000 claims 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims 1
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 abstract description 14
- 230000001882 diuretic effect Effects 0.000 abstract description 9
- 108091006146 Channels Proteins 0.000 abstract description 7
- 238000011321 prophylaxis Methods 0.000 abstract description 5
- 208000029422 Hypernatremia Diseases 0.000 abstract description 4
- 239000002833 natriuretic agent Substances 0.000 abstract description 3
- 102100033056 ATP-sensitive inward rectifier potassium channel 1 Human genes 0.000 abstract description 2
- 208000017667 Chronic Disease Diseases 0.000 abstract description 2
- 101000944272 Homo sapiens ATP-sensitive inward rectifier potassium channel 1 Proteins 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 216
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 160
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 143
- 239000000203 mixture Substances 0.000 description 142
- 239000000243 solution Substances 0.000 description 111
- 235000019439 ethyl acetate Nutrition 0.000 description 95
- 239000000543 intermediate Substances 0.000 description 63
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 54
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 50
- 239000012044 organic layer Substances 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 42
- 239000011541 reaction mixture Substances 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 35
- 239000011734 sodium Substances 0.000 description 32
- 239000002904 solvent Substances 0.000 description 32
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 29
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- 239000012267 brine Substances 0.000 description 24
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 22
- 238000003756 stirring Methods 0.000 description 21
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 238000003818 flash chromatography Methods 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000010410 layer Substances 0.000 description 19
- 239000000741 silica gel Substances 0.000 description 19
- 229910002027 silica gel Inorganic materials 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 150000002924 oxiranes Chemical class 0.000 description 18
- 238000004808 supercritical fluid chromatography Methods 0.000 description 18
- 238000004809 thin layer chromatography Methods 0.000 description 18
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 17
- QYJKUXKIJXNAHY-UHFFFAOYSA-N (4-methyl-5-oxo-2h-furan-3-yl) trifluoromethanesulfonate Chemical compound CC1=C(OS(=O)(=O)C(F)(F)F)COC1=O QYJKUXKIJXNAHY-UHFFFAOYSA-N 0.000 description 16
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 150000001412 amines Chemical class 0.000 description 13
- 230000004907 flux Effects 0.000 description 13
- 239000012071 phase Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 239000002002 slurry Substances 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- 229910052716 thallium Inorganic materials 0.000 description 11
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 11
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 10
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 230000036772 blood pressure Effects 0.000 description 10
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 10
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 239000011591 potassium Substances 0.000 description 9
- 229910052700 potassium Inorganic materials 0.000 description 9
- 230000036515 potency Effects 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000012453 solvate Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical group [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 8
- 239000012458 free base Substances 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Natural products CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 7
- 150000001299 aldehydes Chemical class 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 6
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 6
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 229960004592 isopropanol Drugs 0.000 description 6
- 238000004811 liquid chromatography Methods 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229960001407 sodium bicarbonate Drugs 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 0 CCCCOC(C(C)=C[C@](C)(C=C(C(C)C*1)C1=O)N)=C Chemical compound CCCCOC(C(C)=C[C@](C)(C=C(C(C)C*1)C1=O)N)=C 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 150000001649 bromium compounds Chemical class 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002001 electrophysiology Methods 0.000 description 5
- 230000007831 electrophysiology Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 5
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 5
- 238000001851 vibrational circular dichroism spectroscopy Methods 0.000 description 5
- 229920002554 vinyl polymer Polymers 0.000 description 5
- ATCBCXMAOKHYCI-UHFFFAOYSA-N 2-bromo-5-(tetrazol-1-yl)pyrazine Chemical compound C1=NC(Br)=CN=C1N1N=NN=C1 ATCBCXMAOKHYCI-UHFFFAOYSA-N 0.000 description 4
- ZBOIJDYZCFRHJL-UHFFFAOYSA-N 2-ethenyl-5-(tetrazol-1-yl)pyrazine Chemical compound C1=NC(C=C)=CN=C1N1N=NN=C1 ZBOIJDYZCFRHJL-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 125000004122 cyclic group Chemical group 0.000 description 4
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 150000004677 hydrates Chemical class 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- SCZNXLWKYFICFV-UHFFFAOYSA-N 1,2,3,4,5,7,8,9-octahydropyrido[1,2-b]diazepine Chemical compound C1CCCNN2CCCC=C21 SCZNXLWKYFICFV-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- IJQHGTAICJVYAH-UHFFFAOYSA-N 1-(4-methyl-5-oxo-2H-furan-3-yl)-3-piperidin-4-ylimidazolidin-2-one Chemical compound CC1=C(COC1=O)N1C(N(CC1)C1CCNCC1)=O IJQHGTAICJVYAH-UHFFFAOYSA-N 0.000 description 3
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 3
- GQSKFTFPHAXZSA-UHFFFAOYSA-N 3-bromo-2h-furan-5-one Chemical compound BrC1=CC(=O)OC1 GQSKFTFPHAXZSA-UHFFFAOYSA-N 0.000 description 3
- AFKQLNRCQPXHOF-UHFFFAOYSA-N 3-hydroxy-4-methyl-2h-furan-5-one Chemical compound CC1=C(O)COC1=O AFKQLNRCQPXHOF-UHFFFAOYSA-N 0.000 description 3
- CPAFRVZPLFANHK-UHFFFAOYSA-N 5-(oxiran-2-yl)-2-(tetrazol-1-yl)pyridine Chemical compound C1OC1C1=CC=C(N2N=NN=C2)N=C1 CPAFRVZPLFANHK-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 208000019025 Hypokalemia Diseases 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 3
- 229940124639 Selective inhibitor Drugs 0.000 description 3
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 150000001805 chlorine compounds Chemical class 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940043279 diisopropylamine Drugs 0.000 description 3
- 150000002084 enol ethers Chemical class 0.000 description 3
- 238000006735 epoxidation reaction Methods 0.000 description 3
- UFGBECWLMBMOGN-UHFFFAOYSA-N ethyl 4-bromo-2-methyl-3-oxobutanoate Chemical compound CCOC(=O)C(C)C(=O)CBr UFGBECWLMBMOGN-UHFFFAOYSA-N 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000012456 homogeneous solution Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000000155 isotopic effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000001452 natriuretic effect Effects 0.000 description 3
- 235000001968 nicotinic acid Nutrition 0.000 description 3
- 239000011664 nicotinic acid Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 208000024896 potassium deficiency disease Diseases 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000010948 rhodium Substances 0.000 description 3
- 238000002390 rotary evaporation Methods 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MKKCHZQCMHHGOY-NSHDSACASA-N (2r)-2-methoxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)acetaldehyde Chemical compound CO[C@@H](C=O)C1=CC=C2C(=O)OCC2=C1C MKKCHZQCMHHGOY-NSHDSACASA-N 0.000 description 2
- XYDXDWXAAQXHLK-UHFFFAOYSA-N (3-bromo-2-methylphenyl)methanol Chemical compound CC1=C(Br)C=CC=C1CO XYDXDWXAAQXHLK-UHFFFAOYSA-N 0.000 description 2
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- ZVTGDQOLUDYVIH-UHFFFAOYSA-N 1-O-tert-butyl 4-O-ethyl 4-(2-oxo-1,3-oxazolidin-5-yl)piperidine-1,4-dicarboxylate Chemical compound O=C1OC(CN1)C1(CCN(CC1)C(=O)OC(C)(C)C)C(=O)OCC ZVTGDQOLUDYVIH-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- PDRMCZOMKQFKLN-UHFFFAOYSA-N 2-(oxiran-2-yl)-5-(tetrazol-1-yl)pyrazine Chemical compound C1OC1C1=CN=C(N2N=NN=C2)C=N1 PDRMCZOMKQFKLN-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- XSWVQBHVHVYSBX-UHFFFAOYSA-N 2-[6-(tetrazol-1-yl)pyridin-3-yl]ethanol Chemical compound N1=CC(CCO)=CC=C1N1N=NN=C1 XSWVQBHVHVYSBX-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 2
- QWFILMGCTBJAQQ-UHFFFAOYSA-N 3-(hydroxymethyl)-2-methylphenol Chemical compound CC1=C(O)C=CC=C1CO QWFILMGCTBJAQQ-UHFFFAOYSA-N 0.000 description 2
- NOIPKVQBLJBCMA-UHFFFAOYSA-N 3-pyridin-4-ylpiperidin-2-one Chemical compound O=C1NCCCC1C1=CC=NC=C1 NOIPKVQBLJBCMA-UHFFFAOYSA-N 0.000 description 2
- LDRPGCITRMNKBI-UHFFFAOYSA-N 4-amino-3-methoxypiperidine-1-carboxylic acid Chemical compound COC1CN(C(O)=O)CCC1N LDRPGCITRMNKBI-UHFFFAOYSA-N 0.000 description 2
- PCIBNCRQRIUZMN-UHFFFAOYSA-N 4-bromo-3-(hydroxymethyl)-2-methylphenol Chemical compound CC1=C(O)C=CC(Br)=C1CO PCIBNCRQRIUZMN-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YQLAZVRXBCSLAI-UHFFFAOYSA-N 4-methyl-5-(oxiran-2-yl)-3h-2-benzofuran-1-one Chemical compound CC1=C2COC(=O)C2=CC=C1C1CO1 YQLAZVRXBCSLAI-UHFFFAOYSA-N 0.000 description 2
- CPAFRVZPLFANHK-ZETCQYMHSA-N 5-[(2R)-oxiran-2-yl]-2-(tetrazol-1-yl)pyridine Chemical compound O1[C@@H](C1)C=1C=CC(=NC1)N1N=NN=C1 CPAFRVZPLFANHK-ZETCQYMHSA-N 0.000 description 2
- KRRTXVSBTPCDOS-UHFFFAOYSA-N 5-bromopyrazin-2-amine Chemical compound NC1=CN=C(Br)C=N1 KRRTXVSBTPCDOS-UHFFFAOYSA-N 0.000 description 2
- XCLSUJASPNFYRV-UHFFFAOYSA-N 5-hydroxy-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(O)C(C)=C2COC(=O)C2=C1 XCLSUJASPNFYRV-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000005485 Azilsartan Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- 239000005537 C09CA07 - Telmisartan Substances 0.000 description 2
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 208000002682 Hyperkalemia Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- WHSOLWOTCHFFBK-ZQGJOIPISA-N Luseogliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)S2)O)=C(OC)C=C1C WHSOLWOTCHFFBK-ZQGJOIPISA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 2
- 229910020889 NaBH3 Inorganic materials 0.000 description 2
- 108700010041 Nicotinic acid receptor Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229910002666 PdCl2 Inorganic materials 0.000 description 2
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 241000720974 Protium Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 2
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 2
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 238000012435 analytical chromatography Methods 0.000 description 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 125000003609 aryl vinyl group Chemical group 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 150000007514 bases Chemical class 0.000 description 2
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 2
- IUSJHUVYQXOGBH-UHFFFAOYSA-N benzyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1C2C(C=O)C2CN1C(=O)OCC1=CC=CC=C1 IUSJHUVYQXOGBH-UHFFFAOYSA-N 0.000 description 2
- 125000001743 benzylic group Chemical group 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 239000012455 biphasic mixture Substances 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004296 chiral HPLC Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- GCUVBACNBHGZRS-UHFFFAOYSA-N cyclopenta-1,3-diene cyclopenta-2,4-dien-1-yl(diphenyl)phosphane iron(2+) Chemical compound [Fe++].c1cc[cH-]c1.c1cc[c-](c1)P(c1ccccc1)c1ccccc1 GCUVBACNBHGZRS-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- CAPGOHOZIOVEOQ-UHFFFAOYSA-N ethyl 2-formylbutanoate Chemical compound CCOC(=O)C(CC)C=O CAPGOHOZIOVEOQ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 2
- 229960000815 ezetimibe Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002171 loop diuretic Substances 0.000 description 2
- PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 2
- 229950004397 luseogliflozin Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 229960002237 metoprolol Drugs 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- 229960004034 sitagliptin Drugs 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 150000003440 styrenes Chemical class 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- NPTZWFCKLAFHIL-UHFFFAOYSA-N tert-butyl 4-(2-oxoimidazolidin-1-yl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1N1C(=O)NCC1 NPTZWFCKLAFHIL-UHFFFAOYSA-N 0.000 description 2
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 239000005458 thiazide-like diuretic Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- VIYXXANHGYSBLY-UHFFFAOYSA-N trimethylsilyl 2,2,2-trifluoroacetate Chemical compound C[Si](C)(C)OC(=O)C(F)(F)F VIYXXANHGYSBLY-UHFFFAOYSA-N 0.000 description 2
- SEDZOYHHAIAQIW-UHFFFAOYSA-N trimethylsilyl azide Chemical compound C[Si](C)(C)N=[N+]=[N-] SEDZOYHHAIAQIW-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- QQQZEFAUOMUXLS-UHFFFAOYSA-N (1-diphenylphosphanyl-9,9-dimethylxanthen-2-yl)-diphenylphosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)C1=C2C(C)(C)C3=CC=CC=C3OC2=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QQQZEFAUOMUXLS-UHFFFAOYSA-N 0.000 description 1
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 description 1
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 1
- DRYUXNLDFNVLIQ-UHFFFAOYSA-N (3-oxocyclopenten-1-yl) methanesulfonate Chemical compound CS(=O)(=O)OC1=CC(=O)CC1 DRYUXNLDFNVLIQ-UHFFFAOYSA-N 0.000 description 1
- IYZRFOAPEUBNQP-JPZLKUPGSA-N (3s)-n-[(2s)-1-[[(5s)-5-amino-6-hydroxyhexyl]amino]-4-methyl-1-oxopentan-2-yl]-3-hydroxy-4-[[3-(1h-imidazol-5-yl)-2-[[3-naphthalen-1-yl-2-(naphthalen-1-ylmethyl)propanoyl]amino]propanoyl]amino]-6-methylheptanamide;dihydrochloride Chemical compound Cl.Cl.C=1C=CC2=CC=CC=C2C=1CC(CC=1C2=CC=CC=C2C=CC=1)C(=O)NC(C(=O)NC(CC(C)C)[C@@H](O)CC(=O)N[C@@H](CC(C)C)C(=O)NCCCC[C@H](N)CO)CC1=CN=CN1 IYZRFOAPEUBNQP-JPZLKUPGSA-N 0.000 description 1
- SYPWPWUSXPWLKW-ZQWQDMLBSA-N (3s,4s)-5-cyclohexyl-n-hexyl-3-hydroxy-4-[[(2s)-2-[[(2s)-2-[(2-morpholin-4-ylacetyl)amino]-3-naphthalen-1-ylpropanoyl]amino]-3-(1,3-thiazol-4-yl)propanoyl]amino]pentanamide Chemical compound C([C@@H]([C@@H](O)CC(=O)NCCCCCC)NC(=O)[C@H](CC=1N=CSC=1)NC(=O)[C@H](CC=1C2=CC=CC=C2C=CC=1)NC(=O)CN1CCOCC1)C1CCCCC1 SYPWPWUSXPWLKW-ZQWQDMLBSA-N 0.000 description 1
- VEUQZWVGMYVTMY-UHFFFAOYSA-N (4-methyl-1-oxo-3h-2-benzofuran-5-yl) trifluoromethanesulfonate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C(C)=C2COC(=O)C2=C1 VEUQZWVGMYVTMY-UHFFFAOYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- LQQKDSXCDXHLLF-UHFFFAOYSA-N 1,3-dibromopropan-2-one Chemical class BrCC(=O)CBr LQQKDSXCDXHLLF-UHFFFAOYSA-N 0.000 description 1
- CYPYTURSJDMMMP-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 CYPYTURSJDMMMP-UHFFFAOYSA-N 0.000 description 1
- WHUGWCMDQSSYCM-UHFFFAOYSA-N 1-(4-methyl-5-oxo-2H-furan-3-yl)-4-piperidin-4-ylpyrrolidin-2-one Chemical compound CC1=C(COC1=O)N1C(CC(C1)C1CCNCC1)=O WHUGWCMDQSSYCM-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- CCWUEMDLFIGLOM-NUJGCVRESA-N 1-[(3R,4R)-3-fluoro-1-[(2R)-2-hydroxy-2-[6-(tetrazol-1-yl)pyridin-3-yl]ethyl]piperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound N1(N=NN=C1)C1=CC=C(C=N1)[C@H](CN1C[C@H]([C@@H](CC1)N1C(N(CC1)C=1COC(C=1C)=O)=O)F)O CCWUEMDLFIGLOM-NUJGCVRESA-N 0.000 description 1
- BGUDQRZMGKNWHB-NXEZZACHSA-N 1-[(3R,4R)-3-fluoropiperidin-4-yl]-3-(4-methyl-5-oxo-2H-furan-3-yl)imidazolidin-2-one Chemical compound F[C@@H]1CNCC[C@H]1N1C(N(CC1)C=1COC(C=1C)=O)=O BGUDQRZMGKNWHB-NXEZZACHSA-N 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- RQAVSDINDRNIKL-UHFFFAOYSA-N 1-chloro-3-isocyanatopropane Chemical compound ClCCCN=C=O RQAVSDINDRNIKL-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- IVVNZDGDKPTYHK-JTQLQIEISA-N 1-cyano-2-[(2s)-3,3-dimethylbutan-2-yl]-3-pyridin-4-ylguanidine Chemical compound CC(C)(C)[C@H](C)N=C(NC#N)NC1=CC=NC=C1 IVVNZDGDKPTYHK-JTQLQIEISA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- FUFSZYFWWBMLBR-UHFFFAOYSA-N 2,5-dihydrofuran-3-yl trifluoromethanesulfonate Chemical compound O1CC(=CC1)OS(=O)(=O)C(F)(F)F FUFSZYFWWBMLBR-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- PHGLYQGVAGLHTN-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetic acid Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC(=O)O)C1=CC=CC=C1 PHGLYQGVAGLHTN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- MSUPJSNTXOBJRH-UHFFFAOYSA-N 2-bromo-1-(4-methyl-1,3-dihydro-2-benzofuran-5-yl)ethanone Chemical compound C1=C(C(=O)CBr)C(C)=C2COCC2=C1 MSUPJSNTXOBJRH-UHFFFAOYSA-N 0.000 description 1
- BZUUVQCSPHPUQA-UHFFFAOYSA-N 2-bromo-5-chloropyridine Chemical compound ClC1=CC=C(Br)N=C1 BZUUVQCSPHPUQA-UHFFFAOYSA-N 0.000 description 1
- REXUYBKPWIPONM-UHFFFAOYSA-N 2-bromoacetonitrile Chemical compound BrCC#N REXUYBKPWIPONM-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- OJZJQUTYHWGKCV-UHFFFAOYSA-N 2-ethenyl-5-(tetrazol-1-yl)pyridine Chemical compound C=CC1=NC=C(C=C1)N1C=NN=N1 OJZJQUTYHWGKCV-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical class BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FBBGEVJLVHQTOC-UHFFFAOYSA-N 3-(6-piperazin-1-ylpyridin-3-yl)-2H-furan-5-one Chemical compound N1(CCNCC1)C1=CC=C(C=N1)C1=CC(OC1)=O FBBGEVJLVHQTOC-UHFFFAOYSA-N 0.000 description 1
- ZSPNSBHDXVAGIV-UHFFFAOYSA-N 3-[3-(3-azabicyclo[3.1.0]hexan-6-yl)pyrrol-1-yl]-2H-furan-5-one Chemical compound C12CNCC2C1C=1C=CN(C=1)C=1COC(C=1)=O ZSPNSBHDXVAGIV-UHFFFAOYSA-N 0.000 description 1
- MUXSLIWTUSNMHK-UHFFFAOYSA-N 3-amino-3h-furan-2-one Chemical class NC1C=COC1=O MUXSLIWTUSNMHK-UHFFFAOYSA-N 0.000 description 1
- BJGKVCKGUBYULR-UHFFFAOYSA-N 3-bromo-2-methylbenzoic acid Chemical compound CC1=C(Br)C=CC=C1C(O)=O BJGKVCKGUBYULR-UHFFFAOYSA-N 0.000 description 1
- USEGQJLHQSTGHW-UHFFFAOYSA-N 3-bromo-2-methylprop-1-ene Chemical compound CC(=C)CBr USEGQJLHQSTGHW-UHFFFAOYSA-N 0.000 description 1
- JSGJVHAOXSDSEE-UHFFFAOYSA-N 3-bromo-2-oxopyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(Br)C1=O JSGJVHAOXSDSEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- BUYCLJIISQGRBR-UHFFFAOYSA-N 3-fluoro-4-oxopiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(=O)C(F)C1 BUYCLJIISQGRBR-UHFFFAOYSA-N 0.000 description 1
- RIERSGULWXEJKL-UHFFFAOYSA-N 3-hydroxy-2-methylbenzoic acid Chemical compound CC1=C(O)C=CC=C1C(O)=O RIERSGULWXEJKL-UHFFFAOYSA-N 0.000 description 1
- XVNOUZPPUJBURL-UHFFFAOYSA-N 3-methoxy-4-(2-oxoimidazolidin-1-yl)piperidine-1-carboxylic acid Chemical compound COC1CN(CCC1N1CCNC1=O)C(O)=O XVNOUZPPUJBURL-UHFFFAOYSA-N 0.000 description 1
- VELDYINPQIUQAG-UHFFFAOYSA-N 3-methyl-3-piperidin-4-ylpyrrolidin-2-one Chemical compound CC1(C(NCC1)=O)C1CCNCC1 VELDYINPQIUQAG-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- YRZKUGKRJMSWSX-UHFFFAOYSA-N 3-piperazin-1-ylpyrrolidin-2-one Chemical compound N1(CCNCC1)C1C(NCC1)=O YRZKUGKRJMSWSX-UHFFFAOYSA-N 0.000 description 1
- VBNLNMCGMZQNQW-UHFFFAOYSA-N 4-(2-oxopyrrolidin-3-yl)piperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC(CC1)C1CCNC1=O VBNLNMCGMZQNQW-UHFFFAOYSA-N 0.000 description 1
- OEVZXILPFZTSFQ-UHFFFAOYSA-N 4-(4-methoxy-1-nitro-4-oxobutan-2-yl)piperidine-1-carboxylic acid Chemical compound COC(=O)CC(C[N+]([O-])=O)C1CCN(CC1)C(O)=O OEVZXILPFZTSFQ-UHFFFAOYSA-N 0.000 description 1
- BKYIYGMVZFLYJU-UHFFFAOYSA-N 4-(4-methyl-2-oxoimidazolidin-1-yl)piperidine-1-carboxylic acid Chemical compound CC1CN(C2CCN(CC2)C(O)=O)C(=O)N1 BKYIYGMVZFLYJU-UHFFFAOYSA-N 0.000 description 1
- VLTUSGXXXXEUNV-UHFFFAOYSA-N 4-[(3-methoxy-2-methyl-3-oxopropyl)amino]piperidine-1-carboxylic acid Chemical compound COC(=O)C(C)CNC1CCN(CC1)C(O)=O VLTUSGXXXXEUNV-UHFFFAOYSA-N 0.000 description 1
- AGBNFQWXPRZYJG-UHFFFAOYSA-N 4-[1-(4-methyl-5-oxo-2H-furan-3-yl)-5-oxopyrrolidin-3-yl]piperidine-1-carboxylic acid Chemical compound CC1=C(COC1=O)N1CC(CC1=O)C1CCN(CC1)C(O)=O AGBNFQWXPRZYJG-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- NTMSPTQWKSOLHE-UHFFFAOYSA-N 4-[4-methyl-5-(4-methyl-5-oxo-2H-furan-3-yl)pyridin-2-yl]piperazine-1-carboxylic acid Chemical compound CC1=C(COC1=O)c1cnc(cc1C)N1CCN(CC1)C(O)=O NTMSPTQWKSOLHE-UHFFFAOYSA-N 0.000 description 1
- NQNQKLBWDARKDG-UHFFFAOYSA-N 4-amino-1-piperidinecarboxylic acid Chemical compound NC1CCN(C(O)=O)CC1 NQNQKLBWDARKDG-UHFFFAOYSA-N 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- OOTNNWAOSACPMF-UHFFFAOYSA-N 4-methyl-3-(4-methyl-6-piperazin-1-ylpyridin-3-yl)-2H-furan-5-one Chemical compound CC=1C(OCC=1C=1C=NC(=CC=1C)N1CCNCC1)=O OOTNNWAOSACPMF-UHFFFAOYSA-N 0.000 description 1
- GAHGGBYSEOQNER-UHFFFAOYSA-N 5-(2-bromoacetyl)-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C(C(=O)CBr)C(C)=C2COC(=O)C2=C1 GAHGGBYSEOQNER-UHFFFAOYSA-N 0.000 description 1
- CPAFRVZPLFANHK-SSDOTTSWSA-N 5-[(2S)-oxiran-2-yl]-2-(tetrazol-1-yl)pyridine Chemical compound C1O[C@H]1c1ccc(nc1)-n1cnnn1 CPAFRVZPLFANHK-SSDOTTSWSA-N 0.000 description 1
- YBMHJWFLYFYWBM-UHFFFAOYSA-N 5-bromo-2-(tetrazol-1-yl)pyridine Chemical compound N1=CC(Br)=CC=C1N1N=NN=C1 YBMHJWFLYFYWBM-UHFFFAOYSA-N 0.000 description 1
- WGOLHUGPTDEKCF-UHFFFAOYSA-N 5-bromopyridin-2-amine Chemical compound NC1=CC=C(Br)C=N1 WGOLHUGPTDEKCF-UHFFFAOYSA-N 0.000 description 1
- IJYKNWNBJDYCRK-UHFFFAOYSA-N 5-ethenyl-2-(tetrazol-1-yl)pyridine Chemical compound N1=CC(C=C)=CC=C1N1N=NN=C1 IJYKNWNBJDYCRK-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- DENROHFRASSYJK-UHFFFAOYSA-N 6-(3-methoxy-3-oxoprop-1-enyl)-3-azabicyclo[3.1.0]hexane-3-carboxylic acid Chemical compound COC(=O)C=CC1C2C1CN(C2)C(=O)O DENROHFRASSYJK-UHFFFAOYSA-N 0.000 description 1
- YXRDWUJAJLDABJ-UHFFFAOYSA-N 6-bromo-2-chloroquinoline Chemical compound C1=C(Br)C=CC2=NC(Cl)=CC=C21 YXRDWUJAJLDABJ-UHFFFAOYSA-N 0.000 description 1
- UIYUUEDFAMZISF-FTBISJDPSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;(2s)-3-methyl-2-[pentanoyl-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NNN=N1 UIYUUEDFAMZISF-FTBISJDPSA-N 0.000 description 1
- GBMIVDMAHNBPIH-UHFFFAOYSA-N 6-chloro-1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide;1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O.C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GBMIVDMAHNBPIH-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 208000003918 Acute Kidney Tubular Necrosis Diseases 0.000 description 1
- 229940123338 Aldosterone synthase inhibitor Drugs 0.000 description 1
- UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 208000012904 Bartter disease Diseases 0.000 description 1
- 208000010062 Bartter syndrome Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- IEAPEUZGIWOXKV-UHFFFAOYSA-N C(C)OC(=O)C(CNC1CCN(CC1)C(=O)OC(C)(C)C)CC Chemical compound C(C)OC(=O)C(CNC1CCN(CC1)C(=O)OC(C)(C)C)CC IEAPEUZGIWOXKV-UHFFFAOYSA-N 0.000 description 1
- NBMMXFIRPPNGSR-NSHDSACASA-N C1O[C@@H]1c1cc(COCOC2)c2cc1 Chemical compound C1O[C@@H]1c1cc(COCOC2)c2cc1 NBMMXFIRPPNGSR-NSHDSACASA-N 0.000 description 1
- QGNIESFRSZYFDL-UHFFFAOYSA-N CC(C(OC1)=O)=C1N(CCCN1C2=CCNCC2)C1=O Chemical compound CC(C(OC1)=O)=C1N(CCCN1C2=CCNCC2)C1=O QGNIESFRSZYFDL-UHFFFAOYSA-N 0.000 description 1
- HYOGWCXTWMTWBG-UHFFFAOYSA-N CC(CC=NN=C1)N1c1ncc(C2OC2)nc1 Chemical compound CC(CC=NN=C1)N1c1ncc(C2OC2)nc1 HYOGWCXTWMTWBG-UHFFFAOYSA-N 0.000 description 1
- VVCISPHXZQKWOV-UHFFFAOYSA-N CCC(c(c(C)c1)ccc1C(CC)=N)=C Chemical compound CCC(c(c(C)c1)ccc1C(CC)=N)=C VVCISPHXZQKWOV-UHFFFAOYSA-N 0.000 description 1
- RWWGYPAGDMIZPT-UHFFFAOYSA-N COC(=O)C=CC1CCN(C(O)=O)CC1 Chemical compound COC(=O)C=CC1CCN(C(O)=O)CC1 RWWGYPAGDMIZPT-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GUKWXJGLJAZDFR-UHFFFAOYSA-N ClCCNC(NC1CCN(CC1)C(=O)OC(C)(C)C)=O Chemical compound ClCCNC(NC1CCN(CC1)C(=O)OC(C)(C)C)=O GUKWXJGLJAZDFR-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JVHXJTBJCFBINQ-ADAARDCZSA-N Dapagliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=CC=C1Cl JVHXJTBJCFBINQ-ADAARDCZSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- DVJAMEIQRSHVKC-BDAKNGLRSA-N Dutogliptin Chemical compound OB(O)[C@@H]1CCCN1C(=O)CN[C@H]1CNCC1 DVJAMEIQRSHVKC-BDAKNGLRSA-N 0.000 description 1
- 108010078772 ES 8891 Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- MCIACXAZCBVDEE-CUUWFGFTSA-N Ertugliflozin Chemical compound C1=CC(OCC)=CC=C1CC1=CC([C@@]23O[C@@](CO)(CO2)[C@@H](O)[C@H](O)[C@H]3O)=CC=C1Cl MCIACXAZCBVDEE-CUUWFGFTSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101001110310 Lentilactobacillus kefiri NADP-dependent (R)-specific alcohol dehydrogenase Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- GSINGUMRKGRYJP-VZWAGXQNSA-N Remogliflozin Chemical compound C1=CC(OC(C)C)=CC=C1CC1=C(C)N(C(C)C)N=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 GSINGUMRKGRYJP-VZWAGXQNSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010038540 Renal tubular necrosis Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 102000003673 Symporters Human genes 0.000 description 1
- 108090000088 Symporters Proteins 0.000 description 1
- 206010071436 Systolic dysfunction Diseases 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 108010036928 Thiorphan Proteins 0.000 description 1
- ZXOCGDDVNPDRIW-NHFZGCSJSA-N Tofogliflozin Chemical compound O.C1=CC(CC)=CC=C1CC1=CC=C(CO[C@@]23[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C2=C1 ZXOCGDDVNPDRIW-NHFZGCSJSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- CBMCZKMIOZYAHS-NSCUHMNNSA-N [(e)-prop-1-enyl]boronic acid Chemical compound C\C=C\B(O)O CBMCZKMIOZYAHS-NSCUHMNNSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DFDGRKNOFOJBAJ-UHFFFAOYSA-N acifran Chemical compound C=1C=CC=CC=1C1(C)OC(C(O)=O)=CC1=O DFDGRKNOFOJBAJ-UHFFFAOYSA-N 0.000 description 1
- 229950000146 acifran Drugs 0.000 description 1
- 229960003526 acipimox Drugs 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940077379 adcirca Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000002170 aldosterone antagonist Substances 0.000 description 1
- 229940083712 aldosterone antagonist Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960004601 aliskiren Drugs 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940112147 atacand hct Drugs 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- FQCKMBLVYCEXJB-MNSAWQCASA-L atorvastatin calcium Chemical compound [Ca+2].C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1.C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC([O-])=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 FQCKMBLVYCEXJB-MNSAWQCASA-L 0.000 description 1
- 229960001770 atorvastatin calcium Drugs 0.000 description 1
- 229940000201 avapro Drugs 0.000 description 1
- OISFUZRUIGGTSD-LJTMIZJLSA-N azane;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound N.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO OISFUZRUIGGTSD-LJTMIZJLSA-N 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- IHWFKDWIUSZLCJ-UHFFFAOYSA-M azilsartan kamedoxomil Chemical compound [K+].C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3[N-]C(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C IHWFKDWIUSZLCJ-UHFFFAOYSA-M 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940055053 benicar Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KKBIUAUSZKGNOA-HNAYVOBHSA-N benzyl (2s)-2-[[(2s)-2-(acetylsulfanylmethyl)-3-(1,3-benzodioxol-5-yl)propanoyl]amino]propanoate Chemical compound O=C([C@@H](NC(=O)[C@@H](CSC(C)=O)CC=1C=C2OCOC2=CC=1)C)OCC1=CC=CC=C1 KKBIUAUSZKGNOA-HNAYVOBHSA-N 0.000 description 1
- RKRKELORNFODMN-NEPJUHHUSA-N benzyl (3r,4s)-3-fluoro-4-hydroxypiperidine-1-carboxylate Chemical compound C1[C@@H](F)[C@@H](O)CCN1C(=O)OCC1=CC=CC=C1 RKRKELORNFODMN-NEPJUHHUSA-N 0.000 description 1
- SEQIAIADXKZAFN-UHFFFAOYSA-N benzyl 4-trimethylsilyloxy-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1CC(O[Si](C)(C)C)=CCN1C(=O)OCC1=CC=CC=C1 SEQIAIADXKZAFN-UHFFFAOYSA-N 0.000 description 1
- FLNRSCPSHHKUPG-UHFFFAOYSA-N benzyl 6-(4-methoxy-1-nitro-4-oxobutan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound COC(CC(C[N+](=O)[O-])C1C2CN(CC12)C(=O)OCC1=CC=CC=C1)=O FLNRSCPSHHKUPG-UHFFFAOYSA-N 0.000 description 1
- MLEVENZWZRZDLD-UHFFFAOYSA-N benzyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1C2C(CO)C2CN1C(=O)OCC1=CC=CC=C1 MLEVENZWZRZDLD-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- NDKBVBUGCNGSJJ-UHFFFAOYSA-M benzyltrimethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)CC1=CC=CC=C1 NDKBVBUGCNGSJJ-UHFFFAOYSA-M 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- 229960003665 bepridil Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- VIHAEDVKXSOUAT-UHFFFAOYSA-N but-2-en-4-olide Chemical compound O=C1OCC=C1 VIHAEDVKXSOUAT-UHFFFAOYSA-N 0.000 description 1
- RHDGNLCLDBVESU-UHFFFAOYSA-N but-3-en-4-olide Chemical compound O=C1CC=CO1 RHDGNLCLDBVESU-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 229960001713 canagliflozin Drugs 0.000 description 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- NQZFAUXPNWSLBI-UHFFFAOYSA-N carbon monoxide;ruthenium Chemical compound [Ru].[Ru].[Ru].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] NQZFAUXPNWSLBI-UHFFFAOYSA-N 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229940117229 cialis Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940097499 cozaar Drugs 0.000 description 1
- 229940066901 crestor Drugs 0.000 description 1
- 229950004210 cromakalim Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- LOGSONSNCYTHPS-UHFFFAOYSA-N cyclopentane-1,3-dione Chemical compound O=C1CCC(=O)C1 LOGSONSNCYTHPS-UHFFFAOYSA-N 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960003834 dapagliflozin Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- XLQDQRMFMXYSQS-UHFFFAOYSA-N dichloromethane;hydrochloride Chemical compound Cl.ClCCl XLQDQRMFMXYSQS-UHFFFAOYSA-N 0.000 description 1
- RVFZOTGUPNHVRA-UHFFFAOYSA-N dicyclohexyl-(1-phenylpyrrol-2-yl)phosphane Chemical compound C1CCCCC1P(C=1N(C=CC=1)C=1C=CC=CC=1)C1CCCCC1 RVFZOTGUPNHVRA-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940074620 diovan hct Drugs 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical class CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- CPGLZCPYWQALMI-UHFFFAOYSA-N dodecane-1-sulfinic acid Chemical compound CCCCCCCCCCCCS(O)=O CPGLZCPYWQALMI-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229950003693 dutogliptin Drugs 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 229960003345 empagliflozin Drugs 0.000 description 1
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- MZYVOFLIPYDBGD-MLZQUWKJSA-N enalaprilat dihydrate Chemical compound O.O.C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 MZYVOFLIPYDBGD-MLZQUWKJSA-N 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 239000002792 enkephalinase inhibitor Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960000573 eprosartan mesylate Drugs 0.000 description 1
- DJSLTDBPKHORNY-XMMWENQYSA-N eprosartan methanesulfonate Chemical compound CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 DJSLTDBPKHORNY-XMMWENQYSA-N 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 229950006535 ertugliflozin Drugs 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- BADWIIDKTXQYLW-UHFFFAOYSA-N ethenylstannane Chemical compound [SnH3]C=C BADWIIDKTXQYLW-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- FNENWZWNOPCZGK-UHFFFAOYSA-N ethyl 2-methyl-3-oxobutanoate Chemical compound CCOC(=O)C(C)C(C)=O FNENWZWNOPCZGK-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950005203 fasidotril Drugs 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002458 gemigliptin Drugs 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000000396 hypokalemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229940090022 hyzaar Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229950000991 ipragliflozin Drugs 0.000 description 1
- AHFWIQIYAXSLBA-RQXATKFSSA-N ipragliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(F)C(CC=2SC3=CC=CC=C3C=2)=C1 AHFWIQIYAXSLBA-RQXATKFSSA-N 0.000 description 1
- YOSHYTLCDANDAN-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2NN=NN=2)C(CCCC)=NC21CCCC2 YOSHYTLCDANDAN-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 229940103445 janumet Drugs 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NXFFJDQHYLNEJK-CYBMUJFWSA-N laropiprant Chemical compound C=1([C@@H](CC(O)=O)CCC=1C=1C=C(F)C=C(C2=1)S(=O)(=O)C)N2CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-CYBMUJFWSA-N 0.000 description 1
- 229950008292 laropiprant Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940095570 lescol Drugs 0.000 description 1
- 229940097443 levitra Drugs 0.000 description 1
- 229960002397 linagliptin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940002661 lipitor Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000000210 loop of henle Anatomy 0.000 description 1
- UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 description 1
- 229960003019 loprazolam Drugs 0.000 description 1
- 229960000519 losartan potassium Drugs 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004937 luminal membrane Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CTSAXXHOGZNKJR-UHFFFAOYSA-N methyl 2-diethoxyphosphorylacetate Chemical compound CCOP(=O)(OCC)CC(=O)OC CTSAXXHOGZNKJR-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- YVPRZSXSMPFLJU-UHFFFAOYSA-N methyl 4-cyano-2-pyridin-4-ylbutanoate Chemical compound C(#N)CCC(C(=O)OC)C1=CC=NC=C1 YVPRZSXSMPFLJU-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940099246 mevacor Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 229960000698 nateglinide Drugs 0.000 description 1
- OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- VZWXXKDFACOXNT-UHFFFAOYSA-N niludipine Chemical compound CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1C1=CC=CC([N+]([O-])=O)=C1 VZWXXKDFACOXNT-UHFFFAOYSA-N 0.000 description 1
- 229950000109 niludipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000010943 off-gassing Methods 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 description 1
- 229950000074 omarigliptin Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 description 1
- 108010072906 phosphoramidon Proteins 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229960002310 pinacidil Drugs 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- GJQNVZVOTKFLIU-UHFFFAOYSA-N piperidin-1-ium-4-one;chloride Chemical compound Cl.O=C1CCNCC1 GJQNVZVOTKFLIU-UHFFFAOYSA-N 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 108010029667 pramlintide Proteins 0.000 description 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical compound C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 description 1
- 229960004457 pramlintide acetate Drugs 0.000 description 1
- 229940089484 pravachol Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- UZQBKCWYZBHBOW-UHFFFAOYSA-N propan-2-yl 4-cyclohexyl-2-hydroxy-3-[[3-methylsulfanyl-2-[[2-(morpholine-4-carbonylamino)-3-phenylpropanoyl]amino]propanoyl]amino]butanoate Chemical compound C1CCCCC1CC(C(O)C(=O)OC(C)C)NC(=O)C(CSC)NC(=O)C(NC(=O)N1CCOCC1)CC1=CC=CC=C1 UZQBKCWYZBHBOW-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940126844 remogliflozin Drugs 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 229960002354 repaglinide Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 229940039245 revatio Drugs 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960000672 rosuvastatin Drugs 0.000 description 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229950001780 sampatrilat Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229960004937 saxagliptin Drugs 0.000 description 1
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 description 1
- 108010033693 saxagliptin Proteins 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012363 selectfluor Substances 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910000080 stannane Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000948 sympatholitic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229960005187 telmisartan Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- 108010069247 terlakiren Proteins 0.000 description 1
- POLXPVLCKAQONL-UHFFFAOYSA-N tert-butyl 3-(2-oxoimidazolidin-1-yl)pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1N1C(=O)NCC1 POLXPVLCKAQONL-UHFFFAOYSA-N 0.000 description 1
- CMIBWIAICVBURI-UHFFFAOYSA-N tert-butyl 3-aminopyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)C1 CMIBWIAICVBURI-UHFFFAOYSA-N 0.000 description 1
- JZNWQLLPLOQGOI-UHFFFAOYSA-N tert-butyl 3-fluoro-4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)C(F)C1 JZNWQLLPLOQGOI-UHFFFAOYSA-N 0.000 description 1
- OBFKNZZQOKKMKC-UHFFFAOYSA-N tert-butyl 4-(1-methoxy-4-methyl-1-oxopent-4-en-2-yl)piperidine-1-carboxylate Chemical compound COC(C(CC(=C)C)C1CCN(CC1)C(=O)OC(C)(C)C)=O OBFKNZZQOKKMKC-UHFFFAOYSA-N 0.000 description 1
- LVXCTEKFNSOHDB-UHFFFAOYSA-N tert-butyl 4-(2-oxopyrrolidin-3-yl)piperidine-1-carboxylate Chemical compound O=C1NCCC1C1CCN(CC1)C(=O)OC(C)(C)C LVXCTEKFNSOHDB-UHFFFAOYSA-N 0.000 description 1
- DSLVSFMWCDGZIL-UHFFFAOYSA-N tert-butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Br)C=N1 DSLVSFMWCDGZIL-UHFFFAOYSA-N 0.000 description 1
- FROYIVDQMKSAJT-UHFFFAOYSA-N tert-butyl 4-(5-oxopyrrolidin-3-yl)piperidine-1-carboxylate Chemical compound O=C1CC(CN1)C1CCN(CC1)C(=O)OC(C)(C)C FROYIVDQMKSAJT-UHFFFAOYSA-N 0.000 description 1
- BQXPDIMADWECDV-AATRIKPKSA-N tert-butyl 4-[(e)-3-methoxy-3-oxoprop-1-enyl]piperidine-1-carboxylate Chemical compound COC(=O)\C=C\C1CCN(C(=O)OC(C)(C)C)CC1 BQXPDIMADWECDV-AATRIKPKSA-N 0.000 description 1
- YQNKYMMRGOLIBE-UHFFFAOYSA-N tert-butyl 4-[3-(4-methyl-5-oxo-2H-furan-3-yl)-2-oxoimidazolidin-1-yl]piperidine-1-carboxylate Chemical compound CC1=C(COC1=O)N1C(N(CC1)C1CCN(CC1)C(=O)OC(C)(C)C)=O YQNKYMMRGOLIBE-UHFFFAOYSA-N 0.000 description 1
- DEZMISXFQBKREW-UHFFFAOYSA-N tert-butyl 4-[4-methyl-5-(4-methyl-5-oxo-2H-furan-3-yl)pyridin-2-yl]piperazine-1-carboxylate Chemical compound CC1=CC(=NC=C1C=1COC(C=1C)=O)N1CCN(CC1)C(=O)OC(C)(C)C DEZMISXFQBKREW-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- DTHBUMVMCKXRAP-UHFFFAOYSA-N tert-butyl 4-hydroxy-4-(2-oxopyrrolidin-3-yl)piperidine-1-carboxylate Chemical compound OC1(CCN(CC1)C(=O)OC(C)(C)C)C1C(NCC1)=O DTHBUMVMCKXRAP-UHFFFAOYSA-N 0.000 description 1
- YHLGDPDPDQJEOI-UHFFFAOYSA-N tert-butyl 6-(2-chloroethylcarbamoylamino)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound ClCCNC(NC1C2CN(CC12)C(=O)OC(C)(C)C)=O YHLGDPDPDQJEOI-UHFFFAOYSA-N 0.000 description 1
- BZUMXXCFQUZQAV-UHFFFAOYSA-N tert-butyl 6-(aminomethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2C(CN)C21 BZUMXXCFQUZQAV-UHFFFAOYSA-N 0.000 description 1
- UWWZMHWHRBGMIT-UHFFFAOYSA-N tert-butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC2C(N)C21 UWWZMHWHRBGMIT-UHFFFAOYSA-N 0.000 description 1
- ACNRTYKOPZDRCO-UHFFFAOYSA-N tert-butyl n-(2-oxoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC=O ACNRTYKOPZDRCO-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 150000001467 thiazolidinediones Chemical class 0.000 description 1
- LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229950006667 tofogliflozin Drugs 0.000 description 1
- 229960002277 tolazamide Drugs 0.000 description 1
- OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- KANZWHBYRHQMKZ-UHFFFAOYSA-N vinyl-pyrazine Natural products C=CC1=CN=CC=N1 KANZWHBYRHQMKZ-UHFFFAOYSA-N 0.000 description 1
- PNAMDJVUJCJOIX-XVZWKFLSSA-N vytorin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1.N1([C@@H]([C@H](C1=O)CC[C@@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 PNAMDJVUJCJOIX-XVZWKFLSSA-N 0.000 description 1
- 229940009349 vytorin Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940072168 zocor Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- ROMK Renal Outer Medullary Potassium channel
- TALH thick ascending loop of Henle
- CCD cortical collecting duct
- ROMK provides a pathway for potassium secretion that is tightly coupled to sodium uptake through the amiloride-sensitive sodium channel (see Reinalter, S.C., et al., Pharmacotyping o ' hypokalemic salt-losing tubular disorders, Acta Physiol Scand, 2004, 181(4): p. 513-21; and Wang, W., Renal potassium channels: recent developments, Curr Opin Nephrol Hypertens, 2004, 13(5): p. 549- 55).
- ROMK channel also referred to herein as inhibitors of ROMK or ROM K inhibitors
- ROMK or ROM K inhibitors are expected to represent novel diuretics for the treatment of hypertension and other conditions where treatment with a diuretic would be beneficial with potentially reduced liabilities (i.e., hypo- or hyperkalemia, new onset of diabetes, dyslipidemia) over the currently used clinical agents (see Lifton, R.P., A.G. Gharavi, and D. S. Geller, Molecular mechanisms of human hypertension, Cell, 2001, 104(4): p. 545-56).
- Human genetics Ji, W., et al., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat Genet, 2008, 40(5): p. 592-9; and Tobin, M.D., et al., Common variants in genes underlying monogenic hypertension and hypotension and blood pressure i the general population.
- the continued discovery of selective small molecule inhibitors of ROMK is needed for the development of new treatments for hypertension, heart failure, edematous states and related disorders.
- the compounds of Formula I and salts thereof of this invention are selective inhibitors of the ROMK channel and could be used for the treatment of hypertension, heart failure and other conditions where treatment with a diuretic or natriuretic would be beneficial.
- the present invention rovides compounds of Formula I
- the compounds of Formula I are inhibitors of the ROMK (Kirl .1) channel.
- the compounds of Formula I could be used in methods of treatment, inhibition or amelioration of one or more disease states that could benefit from inhibition of ROMK.
- the compounds of this invention could be used in methods of treatment which comprise administering a therapeutically or prophyiactically effective amount of a compound of Formula I to a patient in need of a diuretic and/or natriuretic agent. Therefore, the compounds of Formula I could be valuable pharmaceutically active compounds for the therapy, prophylaxis or both of medical conditions, including, but not limited to, cardiovascular diseases such as hypertension and heart failure as well as chronic kidney disease, and conditions associated with excessive salt and water retention.
- the compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs which are useful for the treatment of hypertension, heart failure and conditions associated with excessive salt and water retention.
- the invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which compri se compounds of Formula I.
- the resent invention provides compounds of Formula I
- R 1 is H, OH or 0(C 1-3 alkyl);
- R 2 is H or C 1-3 aikyl
- R 4 is H or C 1-3 alkyl
- R 5 is H or C 1-3 alkyl, R" is H or C]_3 alkyl;
- R 7 is H, C 1 .3 alkyl or 0(Ci. 3 alkyl),
- R b is H, OH, ⁇ ' ,., alkyl or (C 0)(K , alkyl;
- R is H, halo, C 1-3 alkyl or 0(C 1-3 alkyl),
- n 0, 1 or 2;
- the resent invention also relates to compounds of F
- R is H or C 1-3 alkyl
- R 4 is H or C 1- alkyl
- R" is H or C , alkyl
- R 6 is H or C 1-3 alkyl
- R :i is Il orO,.;alkyi:
- R is H, OH, C 1-3 alkyl or (OO C ⁇ alkyl;
- R is H, halo, C 1-3 alkyl or 0(C 1-3 alkyl); or a pharmaceutically acceptable salt thereof.
- X is N. In another embodiment of the invention, N is CR .
- Z is O. In another embodiment of the invention, Z i CH 2 .
- A is a first compound having the same in an embodiment of the invention.
- pyridinyl, pyrazinyl or pyndazinyl wherein said pyridinyi, pyrazinyi or pyndazinyl are optionally substituted with one or two substituents independently selected from the roup
- A is In
- A is .
- A is pyridinyl, which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C 1-3 alkyl.
- A is pyrazinyl, which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C ? alkyl.
- A is pyridazinyl, which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C 1-3 alkyl.
- R 1 is I E n another embodiment of the invention, R 1 is OH. In another embodiment of the invention, R 1 is ⁇ (0 1-3 alkyl). In a class of the embodiment, R 1 is OCH 3 . In another class of the embodiment, R 1 is OCH 2 CH 3 .
- R is I E In another embodiment of the invention, R is C 1-3 alkyl. In a class of the embodiment, R " is CH In an embodiment of the invention, R 4 is H. In another embodiment of the invention, R 4 i s C 1-3 aikyl. In a class of the embodiment, R 4 is CH 3 .
- R 5 is H. In another embodiment of the invention, R 5 is C 1-3 alkyl. In a class of the embodiment, R' is CI3 ⁇ 4. In another class of the embodiment, R 5 is CH 2 CH 3 .
- R 6 is H. In another embodiment of the invention, R 6 is C 1-3 alkyl. In a class of the embodiment, R 6 is CH 3 .
- R ' is H. In another embodiment of the invention, R' is 0(C 1 -3 aikyl). In a class of the embodiment, R' is OCH .
- R d is H.
- R a is C 1-3 alkyl.
- R a is CH 3 .
- iV is I E
- R x is halo.
- R 3 ⁇ 4 is Q. 3 alkyl.
- R x is 0(C 1-3 alkyl).
- n is 0. In another embodiment of the invention, n is 1. In another embodiment of the invention, n is 2.
- Specific embodiments of the present invention include, but are not limited to the compounds identified herein as Examples 1 to 61, or pharmaceutically acceptable salts thereof.
- compositions which is comprised of a compound of Formula I or Formula la as described above and a pharmaceutically acceptable carrier.
- the invention is also contemplated to encompass a pharmaceutical composition which is comprised of a pharmaceutically acceptable carrier and any of the compounds specifically disclosed in the present application.
- the compounds of the instant invention can also include the pharmaceutically acceptable salts, and also salts that are not pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
- the compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt.
- pharmaceutically acceptable salt refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term “pharmaceutically acceptable salt” refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, ascorbate, adipate, alginate, aspirate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, eamphorate,
- suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like.
- Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, dicyclohexyl amines and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanoi, 2-dimethylaminoethanol, ethanolamine, ethylamine, ethyl enedi amine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, moipholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, tri ethyl amine,
- the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; di alkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and steaiyl chlorides, bromides and iodides, aralkyf halides like benzyl and phenethyl bromides and others.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
- di alkyl sulfates like dimethyl, diethyl, dibutyl
- diamyl sulfates long chain halides
- salts can be obtained by known methods, for example, by mixing a compound of the present invention with an equivalent amount and a solution containing a desired acid, base, or the like, and then collecting the desired salt by filtering the salt or distilling off the solvent.
- the compounds of the present invention and salts thereof may form solvates with a solvent such as water, ethanol, or glycerol.
- the compounds of the present invention may form an acid addition salt and a salt with a base at the same time according to the type of substituent of the side chain.
- the present invention encompasses all stereoisomer! c forms of the compounds of Formula I or Formula la. Unless a specific stereochemistry is indicated, the present invention is meant to comprehend all such isomeric forms of these compounds. Centers of asymmetry that are present in the compounds of Formula I or Formula la can all independently of one another have (R) configuration or (S) configuration. When bonds to the chiral carbon are depicted as straight lines in the structural Formulas of the invention, it is understood that both the (R) and (S ) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the Formula.
- the invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios.
- enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in ail ratios.
- the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios.
- the preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis.
- a derivatization can be carried out before a separation of stereoisomers.
- the separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or Formula la or it can be done on a final racemic product.
- Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration.
- the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
- the present invention is meant to include all suitable isotopic variations of the specifically and generically described compounds.
- different isotopic forms of hydrogen (H) include protium (iH) and deuterium (3 ⁇ 4).
- Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
- Isotopically-enriched compounds can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the general process schemes and examples herein using appropriate isotopically- enriched reagents and/or intermediates.
- one or more silicon (Si) atoms can be incorporated into the compounds of the instant i nvention in place of one or more carbon atoms by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art from readily available starting materials.
- Carbon and silicon differ in their covalent radius leading to differences in bond distance and the steric arrangement when comparing analogous C-eiement and Si-element bonds. These differences lead to subtle changes in the size and shape of silicon-containing compounds when compared to carbon.
- size and shape differences can lead to subtle or dramatic changes in potency, solubility, lack of off -target activity, packaging properties, and so on. (Diass, J. O. et al. Organometallics (2006) 5: 1 188-1198, Showell, G.A. et al. Bioorganic & Medicinal Chemistry Letters (2006) 16:2555-2558).
- compounds of the present invention may exist in amorphous form and/or one or more crystalline forms, and as such all amorphous and crystalline forms and mixtures thereof of the compounds of Formula I or Formula la are intended to be included within the scope of the present invention.
- some of the compounds of the instant invention may form solvates with water (i.e., a hydrate) or common organic solvents.
- solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the instant compounds are likewise encompassed within the scope of this invention, along with un-soivated and anhydrous forms.
- esters of carboxylic acid derivatives such as methyl, ethyl, or pivaloyloxymethyl
- acyl derivatives of alcohols such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl
- esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
- the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). Salts can be obtained from the compounds of Formula I or Formula la by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts.
- the present invention also includes all salts of the compounds of Formula I or Formula la which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
- esters can optionally be made by esterification of an available carboxylic acid group or by formation of an ester on an available hydroxy group in a compound.
- labile amides can be made.
- Pharmaceutically acceptable esters or amides of the compounds of this invention may be prepared to act as prodrugs which can be hydrolyzed back to an acid (or -COO- depending on the pH of the fluid or tissue where conversion takes place) or hydroxy form particularly in vivo and as such are encompassed within the scope of this invention.
- Examples of pharmaceutically acceptable pro- drug modifications include, but are not limited to, -C 1-6 alkyi esters and ⁇ C 1-6 alkyl substituted with phenyl esters.
- alkyl is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification, e.g. methyl, may be represented by conventional abbreviations including "Me" or CH 3 or a symbol that is an extended bond as the terminal group, e.g.
- ethyl may be represented by "Et” or CH2.CH3
- propyl may be represented by “Pr” or CH 2 CH 2 CH 3
- butyl may be represented by "Bu” or CH 2 CH 2 CH 2 CH 3 , etc.
- 4 alkyl (or "C1-C4 alkyl") for example, means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms.
- C 1-4 alkyl includes n ⁇ , iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. If no number is specified, 1-4 carbon atoms are intended for linear or branched alkyl groups.
- alkanol is intended to include aliphatic alcohols having the specified number of carbon atoms, such as methanol, ethanol, propanol, etc., where the -OH group is attached at any aliphatic carbon, e.g., propan-l -ol, propan-2-ol, etc.
- halogen or halo means fluorine, chlorine, bromine or iodine.
- Ceramic® (Fiuka) diatomite is diatomaceous earth, and can be referred to as
- variable R shown in the above structure can be attached to any one of 6 bicyclic ring carbon atoms i, ii, iii, iv, v or vi.
- bi cyclic ring systems include fused ring systems, where two rings share two atoms, and spiro ring systems, where two rings share one atom.
- the invention also includes derivatives of the compounds of Formula I or Formula la, acting as prodrugs and solvates.
- Prodrugs following administration to the patient, are converted in the body by normal metabolic or chemical processes, such as through hydrolysis in the blood, to the compound of Formula I or Formula la.
- Such prodrugs include those that demonstrate enhanced bioavailability, tissue specificity, and/or cellular delivery, to improve drag absorption of the compound of Formula I or Formula la.
- the effect of such prodnigs may result from modification of physicochemical properties such as iipophilicity, molecular weight, charge, and other physicochemical properties that determine the permeation properties of the drug.
- the invention also relates to medicaments containing at least one compound of the Formula I or Formula la and/or of a pharmaceutically acceptable salt of the compound of the Formula I or Formula la and/or an optionally stereoisomeric form of the compound of the Formula I or Formula la or a pharmaceutically acceptable salt of the stereoisomeric form of the compound of Formula I or Formula la, together with a pharmaceutically suitable and
- the compounds of Formula I or Formula la according to the invention are inhibitors of ROMK, and therefore could be used as diuretic and/or natriuretic agents.
- ROMK. inhibitors may be used to help to increase urination and increase urine volume and also to prevent or reduce reabsorption of sodium in the kidneys leading to increased excretion of sodium and water. Therefore, the compounds could be used for treatment or prophylaxis or both of disorders that benefit from increased excretion of water and sodium from the body. Accordingly, the compounds of this invention could be used in a method for inhibiting ROMK comprising administering a compound of Formula I or Formula la in a ROMK-inhibitory effective amount to a patient in need thereof. This also encompasses the use of the compounds for inhibiting ROMK in a patient comprising administering a compound of Formula I or Formula la in a
- the compounds of this invention could be used in a method for causing diuresis, natriuresis or both, comprising administering a compound of Formula I or Formula la in a therapeutically effective amount to a patient in need thereof. Therefore, the compounds of Fonnual I of this invention could be used in methods for treatment of prevention of or reduction of risk for developing medical conditions that benefit from increased excretion of water and sodium, such as but not limited to one or more of hypertension, such as essential hypertension (also known as primary or idiopathic hypertension) which is a fonn of hypertension for which no cause can be found, heart failure (which includes both acute heart failure and chronic heart failure, the latter also known as congestive heart failure) and/or other conditions associated with excessive salt and water retention.
- hypertension such as essential hypertension (also known as primary or idiopathic hypertension) which is a fonn of hypertension for which no cause can be found
- heart failure which includes both acute heart failure and chronic heart failure, the latter also known as congestive heart failure
- the compounds could also be used to treat hypertension which is associated with any of several primary diseases, such as renal, pulmonary, endocrine, and vascular di seases, including treatment of patients with medical conditions such as heart failure and/or chronic kidney disease.
- the compounds of Formula I or Formula la could be used in methods for treatment of, prevention of or reduction of risk for developing one or more disorders such as pulmonary hypertension, particularly pulmonary arterial hypertension (PAH), cardiovascular disease, edematous states, diabetes meliitus, diabetes insipidus, post- operative volume overload, endothelial dysfunction, diastolic dysfunction, systolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, preeclampsia, cerebral edema, nephropathy, glomerulonephritis, nephrotic syndrome
- prophylactic benefit such as those described herein.
- the compounds of Formula I or Formula la may potentially have reduced unintended effects (for example, hypo- or hyperkalemia, new onset of diabetes, dyslipidemia, etc.) over currently used clinical agents. Also the compounds may have reduced risk for diuretic tolerance, which can be a problem with long-term use of loop diuretics,
- compounds that are ROMK inhibitors can be identified as those compounds which, when tested, have an IC50 of 5 ⁇ , ⁇ or less, preferably 1 ⁇ or less, and more particularly 0.25 uM or less, in the Thallium Flux Assay, described in more detail further below.
- the dosage amount of the compound to be administered depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect.
- the compound will be administered chronically on a daily basis for a length of time appropriate to treat or prevent the medical condition relevant to the patient, including a course of therapy lasting days, months, years or the life of the patient.
- a daily dose of approximately 0.001 to 100 mg/kg, particularly 0.001 to 30 mg/kg, in particular 0.001 to 10 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results.
- the daily dose is particularly administered in a single dose or can be divided into several, for example two, three or four individual doses, and may be, for example but not limited to, 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.25 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, etc., on a daily basis.
- the compound may be formulated for immediate or modified release such as extended or controlled release.
- the term "patient” includes animals, particularly mammals and especially humans, who use the instant active agents for the prophylaxis or treatment of a medical condition.
- Administering of the daig to the patient includes both self-administration and administration to the patient by another person.
- the patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk for developing said disease or medical condition or developing long-term complications from a disease or medical condition.
- terapéuticaally effective amount is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
- a “prophylactically effective amount” is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician.
- the terms "preventing,” “prevention,” “prophylactic” and deri vatives of these term s as used herein refer to administering a compound to a patient before the onset of clinical symptoms of a condition not yet present in the patient.
- a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention or reduction of risk of myocardial infarction or prevention or reduction of risk for complications related to hypertension.
- the ROMK inhibitors may be administered via any suitable route of administration such as, for example, orally, parenterally, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
- parenteral as used herein includes subcutaneous injections, intravenous (IV), intramuscular, intrasternal inj ection or infusion techniques.
- Oral formulations are preferred for treatment of chronic indications such as hypertension or chronic heart failure, particularly solid oral dosage units such as pills, tablets or capsules, and more particularly tablets, IV dosing is preferred for acute treatment, for example for the treatment of acute heart failure.
- compositions comprised of a compound of Formula I or Formula la and a pharmaceutically acceptable carrier which is comprised of one or more excipients or additives.
- An excipient or additive is an inert substance used to formulate the active drug ingredient.
- the pharmaceutical compositions of this invention containing the active ingredient may be in forms such as pills, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions.
- Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- the excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, mannitol, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
- compositions may also contain other customary additives, for example but not limited to, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
- Oral immediate-release and time-controlled release dosage forms may be employed, as well as enterically coated oral dosage forms. Tablets may be uncoated or they may be coated by known techniques for aesthetic purposes, to mask taste or for other reasons.
- Coatings can also be used to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water or miscible solvents such as propylene glycol, PEGs and ethanol
- an oil medium for example peanut oil, liquid paraffin, or olive oil.
- Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
- Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti -oxidant such as ascorbic acid.
- Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
- the instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining a compound of Formula I or Formula la with a
- a pharmaceutically acceptable carrier is also encompassed.
- the pharmaceutical composition which is made by combining a compound of Formula I or Formula la with a pharmaceutically acceptable carrier.
- a therapeutically effective amount of a compound of this invention can be used for the preparation of a medicament useful for inhibiting OMK, for causing diuresis and/or natriuresis, and/or for treating, preventing or reducing the risk for any of the medical conditions described herein, in dosage amounts described herein.
- the amount of active compound of Formula I or Formula la and/or its pharmaceutically acceptable salts in the pharmaceutical composition may be, for example but j 7 not limited to, from about 0. 1 mg to 1 g, particularly 0.1 mg to about 200 mg, more particularly from about 0.1 mg to about 100 mg, and even more particularly from about 0.1 to about 50 mg, per dose on a free acid/free base weight basis, but depending on the type of the pharmaceutical composition, potency of the active ingredient and/or the medical condition being treated, it could also be lower or higher.
- Pharmaceutical compositions usually comprise about 0.5 to about 90 percent by weight of the active compound on a free acid/free base weight basis.
- the compounds of Formula I or Formula la inhibit ROMK. Due to this property, apart from use as pharmaceutically active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on ROMK is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples.
- the compounds of Formula I or Formula la can also be employed as intermediates for the preparation of other pharmaceutically active compounds.
- One or more additional pharmacologically active agents may be administered in combination with a compound of Formula I or Formula la.
- the additional active agent (or agents) is intended to mean a medicinal compound that is different from the compound of Formula I or Formula la, and which is a pharmaceutically active agent (or agents) that is active in the body, including pro-drugs, for example esterified forms, that convert to pharmaceutically active form after administration, and also includes free-acid, free-base and pharmaceutically acceptable salts of said additional active agents when such forms are sold commercially or are otherwise chemically possible.
- any suitable additional active agent or agents including but not limited to anti-hypertensive agents, additional diuretics, anti-atherosclerotic agents such as a lipid modifying compound, anti-diabetic agents and/or anti-obesity agents may be used in any combination with the compound of Formula I or Formula la in a single dosage formulation (a fixed dose drug combination), or may be administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents).
- thiazide-like diuretics e.g., hydrochlorothiazide (HCTZ or HCT); angiotensin converting enzyme inhibitors (e.g, alacepiil, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril); dual inhibitors of angiotensin converting enzyme (ACE) and neutral
- ACE angiotensin converting enzyme
- endopeptidase such as omapatrilat, sampatrilat and fasidotril
- angiotensin II receptor antagonists also known as angiotensin receptor blockers or ARBs, which may be in free-base, free-acid, salt or pro-drug form, such as azilsartan, e.g., azilsartan medoxomil potassium
- candesartan e.g., candesartan cilexetii (AT AC AND®)
- eprosartan e.g., eprosartan mesylate (TEVETAN®), irbesartan (AVAPRO®)
- losartan e.g., losartan potassium
- olmesartan e.g, olmesartan medoximil (BENICAR®), telmisartan
- thiazide-like diuretic such as hydrochlorothiazide (e.g., HYZAAR®, DIOVAN HCT®,
- potassium sparing diuretics such as amiloride HQ, spironolactone, epleranone, triamterene, each with or without HCTZ; carbonic anhydrase inhibitors, such as acetazoiamide; neutral endopeptidase inhibitors (e.g., thi orphan and phosphoramidon);
- angiotensin receptor neprilysin inhibitors e.g., LCZ696
- aldosterone antagonists aldosterone synthase inhibitors
- renin inhibitors e.g., enalkrein; RO 42-5892; A 65317; CP 80794; ES 1005; ES 8891; SQ 34017, aliskiren (2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4- hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)-phenyl]-octanamid
- calcium channel blockers e.g., ami odi pine, nifedipine, verapamil, diltiazem, felodipine, gallopamil, niludipine, nimodipine, nicardipine, bepridil, nisoldipine
- potassium channel activators e.g., nicorandil, pinacidil, cromakalim, minoxidil, apriikalim, loprazolam
- sympatholitics e.g., beta-adrenergic blocking drags (e.g., acebutoiol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, metoprolol tartate, nadolol, propranolol, sotalol, timolol); alpha adrenergic blocking drugs (e.g., doxazocin, prazoc
- lipid lowering agents e.g., HMG-CoA reductase inhibitors such as simvastatin and lovastatin which are marketed as ZOCOR® and MEVACOR® in lactone pro-drug form and function as inhibitors after administration, and pharmaceutically acceptable salts of dihydroxy open ring acid HMG-CoA reductase inhibitors such as atorvastatin (particularly the calcium salt sold in LIPITOR®), rosuvastatin (particularly the calcium salt sold in CRESTOR®), pravastatin (particularly the sodium salt sold in PRAVACHOL®), and fluvastatin (particularly the sodium salt sold in LESCOL®); a cholesterol absorption inhibitor such as ezetimibe (ZETTA®), and ezetimibe in combination with any other lipid lowering agents such as the HMG-CoA reductase inhibitors noted above and particularly
- HMG-CoA reductase inhibitors such as simvastatin and lovastatin which are marketed as ZOCOR®
- Amines 1.2 may be free bases, or they may be salts, in which case a base such as triethylamine or N;N-diisopropylethylamine may be added.
- Compounds of formula 2,3 can be prepared by the sequence detailed in Scheme 2, Aldehydes or ketones 2.1 may be used in reductive alkylation reactions of amines 1.2 to afford ROMK inhibitors of the formul a 2.3 by using various conditions (for example using sodium cyanoborohydride, sodium triacetoxy borohydride, or titanium tetra-isopropoxide, followed by sodium borohydride or sodium cyanoborohydride).
- compounds of formula 2.3 can be prepared by addition of amine 1.2 to an olefin of type 2.2 in the presence of a catalyst Rh(COD) 2 BF 4 /DPEPhos. Under this condition, the olefins of type 2.2 may be required to be activated by a nitrogen atom or other electron-withdrawing group at the position ortho to the double bond on the aromatic ring.
- formation of the tetrazol e ring can be accomplished by stirring CF 3 C0 2 TMS, N 3 TMS and CH(OEt) 3 in ethyl acetate or NaN 3 and CH(OEt) 3 in acetic acid at room temperature.
- the epoxide ring in intermediate 3.5 can be built by treatment of 3.2 (where X is chloride, bromide, iodide, or trifluoromethane sulfonate) with potassium vinyl trifluoroborate (Molander, G.; Luciana, A. journal of Organic Chemistry, 2005, 70(10), 3950-3956) under palladium catalyzed coupling conditions followed by epoxidation of the formed styrene with NBS/NaOH.
- the intermediate styrene 3.4 can be used to prepare ROMK inhibitors in place of 2.2 according to Scheme 2.
- styrene may be formed using vinylstannane reagents and palladium catalysis, and other methods for epoxidation of the styrene may be used, for rexample, mCPBA.
- the racemic epoxides of formula 3.5 can be resolved under chiral HPLC chromatography conditions to afford its enantiomers (R)-3.5 and (S)-3.5, which can be used in place of 1.1 according to Scheme I .
- Aldehydes 4.3 can he prepared in numerous ways, including as described in Scheme 4, Aldehyde 4.3 can be prepared by hydrogenation of intermediate epoxides 3.5 followed by oxidation with Dess-Martin peiiodinane. Aldehydes 4.3 can be used in place of intermediates 2.1 in Scheme 2 to prepare ROMK inhibitors.
- the epoxides 5.3 (and single enatiomers (R)-5.3 and (S)-5.3) can be prepared following the method detailed in Scheme 5, Treatment of 5.1 (where X is chloride, bromide, iodide, or trifluoromethane sulfonate) with commercially available potassium vinyl trifluoroborate (Molander, G.; Luciana, A. Journal of Organic Chemistry, 2005, 70(10), 3950-3956) under palladium catalyzed coupling conditions with an appropriate phosphine ligand gives rise to styrene 5.2 (Molander, G.; Brown, A. journal of Organic Chemistry, 2006, 71(26), 9681-9686).
- styrenes 5 can be converted to the corresponding epoxides 5.3 under various epoxidation conditions, for example, with mCPBA (Fringuelli, F. et al. Organic Preparations and Procedures International, 1989, 21(6), 757-761).
- mCPBA Frringuelli, F. et al. Organic Preparations and Procedures International, 1989, 21(6), 757-761).
- the racemic epoxide 5.3 can be resolved under chiral HPLC chromatography conditions to afford its enantiomers (R)-5.3 and (S)-5.3), which can be used in place of 1.1 according to Scheme 1.
- enantiopure epoxides (J?)-5.3 or (S)-5.3 can be prepared as shown in Scheme 6.
- Treatment of 5.1 (where X is bromide, iodide, or trifluoromethane sulfonate) with commercially available vinyl butylether 6.1 under palladium catalyzed conditions with a suitable ligand (for example Pd(OAc) 2 , DPPP) can provide the enol ethers 6.2.
- Enol ethers may be prepared using other methods known to the chemist. Treatment of the resulting enol ethers 6.2 with NBS or other similar reagents affords the corresponding bromomethyl ketones 6.3.
- Aldehydes 7.2 may be prepared in numerous ways, with one approach described in Scheme 7. Treatment of 5.1 (where X is bromide, iodide, or trifluoromethane sulfonate) with allyltnbutylstannane in the presence of palladium catalyst affords the allyl product 7.1.
- Oxidation for example with ozone, followed by reduction of the ozonide with dimethyl sulfide, provides aldehydes 7.2 which can be used in place of 2.1 to prepare ROMK inhibitors according to Scheme 2.
- Heterocyclic furanones 8.4 can be prepared as described in Scheme 8. Heterocycles such as 8.1, where an amine is protected as appropriate (Greene, T.; Wuts, P. G. M. protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York, NY 1991), and where Z represents a heterocycle possessing an N-H group, can be coupled to furanone inflates or bromides 8.2 using a palladium catalyst and ligand, for example palladium acetate and 4,5-
- Intermediates 8.3 are converted to spirocyclic aminofuranones 8.4 by removal of the protective group, for example, rert-butoxycarbonyl can be removed with TFA or HCl.
- the heterocyclic furanones 8.4 can be used in place of Intermediate L2 in Schemes 1 and 2 above to afford ROMK inhibitors.
- the subject compounds may be prepared by modification of the procedures disclosed in the Examples as appropriate. Starting materials are commercially available or made by known procedures or as illustrated. The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.
- reactions sensitive to moisture or air were performed under nitrogen or argon using anhydrous solvents and reagents.
- the progress of reactions was determined by either analytical thin layer chromatography (TLC) usually performed with E. Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm or liquid chromatography-mass spectrometry (LC-MS).
- TLC analytical thin layer chromatography
- LC-MS liquid chromatography-mass spectrometry
- the analytical LC-MS system used consisted of a Waters ZQ platform with eiectrospray ionization in positive ion detection mode with an Agilent 1 100 series HPLC with autosampler.
- the column was usually a Water Xterra MS C18, 3.0 ⁇ 50 mm, 5 ⁇ .
- the flow rate was 1 mL/min, and the injection volume was 10 «L.
- UV detection was in the range 210-400 nm.
- the mobile phase consisted of solvent A (water plus 0,06% TFA) and solvent B (acetonitrile plus 0.05% TFA) with a gradient of 100% solvent A for 0.7 min changing to 100% solvent B over 3.75 min, maintained for 1.1 min, then reverting to 100% solvent A over 0.2 min.
- Preparative HPLC purifications were usually performed using a mass spectrometry directed system. Usually they were performed on a Waters Chromatography Workstation configured with LC-MS System Consisting of: Waters ZQ single quad MS system with
- Flash chromatography was usually performed using a Biotage Flash Chromatography apparatus (Dyax Corp.) on silica gel (32-63 niM, 60 A pore size) in pre-packed cartridges of the size noted, ⁇ NMR spectra were acquired at 500 MHz spectrometers in CDCl, solutions unless otherwise
- TMS Tetram ethyl silane
- Chiral analytical chromatography was usually performed on one of Chiralpak AS, Chiralpak AD, Chiral eel OD, Chiralcel IA, or Chiralcel OJ columns (250 x 4.6 mm) (Daicel Chemical Industries, Ltd.) with noted percentage of either ethanol in hexane (%Et/Hex) or isopropanol in heptane (%IPA/Hep) as isocratic solvent systems, Chiral preparative
- EtOAc ethyl acetate
- Cbz benzyl oxycarbonyl
- dibenzylideneacetone dba
- 11- chloroethylchioroformate ACE-Ci
- Ph phenyl
- DCM dichloromethane
- SM starting material
- ether or Et 2 0 trill uoroacetic acid
- TFA triethylamine
- TEA triethylamine
- DBU 1,8- Diazabicyclo[5.4.0]undec-7-ene
- DEA Diethanolamine
- DIEA N,N-diisopropylethylamine
- DIPEA dimethyl sulfide
- EDC EDAC, ED AC, or EDO
- ethylene glycol tetraacetic acid EGTA
- DMAP dimethylacetamide
- DMAC Lithium bis(trimethylsilyl)amide
- LiHMDS 3- chloroperoxybenzoic acid
- mCPBA nicotinamide adenine dinucleotide phosphate
- PE petroleum ether
- LAH lithium aluminum hydride
- DIP A di-isopropylamine
- NMO methylmorpholine-N-oxide
- XtalFluor-E 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos); iV,iV,A",A"-Tetramethyiethylenediamine (TMEDA); Trimethylsilyl (TMS);[1 ,4- Bis(diphenylphosphino)butane](l.,5-cyclooctadiene)rhodium(I) tetrafluorob orate (Rh(COD)BF 4 ); round-bottom flask (RB or RBF); aqueous (aq); saturated aqueous (sat'd), saturated aqueous sodium chloride solution (brine); medium pressure liquid chromatography (MPLC), high pressure liquid chromatography (HPLC), flash chromatography (FC), liquid chromatography (LC), supercritical fluid chromatography (SFC); thin layer chromatography (TLC), mass spectrum (ms or MS
- X or x may be used to express the number of times an action was repeated (e.g., washed with 2 x 200 mL IN HC1), or to convey a dimension (e.g., the dimension of a column is 30 x 250mm).
- Step A (3-bromo-2-methylphenyl)methanol : To a solution of 3-bromo-2-methyl benzoic acid (35 g, 163 mmol) in THF (200 mL) was added Borane THF Complex (1.0 M, 212 mL, 212 mmol). The mixture was allowed to stir for 24 h. TLC showed one single product spot. The reaction was quenched with water. The solvent THF was removed under reduced pressure. The resulting solid was dissolved in ethyl acetate (500 mL), washed with IN HC1, sodium carbonate, and brine. The organic layer was dried over sodium sulfate and concentrated to afford (3-bromo- 2-methylphenyl)methanol.
- Step B 5-bromo-4-methyl-2-benzofuran- l (3H)-one: To a flask charged with (3-bromo ⁇ 2- methylphenyl)methanol (6.0 g, 30 mmol) was added a 1M TFA solution of Thallium
- Trifluoroacetate (16.2 g, 29.8 mmol). The mixture was stirred at RT overnight. Analysis by TLC showed no starting material remaining. The solvent was removed under vacuum, and the residue was pumped under high vacuum for 30 min to ensure complete removal of TFA. To the residue was then added Palladium(II) Chloride (529 mg, 2.98 mmol), Lithium Chloride (2,53 g, 59.7 mmol), Magnesium Oxide (2.41 g, 59.7 mmol), and MeOH (150 mL). The reaction was flushed with CO twice, and kept under CO at room temperature. Analysis by LC showed a big product spot within 2 hours. To this solution was added ethyl acetate to precipitate the salts.
- Step B (4-M.ethyl-l -oxo- L3-dihvdro-2-benzofuran-5-yl acetaldehvde: A solution of the above olefin (220 mg, 1.2 mmol) in MeOH (20 mL) was cooled to -78°C. To this solution was bubbled ozone until the reaction turned blue. Nitrogen was bubbled through the reaction to drive off excess ozone, followed by addition of DMS (0.870 mL, 1 1.7 mmol). The reaction was allowed to warm up to RT.
- Step A 5-ethenyl-4-methyl-2-benzofuran-l (3H)-one: 5-Bromo-4-methyl-2-benzofuran-l(3H)- one (598 mg, 4.47 mmol), potassium vinyl trifluoroborate (507 mg, 2.23 mmmol), PdCl 2 (dppf)- CH 2 Cl 2 Adduct (182 mg, 0.223 mmmol) , and TEA (0.622 mL, 4.47 mmol) were added to 10 mL ethanol in a 20 mL microwave tube. The tube was sealed and degassed, then heated to 140°C for 20 min. Analysis by LC-MS showed product peak.
- Step B 4-methyl-5-oxiran-2-yl-2-benzofuran- 1 (3H)-one: 5-ethenyl-4-methyl-2-benzofuran- l(3H)-one (1.46 g, 8.38 mmol) was added to DCM (25 mL) at 0°C then mCPBA (2,89 g, 16.8 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was washed once each with saturated aqueous Na 2 S 2 0 3 , NaHC0 3 , and brine. The organic layer was dried over Na 2 S0 , filtered, and evaporated to dryness.
- the crude material was purified by MPLC chromatography through 120g Redi-sep column eluting with 0-80% EtOAc/hexane solvent system to yield target 4-methyl-5-oxiran-2-yl-2-benzofuran-l(3H)-one.
- Racemic 4-methyl-5-oxiran-2-yl-2-benzofuran-l(3H)-one was resolved on a ChiralPak® AD-H column (5x25cm)under supercritical fluid chromatography (SFC) conditions on a Berger ⁇ !( ⁇ preparative SFC instrument.
- the racemate was diluted to 50 mg/mL in 1 : 1 DCM:MeOH. The separation was accomplished using 10% EtOH/CO?, flow rate 200 mL/min, 100 bar, 25°C. 500ul Injections were spaced every 2.12 mins.
- the resolution could also be achieved using a mobile phase of 8%MeOH / 98% C0 2 with a flow rate of lOOmL/min.
- the sample was prepared by dissolving in methanol, 20mg/mL, and using a 1 raL volume per injection. After separation, the fractions were dried off via rotary evaporator at bath temperature 40°C,
- Step A 3-hydroxymethyl-2-methyl phenol: To a 5L 3 neck RB equipped with overhead stirrer was charged NaBH 4 (87.0 g, 2.30 mol) and THE (3.0 L) and the resulting slurry was cooled to 10°C. To the slurry was then added 3-hydroxy-2-methyl benzoic acid (175 g, 1.15 mol) portionwise over 20 min (Tmax 17°C). A stirrable slurry formed, and was aged for an additional 45 min at 10-15°C after which BF 3 -OEt 2 (321 mL, 2.53 mol) was added slowly over 1.5 hours. The slurry was aged at 10°C-15°C for 2 h then assayed for reaction completion.
- the slurry was cooled to ⁇ 10 °C and quenched with 931 mL MeOH slowly over 1.5 h (gas evolution). The resulting slurry was aged overnight at RT. The batch was cooled to ⁇ 10°C then quenched with 1 N HC1 (1.5 L) to get a homogeneous solution (pH solution ⁇ 1), which was aged for 30 min and then the organic solvents were removed by rotary evaporation to approximately 1.8 L of total reaction volume (bath temperature was set to 50°C; internal temp of concentrate after rotary evaporation was ⁇ 40°C). The slurry was held at 45°C for 30 min then cooled slowly to 15°C.
- Step B 4-Bromo-3-hvdroxymethyl-2-methyl phenol: 3 -Hydroxymethyl-2-methyi phenol (1 13.9 g, 824.0 mmol) was dissolved in a mixture of acetonitrile (850 mL) and trifluoroacetic acid (750.0 mL, 9,735 mmol) in a 3 -neck 5-L flask under nitrogen. The reaction mixture was cooled to -33°C. N-bromosuccinimide (141 g, 791 mmol) was added over 15 minutes, with the temperature during addition in the range of -35 to -33°C. The reaction mixture was allowed to stir for an additional 15 min during which time the temperature decreased to -40°C.
- the sodium sulfate was removed by filtration, washed with additional MTBE and concentrated under reduced pressure.
- MTBE (684 mL, 2 volumes) was added, and the suspension was heated to 40°C to produce a homogeneous solution. The solution was allowed to cool to room temperature.
- Six volumes of heptane were added, and the supension was stirred overnight.
- the suspension was filtered, and the crystals were washed with 4: 1 heptane: MTBE (500 mL), followed by heptane (500 mL).
- the solid was dried under vacuum, providing 4-bromo-3-hydroxymethyl-2-methyl phenol.
- Step C 5-Hydroxy-4-methyl-3H-isobenzofuran-l-one: To a 2 L 3 neck flask equipped with overhead stirrer, N 2 inlet, and condenser were charged 4-bromo-3-hydroxymethyl-2-methyl phenol (100 g, 461 mmol), CuCN (83.0 g, 921 mmol), and DMF (500 mL). The solution was sparged with N 2 for 15 min then heated to 145°C to obtain a homogeneous solution. The solution was aged at 145°C for 2h, then the reaction mixture was cooled to 95°C. 41.5 mL water was added (sparged with 2 ), and the reaction aged for 20 h.
- the reaction was cooled to RT then the solids filtered through solka flok and the cake washed with 50 mL DMF, To a 3 L flask containing 1 L EtOAc was added the DMF filtrate. A precipitate coating formed in bottom of flask.
- the DMF/EtOAc suspension was filtered through solka flok and the cake was washed with 250 mL EtOAc, The resulting filtrate was washed with 5 % brine solution (3x500 mL).
- the aqueous layers were extracted with 500 mL EtOAc and the combined organics were dried over MgS04, fitered and evaporated.
- Step D 4-methyl-l-oxo-l,3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate
- the biphasic mixture was f ltered over Solka floe, washing with additional dichloromethane, and transferred to a separator ⁇ ' funnel, whereupon it was diluted with additional water (300 mL). The layers were separated, and the organic layer was washed with water (500 mL) and 10% brine (200 mL).
- the dichloromethane solution was dried over sodium sulfate, filtered and evaporated. The solid was adsorbed onto silica gel (27.5 g) and eluted through a pad of silica gel (271 g) with 25% ethyl acetate/hexanes. The resulting solution was concentrated under vacuum with the product crystallizing during concentration.
- Step E 5 -( I -B utoxy-vinylV 4-m ethyl -3H -i sobenzofuran- 1 -one : To a 1 L 3 -neck was charged trifluoromethanesulfonic acid 4-methyl-l-oxo- l,3-dihydro-isobenzofuran-5-yl ester (63.0 g, 213 mmoi), DMF (315 mL), butyl vinyl ether (138 mL, 1063 mmol) )then Et 3 N (35.6 mL, 255 mmol). The solution was sparged with N 2 for 20 min. To the solution was added Pd(OAc) 2 (1.
- Step F 5-(2-Bromo-acetyl)-4-methyl-3H-isobenzofuran-l -one: To a 1 L 3 -neck flask equipped with overhead stirrer was added crude 5-(l-butoxy-vinyl)-4-methyl-3H-isobenzoforan-l-one
- KRED MIF-20 (available from Codexis, Inc., 200 Penobscot Drive, Redwood City, CA 94063, www. codexi s . com , tel . 1 - 650-421-8100) was added to the erlenmeyer flask and the mixture was swirled to dissolve the solids. The resulting solution was added to the 5 L round bottom, which was then heated to 28°C and aged for 6 hours, at which point the reaction was cooled to RT and triethylamine (50,2 mL, 360 mmol) was added. The resulting solution was aged at 40°C for 1 h.
- the light slurry solution was cooled to RT, after which 122 g NaCl was added.
- the solution was aged at RT then extracted with 1.22 L isopropyl acetate (IP Ac).
- IP Ac isopropyl acetate
- the aqueous layer was re-extracted with 400 mL IP Ac and the combined organics were washed with 400 mL 20 % brine solution, dried over MgS0 4 , filtered and concentrated by rotary evaporation.
- the resulting solids were taken up in 100 mL IP Ac (thick slurry).
- Hexanes were added (400 mL) and the suspension aged at RT th en filtered and washed w/ 5: 1 HexanesTPAc solution (150 mL).
- the crystalline solids were dried under vacuum at RT to provide 4-methyl-5-[(2R)-oxiran-2-yl]-2-benzofuran-l(3H)-one. 1H
- Step A ethyl 4-bromo-2-methyl-3-oxobutanoate: To the solution of ethyl 2-methyl-3- oxobutanoate (5,05 g, 35,0 mmol) in water (10 mL) at 0°C was added bromine (1.805 mL, 35.0 mmol) dropwise over 2h. The resulting solution was stirred at rt for 16h. The reaction mixture was extracted with ethyl acetate, the organic phase was dried over sodium sulfate, and concentrated to give ethyl 4-bromo-2-methyl-3-oxobutanoate.
- 1 HNMR 500 MHz, CDC1 3 ), 54.322-4.274 (m, 2H), 2,455(s, 2H), 1.991 (s, 3H), 1.337-1.309 (t, 31 1 )
- Step B 4-hydroxy-3-methylfuran-2(5H)-one: Ethyl 4-bromo-2-methyl-3-oxobutanoate (7.81 g, 35 mmol) was treated with hydrogen bromide (0.040 mL, 48%, 0.35 mmol) and the mixture was heated at 100°C for 6 h. The precipitate was collected by filtration followed by washing with ethyl acetate to give 4-hydroxy-3-methylfuran-2(5H)-one.
- X HNMR 500 MHz, CDC1 3 ), 64.595 (s, 2H), 3.314 (s. 1H), 1.668 (s, 3H).
- Step C 4-methy 1 - 5 -oxo-2.5 -dihydrofuran-3 -yl trifl uoromethanesul fonate : To the solution of 4- hydroxy-3-methylfuran-2(5H)-one (400 mg, 3.51 mmol) in dichloromethane (10 mL) at -78°C was added 2,6-lutidine (0.612 mL, 5.26 mmol) and triflic anhydride (0.71 mL, 4.21 mmol) dropwise. The reaction temperature was maintained at -78°C for 0.5 h before being warmed to rt for Ih.
- Step A 5-Bromo-2-(lH-tetrazol- 1 -yOpyridine
- Step B 5-Ethenyl-2-(lH-tetrazol-l -yOpyridine
- Step C 5-(Oxiran-2-yl)-2-(lH-tetrazol-l -yl)pyridine (5)
- Step A 2-Bromo-5-(lH-tetrazol-l-yl)pyrazine: To a solution of 5-bromopyrazin-2-amine (10.75 g, 57,5 mmol) in ethyl acetate (150 ml) was added trimethylsilyl 2,2,2-trifluoroacetate (16,88 ml, 98 mmol). After the mixture was stirred for 5 min, triethoxymethane (17.21 ml, 103 mmol) was added. The resulting mixture was stirred for another five min, and this was followed by addition of azidotrim ethyl silane (12,09 ml, 92 mmol).
- Step B 2-( 1 H-Tetrazol - 1 -y 1 )-5 - vinyl pyrazine : A solution of 2-bromo-5-(lH-tetrazol-l- yl)pyrazine (1 1 .2 g, 49.3 mmol), potassium vinyltrifluoroborate (13.22 g, 99.0 mmol), ⁇ , ⁇ - bis(diphenylphosphino)ferrocene-palladium(ii)dic-hloride dichloromethane complex (2.01 g, 2.47 mmol), and TEA (13.75 mi, 99.0 mmol) in ethanol (150 mi) was heated at reflux at 82 °C for 4 h.
- Step C 2-(Oxiran-2-yl)-5-(lH-tetrazol-l-yl)pyrazine: To a suspension of 2-(lH-tetrazol-l-yl)-5- virryl pyrazine (6.7 g, 38.5 mmol) in t-BuOH: water (96 ml: 190 ml) was added N- bromosuccinimide (7.53 g, 42.3 mmol) in portions at rt. The mixture was heated at 50 C 'C for 1 h, and cooled to 0°C in an ice bath.
- Step B 2-(lH-Tetrazol-l -yl)-5-vinylpyrazine: A solution of 2-bromo-5-(lH-tetrazol -l - yl)pyrazine (1 1.2 g, 49.3 mmol), potassium vinyltrifluoroborate (13.2 g, 99.0 mmol), 1, 1 '- bis(diphenylphosphino)ferrocene-palladium(ii)di chloride dichloromethane complex (2.0 1 g, 2.47 mmol ), and TEA (13 ,8 mL, 99.0 mmol) in ethanol (1 50 mL) was heated at reflux at 82°C for 4 h.
- Step A: 7-bromotetrazolo[L5-a]quinoline: A solution of 6-bromo-2-chloroquinoline (4.00 g, 16.6 mmol) and sodium azide (2.16 g, 3.32 mmol) in 20 mL DMF was stirred at 130°C for 18 h. Then the solution was poured into cold water (200 mL) and stirred for 30 min, filtered and washed with cold water, dried to afford the title compound, LC MS[M+ 1] + ; : 248.9.
- Step B 7-vinyltetrazol oj " 1 ,5-a jquinoline: To a mi ture of 7-bromotetrazolo [ 1 , 5 ⁇ a] qui noline (3.35 g, 13.4 mmol), potassium vinyltrifluoroborate (3.62 g, 8.0 mmol), Pd(dppf)Cl 2 (335 mg, 0.44 mmol) in EtOH (100 mL) was added Et 3 N (1.31 g, 13.2 mmol), the mixture was heated at 80 °C for 2 hours.
- Step C 7-(oxiran-2-yl)tetrazolo
- LC/MSfM+l] 1" 213.1.
- Step A 2-(6-( lH-Tetrazol- 1 -yl pyridin-3 -yOethanol : To a solution of 5-(oxiran-2-yl)-2-(lH- tetrazol-l -yl)pyridine (500 mg, 2.64 mmol) in ethanoi (5.3 mL) were added 10% Pd/C (101 mg, 0.952 mmol) and HCOONH 4 (500 mg, 7.93 mmol). The reaction mixture was vigorously stirred for 1.5 h, and filtered through a pad of silica gel. The filtrate was evaporated to give 2-(6-(lH- tetrazol-l-yl)pyridin-3-yl)ethanol.
- Step S3 2-(6-( lH-Tetrazol - 1 -yl)pyridin-3 -yPacetal dehy de : To a solution of 2-(6-(lH-tetrazol-l- yl)pyridin-3-yl)ethanol (100 mg, 0.523 mmol) in DCM (2.6 mL) was added Dess-Martin periodinane (333 mg, 0.785 mmol). The mixture was stirred for 1.5 h, diluted with 10%
- Step A (R -5 -(2-hydroxy- 1 -meth oxyeth vP-4-m ethyl i sobenzofuran- 1 (3H)-one : To a solution of (S)-4-methyl-5-(oxiran-2-yl)isobenzofuran-l(3H)-one (300 mg, 1.58 mol) in MeOH (10 mL) was added TsOH (30 mg, 0.16 mmol). The resulting mixture was stirred at 70 °C for 2 h. The mixture was concentrated and partitioned between EtOAc and water; the organic layer was separated and concentrated to afford the title compound.
- Step B (R)-2-methoxy-2-(4-methyl-l -oxo-1.3-dihydroisobenzofuran-5-yl)acetaldehyde: DMP (405 mg, 0.96 mmol) was added to a solution of (R)-5-(2-hydroxy-l-methoxyethyl)-4- methylisobenzofuran-l(3H)-one (212 mg, 0.96 mmol) in DCM (3 mL) in one portion. The resulting mixture was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water; the organic layer was concentrated to afford the title compound.
- Step A tert-butyl 6-(3-(2-chloroethyl)ureido)-3-azabicyclo[3. 1.0]hexane-3-carbox late: To an ice-cooled DCM (10 ml) solution of tert-butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.01 g, 5.09 mmol) was added triethylamine (1.775 mL, 12.74 mmol) and then 2-chloroethyl i socyanate (0.591 g, 5.60 mmol).
- StepB fe/7-butyl 6-(2-oxoimidazolidin- 1 -yl)-3-azabicvclo
- fert-butyl 4-f 2-oxoimidazolidin- 1 -vDpiperidine- 1 -carboxylate Step A: fert-butyl 4-(3-(2-chloroethyl)ureido)piperidine-l-carboxylate: To an ice-cooied solution of te/f-butyl 4-aminopiperi dine- 1 -carboxyl ate (25.00 g, 125 mmol) in DCM (160 mL) was added TEA (31.00 g, 312 mmol) and l-chloro-2-isocyanatoethane (14.50 g, 138 mmol). After 10 min, the mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM (200 mL), washed with aqueous sodium bicarbonate (200 mL X 2), then dried and concentrated to afford the title compound.
- Step B fe/ -butyl 4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate: To a solution of tert-butyl 4-(3-(2-chloroethyl)ureido)piperidine-l-carboxylate (6.87 g, 22.5 mmol) in THF (50 mL) was added LiHMDS (1.0 M, 27 mL, 27 mmol) dropwise at 0°C, then the mixture was allowed to warm to room temperature gradually and stirred for 2 h. The mixture was quenched with aqueous sodium bicarbonate, extracted with EtO Ac (50 mL X 3), the combined organic layers were dried and concentrated. The residue was purified via silica gel to afford the title compound. "
- fert-butyl 4-(4-methyl-2-oxoimidazolidin-l-yl piperidine-l -carboxylate Step A: fert-butyl 4-((3-methoxy-2-methyl-3-oxopropyl amino)piperidine-l-carboxylate: To a solution of tert-butyl 4-aminopiperidine-l-carboxylate (8.00 g, 40 mmol) in MeOH (80 mL) was added methyl methacrylate (6,00 g, 60 mmol), the resulting mixture was heated to 65 °C and stirred for 5 days. The mixture was diluted with DCM, washed with water, brine, dried over Na?S0 4 , filtered and concentrated to afford the title compound.
- Step B 3-(( l-(tgrt-butoxycarbonyl)piperidin-4-yl amino)-2-rnethylpropanoic acid: To a solution of ferf-hutyl 4-((3-methoxy-2-methyl-3-oxopropyl)amino)piperidine-l-carboxylate (7.30 g, 24 mmol) in MeOH (40 mL) and water (20 mL) was added NaOH (1.40 g, 35 mmol) at room temperature, the mixture was stirred at room temperature for 16 hours. The mixture was washed by DCM; aqueous phase was acidified with 3 HCl to pH 7, concentrated to afford the title compound.
- Step C fert-butyl 4-(4-methyl-2-oxoimidazolidin- 1 -yl)piperidine- 1 -carboxylate: To a solution of DPPA (14.0 g, 51 mmol), TEA (5.60 g, 55 mmol) in toluene (40 mL) was added 3- ⁇ -(tert- butoxycarbonyl)piperidin-4-yl)amino)-2-methylpropanoic acid (6,60 g, crude), the resulting mixture was heated to reflux and stirred for 16 hours under N 2 protection. The mixture was diluted with DCM, washed with water, saturated sodium bicarbonate and concentrated; the residue was washed with a mixture of PE EtOAc (10: 1) to afford the title compound. " N TERMED I A TE 23
- Step B ferf-butyl 4-((2-( ' ethoxycarbonyl)butyl)amino piperidine-l -carboxylate: To a solution of ethyl 2-formylbutanoate (14.00 g, 97.2 mmol) and tert-bv&yl 4-aminopiperidine-l -carboxylate (20.00 g, 100 mmol) in DCM (200 mL) was added AcOH (11.50 g, 192 mmol), the mixture was stirred at room temperature for 4 h, then NaBH 3 CN (18.50 g, 294 mmol) was added, the mixture was stirred at same temperature for 16 h. The mixture was quenched by 100 mL of water, extracted by DCM, washed with water, brine, dried over Na 2 S0 4 and concentrated to afford the title compound.
- Step C 2-(((l-(fert-Butoxycarbonyl)piperidin-4-yl)amino)methyl)butanoic acid: To a solution of tert-butyl 4-((2-(ethoxycarbonyl)butyl)amino)piperidine-l -carboxylate (28.00 g, 85.3 mmol) in MeOH (100 mL) and water (40 mL) was added NaOH (4.10 g, 103 mmol) at room temperature, the mixture was stirred at room temperature for 16 hours. The mixture was washed by DCM; aqueous phase was adjusted to pH7 by 3 HC!, concentrated to afford the title compound.
- Step D ferf-butyl 4-(4-ethyl-2-oxoimidazolidin-l-yl)piperidine-l -carboxylate: To a solution of 2-(((l-(fert-butoxycarbonyl)piperidin-4-yl)amino)methyl)butanoic acid (17.00 g, crude) and TEA (11.00 g, 109 mmol) in toluene (400 mL) was added DPPA (28.00 g, 102 mmol), the resulting mixture was heated to reflux and stirred for 16 hours under N 2 protection. The mixture was cooled and concentrated, the residue was diluted with DCM, washed with water, saturated sodium bicarbonate, dried and concentrated, the residue was purified on silica gel (25% to 50% EtOAc in PE) to give the title compound.
- Step A fenf-butyl 4-(3-(3-chloropropyl )ureido)piperidine-l-carboxylate: 4- Amino- 1-BOC- piperidine ( 1 .00 g, 4.99 mmol), was dissolved in DCM (20 mL). The resulting solution was cooled to 0°C using an ice-water bath and sequentially treated with triethylarnine (1.740 mL, 12.48 mmol) and 3-chloropropyl isocyanate (0.564 mL, 5.49 mmol). The reaction mixture was warmed to ambient temperature and followed by LC/MS. After -1.5 h, LC 'MS indicated formation of the desired product. The reaction mixture was partitioned between DCM and saturated aq. NaHC0 3 . The organic layer was separated, dried (Na 2 S0 4 ), filtered and concentrated to afford the title compound.
- Step B ieri-butyl 4-(2-oxotetrahy dropyrimidin- 1 (2H)-yl)pi peri dine- 1 -carboxylate : fe/7-butyl 4- (3-(3-chloropropyl)ureido)piperidine-l-carboxylate (1.79 g, 5.60 mmol), was diluted in THF (20 mL) and cooled to 0°C using an ice-water bath. A 1M/THF solution of Li HMDS (6.72 mL, 6.72 mmol) was added dropwise over -10 min. The reaction mixture was allowed to gradually warm to ambient temperature.
- Step B benzyl 4-(trimethylsilyloxy )-5,6-dihydropyridine- 1 (2H)-carboxylate: Into a 10L 3 - necked round bottom flask was placed benzyl 4-oxopiperidine-l-carboxylate (1700 g, 7.29 mol, 1 .00 equiv), DMF (8500 ml) and TEA (2590 g, 25.59 mol, 3.51 equiv). To the above was added TMSCl (1587 g, 14,61 mol, 2.01 equiv) dropwise with stirring. The resulting solution was allowed to react, with stirring, overnight while the temperature was maintained at 85 °C.
- Step C 3-fluoro-4-oxopiperidine-l-carboxylate: Into a 10000 mL 3 -necked round bottom flask was placed benzyl 4-(trimethylsilyloxy)-5,6-dihydropyridine-l(2H)-carboxylate (365 g, 1.19 mol, 1 .00 equiv) and acetonitrile (5000 ml). To the above was added SelectFluor® (321 .5 g, 952.03 mmol, 0.99 equiv) in several batches at 0°C over 20 minutes. The resulting solution was allowed to react, with stirring, overnight while the temperature was maintained at room temperature.
- SelectFluor® 321 .5 g, 952.03 mmol, 0.99 equiv
- Step D benzyl czs-3-fluoro-4-hydroxypiperidine-l -carboxylate: Into a 5 L 4-neeked round bottom flask was placed a solution of benzyl 3 -fluoro-4-oxopiperidi ne- 1 -carboxyl ate (687 g, 2.73 mol, 1 .00 equiv) in methanol (3500 ml). To the mixture was added NaBH (83.8 g, 2.22 mol, 0.66 equiv) in several batches at 0°C. The resulting solution was stirred for 4 hours at room temperature.
- Step E fert-butyl c/ ' 5-3-fluoro-4-hydroxypiperidine-l-carboxylate: A mixture of benzyl cis-3- fluoro-4-hydroxypiperi dine- 1 -carboxyl ate (290 g, 1.15 mol, 1.00 equiv), Boc 2 0 (261 ,3 g, 1 .20 mol, 1.05 equiv) and Pd(OH) 2 /C (29 g, 10%) in methanol (2300 mi) was hydrogenated (8 atm) for 3 hours at room temperature. A filtration was performed. The filtrate was concentrated under vacuum.
- Step F fe/f-butyl c/ ' 5-3-fluoro-4-(methylsulfonyloxy)piperi dine- 1 -carboxyl ate: Into a 5000 ml 4- necked round bottom flask was placed a solution of /er/-butyl c/s-3-fluoro-4-hydroxypiperidine- 1-carboxylate (203 g, 925.88 mmol, 1.00 equiv) in DCM (2000 mi) and TEA (121.4 g, 1.20 mol, 1 .30 equiv).
- Step G fert-butyl traw5-4-azido-3-fluoropiperidine-l-carboxylate: Into a 5000 mi 4-necked round bottom flask was placed a solution of te/ -butyl 67s-3-fluoro-4- (methylsulfonyloxy)piperidine-l-carboxylate (275 g, 924.87 mmol, 1.00 equiv) in DMF (2100 ml). To the mixture was added NaN 3 (180,9 g, 2.78 mol, 3 ,02 equiv). The resulting solution was stirred overnight at 90 ⁇ 100°C in an oil bath.
- Step H tert-butyl tra;?s-4-amino-3-fluoropiperidine-l-carboxylate:
- Step I and J tert-butyl tm ⁇ 5-3-fluoro-4-(2-oxoimidazolidin-l -yl)piperidine-l-carboxylate:
- the title compound was prepared in two steps starting from tert-butyl tra «5-4-amino-3- fluoropiperidine-l-carboxylate and l -chloro-2-isocyanatoethane in an analogous fashion as described for tert-butyl 4-(2-oxoimidazolidin-l-yl)piperidine- l -carboxylate above (Intermediate 20).
- Step A eis-tert-butyl 4-(benzylamino)-3-fluoropiperidine-l-carboxylate: Into a 5000 ml 4- necked round bottom flask purged and maintained with an inert atmosphere of nitrogen was placed tert-butyl 3-fluoro-4-oxopiperidine-l-carboxylate (prepared as described above, 257 g, 1. 18 mol, 1.00 equiv) and THF (1850 ml). To the above was added BnNH 2 (143.9 g, 1.34 mol, 1.13 equiv) dropwise with stirring at 0°C.
- Step B c/s-fert-butyl 4-amino-3-fluoropiperidine-l- carboxylate: A mixture of c/s-tert-butyl 4- (benzylammo)-3-fluoropiperidine-l-carboxylate (128 g, 415.58 mmol, 1 .00 equiv) and
- Step C and D tert-butyl tmw5-3-fluoro-4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate:
- the title compound was prepared in two steps starting from rert-butyl tra «s-4-amino-3- fluoropiperidine-1 -carboxylate and l-chloro-2-isocyanatoethane in an analogous fashion as described for fert-butyl 4-(2-oxoimidazolidin-l-yl)piperidine-l -carboxylate above (intermediate 20).
- Step B fer r-butyl 4-( 1 -(fert-butoxycarbonyl)-2-oxopyrrolidin-3 -vDpiperazine- 1 -carboxylate : To an acetonitrile (10 ml) solution of fert-butyl 3-bromo-2-oxopyrrolidine-l-carboxylate ( 1 g, 3.79 mmol) was added potassium carbonate (1.570 g, 1 1.36 mmol) and 1 -BOC-piperazine (0,705 g, 3.79 mmol). The reaction mixture was heated to 40°C for 2 hours, cooled to ambient temperature and solids filtered.
- Step C 3-(piperazin-l-yl pyrrolidin-2-one: To a DCM (10 ml) solution of fer /-butyl A- ⁇ - tert- butoxycarbonyl)-2-oxopyrrolidin-3-yl)piperazine-l -carboxylate (1.15 g, 3.11 mmol) was added TFA (1.199 mL, 15.56 mmol). The mixture was allowed to stir at ambient temperature for 2 hours after which the solution was concentrated in vacuo. The crude residue was then diluted in methanol and passed through a 10G ion exchange resin. The free base was released using 4M ammonia in methanol to afford 3-(piperazin-l-yl)pyrrolidin-2-one.
- Step D /er/-butyl 4-f 2 ⁇ oxopyrrolidm-3 -vDpiperazine- 1 -carboxylate : To a THF (20 mL) solution of 3-(piperazin-l-yl)pyrrolidin-2-one (530 nig, 3.13 mmol) was added Hunig'sBase (0.547 mL, 3.13 mmol) and BOC-Anhydride (0.800 mL, 3.45 mmol). The mixture was heated to 40°C for 15 hours. After this time, the reaction mixture was cooled to ambient temperature, quenched with aqueous sodium bicarbonate and the aqueous layer was extracted with ethyl acetate (3 X 10 mL).
- Hunig'sBase 0.547 mL, 3.13 mmol
- BOC-Anhydride 0.800 mL, 3.45 mmol
- Step A methyl 4-cyano-2-fpyridin-4-yl)butanoate: To a solution of methyl 2-(pyridin-4- yOaeetate ( 10.0 g, 66 mmoi) in 20 mL of tert-butanol was added Triton B (0.4 mL) and acrylonitrile (7.00 g, 132 mmol) at 0°C. The resultant mixture was stirred at room temperature for 48 h.
- Step B 3-(pyridin-4-yl)piperidin-2-one: A mixture of methyl 4-cyano-2-(pyridin-4-yl)butanoate
- Step C j3,4'-bipiperidin]-2-one: 3-(Pyridin-4-yl)piperidin-2-one (3 ,80 g, 21.5 mmol) and Pt0 2 (0.38 g) in acetic acid (40 mL) was hydrogenated at 80°C for 37 h under 800 Psi of hydrogen, and then cooled to room temperature, filtered and concentrated to afford the title compound.
- H-NMR 400 MHz, MeOD) ⁇ ppm 4.19-4.05 (m, 2H), 3.28-3.
- Step A fert-butyl 4-(2-methoxy-2-oxoethylidene)piperidine-l -carboxylate: A mixture of 60% sodium hydride (1.30 g, 33 mmol) in 145 niL of DMF was cooled to 0°C, methyl 2- (dimethoxyphosphoryl)acetate (4.8 mL, 3 1 mmol) was then added drop wise. After 20 minutes at 0°C, a solution of tert-butyl 4-oxopiperidine-l-carboxylate (5.00 g, 25 mmol) in 13 mL of DMF was added dropwise. The reaction mixture was stirred at r.t.
- Step B fe/ -butyl 4-(2-methoxy-2-oxoethyl)piperidine-1 -carboxylate: Crude fert-butyl 4-(2- methoxy-2-oxoethylidene)piperidine-l-carboxylate above was hydrogenated with 0.7 g of 10% Pd/C in EtOAc/MeOH (1 : 1, 50 mL) under 55 Psi overnight, filtered and concentrated. The residue was purified by flash chromatography (PE: EtOAc from 15 : 1 to 8: 1 ) to afford the title compound.
- PE EtOAc from 15 : 1 to 8: 1
- Step C fert-butyl 4-(3 -cyano- 1 -methoxy- 1 -oxopropan-2-yl)piperidine- 1 -carboxylate: To a mixture of diisopropylamine (0.78 g, 7.8 mmol) in THF (10 mL) was added dropwi se with n- BuLi (2.7 mL, 6.8 mmol) at -60°C.
- Step D tert-butyl 4-(2-oxopyrrolidin-3-yl)piperidine-l-carboxylate: A mixture of Raney Ni (0.70 g), fcrt-butyl 4-(3-cyano-l-methoxy-l-oxopropan-2-yl)piperidine-l.-carboxylate (0.71 g, 2.3 rnrnol), 1.0 mL of ammonia in 40 mL of methanol was hydrogenated at 50 Psi and 80°C overnight. The mixture was filtered and concentrated. The residue was purified by
- Step A rert-butyl 4-( 1 -(fer ⁇ -Butoxycarbonyl)-2-oxopyrrolidin-3 -yQpiperidine- 1 -carboxylate: To a solution of ferf-hutyl 4-(2-oxopyrrolidin-3-yl)piperidine-l-carboxylate (1.00 g, 3.73 mmol) in 10 mL of CH 3 CN was added Boc 2 0 (1 ,20 g, 5.58 mmol), followed by DMAP (42 mg, 0,37 mmol), the resulting mixture was stirred at room temperature overnight and then concentrated, the residue was partitioned between H 2 0 and ethyl acetate, the organic layer was washed with 1 HO solution and brine, dried over anhydrous Na 2 S0 4 , filtered and concentrated, the residue was purified by flash chromatography eluted with 0 to 30% of ethyl acetate in PE to afford the title compound.
- Step B fer -butyl 4-(l-(tert-butoxycarbonylV3-methyl-2-oxopyrrolidin-3-yl piperidine-l- carboxylate: To a stirred solution of dry diisopropylamine (684 mg, 6.80 mmol) in 10 mL of dry THF was added w-BuLi (2.5 A/ in hexanes, 2,0 mL, 5.1 mmol) under N 2 atmosphere at -78°C, the reaction mixture was stirred at - 78 C 'C for 5 min and then warmed to 0 °C. After 30 min, the reaction was cooled to -78°C.
- Step C 3 -methyl -3 - piperi din-4-yl pyrrolidin-2-one : To a solution of t rt-butyl 4-(l-(tert- butoxycarbonyl)-3 -methyl -2-oxopyrrolidin-3 -yl )piperi dine- 1-carboxylate (2.75 g, 7.20 mmol) in EtOAc (25 mL) was added HCl/EtOAc (4 M, 28 mL) at room temperature, the resulting mixture was stirred at room temperature for 3 h. The mixture was concentrated to afford the title compound as hydrochloride.
- Step D tert-butyl 4-(3-methyl-2-oxopyrrolidin-3-vnpiperidine-l-carboxylate: To a solution of 3- methyl-3-(piperidin-4-yl)pyrrolidin-2-one (2.10 g, 11.5 mmol) and TEA (3.50 g, 34.6 mmol) in MeCN (25 mL) was added (Boe)?0 (3.80 g, 17.4 mmol) at room temperature, the resulting mixture was heated to 80°C and stirred for 6 hours.
- Step A ferf-butyl 4-(l-methoxy-4-methyl- l -oxopent-4-en-2-yl)piperidine-l-carboxylate:
- LiHMDS (1 .2 M in THF, 25 mL, 30 mL) was added dropwise to a solution of fert-butyl 4-(2- methoxy-2-oxoethyl)piperidine-l-carboxylate (5.00 g, 1.9 mmol) in THF (50 mL ) at -78°C.
- Step B ferr-butyl 4-(l-methoxy-l,4-dioxopentan-2-yl)piperidine-l-carboxylate: To a solution of tert-butyl 4-(l -methoxy-4-methyl-l-oxopent-4-en-2-yl)piperidine-l -carboxylate (300 mg, 0.96 mmol) in MeOH (3 mL) was added Os0 4 (2 mg, 0,01 mmol), followed by NaI0 4 (800 mg, 4.0 mmol ) in H 2 0 (3 mL), the resulting mixture was stirred at room temperature for 12 h. After removing the solvent and partitioned between with H?() and EtOAc, the organic layer was separated and concentrated to get the title compound.
- Step C ferf-butyl 4-(5-methyl-2-oxopyrrolidin-3-yl)piperidine-l-carboxylate: To a solution of fert-butyl 4-(l -methoxy-l ,4-dioxopentan-2-yl)piperidine-l-carboxylate ( 100 mg, 0.32 mmol) in MeOH (3 mL) was added NH 4 QAc (100 mg, 6.4 mmol), NaBH 3 CN (77 mg, 6.4 mmol) and MgS0 (160 mg, 6.4 mmol), and then the reaction mixture was heated under reflux overnight.
- NH 4 QAc 100 mg, 6.4 mmol
- NaBH 3 CN 77 mg, 6.4 mmol
- MgS0 160 mg, 6.4 mmol
- Step B ferf-butyl 4-(4-methoxy- 1 -nitro-4-oxobutan-2-yl)piperidine- 1 -carboxylate : To a mixture of (E tert-butyl 4-(3 -methoxy-3 -oxoprop- 1 -en- 1 -yl)piperidine- 1 -carboxylate (2.00 g, 7.4 mmol), in CH 3 NO 2 (20 mL) was added DBU (1.10 g, 7.4 mmol). The mixture was heated to reflux and stirred for 16 hours.
- Step C fert-butyl 4-(5-oxopyrrolidin-3-yl)piperidine-l -carboxylate: To a mixture of tert-buiyl 4- (4-methoxy-l-nitro-4-oxobutan-2-yl)piperidine-l -carboxylate (1.50 g, 4.5 mmol) in MeOH (20 mL) was added Raney Ni (200 mg). The mixture was stirred under H 2 atmosphere (balloon) at room temperature for 24 hours, then filtered and concentrated to afford the title compound.
- Step A fert-butyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxoimidazolidin-l - yOpiperidi ne- 1 -carboxyl ate: A mixture of fers-butyl 4-(2-oxoimidazolidin-l-yl)piperidine-l - carboxylate (5.38 g, 20 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (4.92 g, 20 mmol), Pd(OAc) 2 (0.22 g, 1 ,0 mmol), Cs 2 C0 3 (13.04 g, 40 mmol) and Xantphos (1.16 g, 2,0 mmol) in toluene (100 mL) and H 2 0 (1.08 g, 60 mmol) was stirred at 60°C
- Step A fert-butyl 4-(4-methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yn-2-oxoimidazolidin-l- vDpiperidi ne- 1 -carboxyl ate: A mixture of fers-butyl 4-(4-methyl-2-oxoimidazolidin-l - yl)piperidine-l-carboxylate (2.50 g, 8.8 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (2.80 g, 1 1 mmol), Pd 2 (dba) 3 (0.50 g, 0.55 mmol) and Xantphos (1.00 g, 1.7 mmol) in toluene (30 mL) was added Cs 2 C0 3 (8,60 g, 26 mmol), the mixture was heated to reflux, and stirred for 16 hours under N
- Step E 4-methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-l -(piperi din-4-yl)imidazolidin-2- one: To a solution of tert-butyl 4-(4-methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2- oxoimidazolidin- l-yl)piperidine-l-carboxylate (faster eluting peak from Step A, 470 mg, 1 .24 mmol) in 4 mL of EtOAc was added 5 mL of HCl / EtOAc, the mixture was stirred at room temperature for 3 h and then concentrated to afford the title compound as a single enantiomer (42A). Similarly, the slower eluting product from Step A could be converted to the enantiomeric title compound (42B) using HC1. The absolute stereochemistry of each product was not established; however, both
- Step E fenf-butyl 4-( " 4-ethyl-3-( " 4-methyl-5-oxo-2,5-dihvdrofuran-3-yl -2-oxoimidazolidin-l- yOpiperidine- 1 -carboxylate: To a mixture of tert -butyl 4-(4-ethyl-2-oxoimidazolidin-l- yl)piperidine-l-carboxylate (2,50 g, 8.41 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (2.70 g, 1 1.0 mmol), Pd 2 (dba) 3 (0.425 g, 0.436 mmol) and Xantphos (1.00 g, 1.73 mmol) in a toluene (100 mL) was added Cs 2 C0 3 (8.30 g, 25.5 mmol), then
- Step F 4-ethyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl )-l-(piperidin-4-yl)imidazolidin-2-one: ert-butyi 4-(4-ethyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxoimidazolidin-l- yl)piperidine-l -carboxylate (faster eluting isomer from Step A, 1 ,30 g, 3.3 mmol) in EtOAc (15 mL) was treated with HCl/EtOAc (4 M, 10 mL) and the resulting mixture was stirred at 25 °C for 18 h.
- Step A fert-butyl 4-(4-methyl-2-oxo-3-(5-oxo-2,5-dihydrofuran-3-yl )imidazolidin-l- yl piperidine-l-carboxylate: To a mixture of ferf-hutyl 4-(4-methyl-2-oxoimidazolidin-l- yl)piperidine-l -carboxylate (2.80 g, 9.88 mmol), 5-oxo-2,5-dihydrofuran-3-yl
- Step B 4-methyl-3-(5-oxo-2,5-dihydrofuran-3-yl)-l- ⁇ piperidin-4-yl )imidazolidin-2-
- (e (-butyl 4-(4-methyl-2-oxo-3-(5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-l - yl)piperidine-l -carboxylate first eluting in Step A under SFC chromatography, 220 mg, 0.60 mmol ) in EtOAc (2.5 mL) was added HCI/EtOAc (4,5 mL), the mixture was then stirred at room temperature for 24 hours, and then concentrated to afford the title compound as a single enantiomer 44A.
- the sl ower eluting product from Step A can be converted to the enantiomeric title compound (44B) using HCl.
- the absolute stereochemistry of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
- Step F l -(4-methyl-5-oxo-2,5-dihydrof iran-3-yl)-3-(piperidin-4-yl)pyrrolidin-2-one: 4-(l-(4- M €thyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxopyrrolidin-3-yl)piperidine-l-carboxylate (first peak in SFC, 100 mg, 0.28 mmol) was dissolved in 4 mL of EtOAc and treated with 6 mL of 4 M HCl/EtOAc. The mixture was then stirred at r.t. over night, and then concentrated to afford the title compound (49A) as a single enantiomer. Similarly, the opposite enantiomer (49B) was obtained from the second peak coming from SFC separation of the precursor using 4 M
- Step E tert-butyl 4-(3 -methyl - 1 -( 4-methyl-5 -oxo-2, 5 -di hydrofuran-3 -yl)-2-oxopyrrolidin-3 - yl )pi peri dine- 1 -carboxylate : A mixture of tert-butyl 4-(3-methyl-2-oxopyrrolidin-3- yl)piperidine-l -carboxylate (920 mg, 3.26 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (1.04 g, 4.22 mmol), Pd 2 (dba) 3 (159 mg, 0.163 mmol) and Xantphos (377 mg, 0.652 mmol) in toluene (30 mL) was added Cs 2 C0 3 (3 , 19 g, 9.79 mmol), the resulting mixture was heated to reflux and stirred
- Step F 3-methyl-l-(4-memyl-5-oxo-2.5-dihydrofuran-3-ylV3-(piperidin-4-yl)pyrroli
- Step A tert-butyl l-(4-methyl-5-oxo-2,5-dihvdrofuran-3-vn-2-oxo-[3.4'-bipiperidine1-l '- carboxylate: To a solution of tert-butyl 2-oxo-[3,4 !
- Step F 1 -(4-methyl-5-oxo-2.5-dihvdrofuran-3-yl)-
- Step A /er -butyl 4-hvdroxy-4-( l-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)-2-oxopyrrolidin-3- yl)piperidine-l -carboxylate: To a solution of tert-butyl 4-hydroxy-4-(2-oxopyrrolidin-3- yl)piperidine-l-carboxylate (2,00 g, 7.0 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (2.25 g, 9.2 mmol) in 40 mL of toluene was added Pd 2 (dba) 3 (322 mg, 0.35 mmol) and Xantphos (404 mg, 0.7 mmol) under N 2 atmosphere, followed by Cs 2 C0 3 (4.58 g, 14 mmol), the resulting mixture was heated at 100°
- Step B 3-(4-hydroxypiperidin-4-yl)-l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidi
- Step A fert-butyl 4-(l -(4-methyl-5-oxo-2.5-dihydrofuran-3-yl)-5-oxopyrrolidin-3-yl)piperidine- 1-carboxylate: The mixture of fert-butyl 4-(5-oxopyrrolidin-3-yl)piperidine-l-carboxylate (500 mg, 1.87 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (504 mg, 2.04 mmol), Xantphos (108 mg, 0, 187 mraol), Pd 2 (dba) 3 (86 rng, 0.094 mmol) and Cs 2 C0 3 (909,5 mg,
- Step B l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-4-(piperidin-4-yl)pyrrolidin-2-one: The mixture of tert-bu y] 4-(l -(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-5-oxopyrrolidin-3- yl)piperi dine- 1-carboxylate (160 mg, 0,44 mmol) in DCM: TFA (1 : 1, 4 mL) was stirred at ambient temperature for 1 hour. The mixture was concentrated to give the title compound. " N TERMED I A TE 54
- Step A benzyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate: To an ice-cooled ( X ' M (10 ml) solution of benzyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (890 mg, 3.60 mmol) was added Dess-Martin Periodinane (1679 mg, 3.96 mmol) portionwise over a period of 20 minutes.
- Step B (EVbenzyl 6-(3-methoxy-3-oxoprop-l-en-l-yl)-3-azabicyclo[3.1 ,0]hexane-3- carboxylate: In a microwave vial a toluene (10 mL) solution of benzyl 6-formyl-3 ⁇
- Step C benzyl 6-(4-methoxy- 1 -nitro-4-oxobutan-2-yl)-3 -azabicyclo[3.1.0]hexane-3 -carboxylate : To a THF (6 mL) solution of (Til-benzyl 6-(3-methoxy-3-oxoprop-l-en-l-yl)-3- azabicyclo[3.1.0]hexane-3 -carboxylate (773 mg, 2.57 mmol) was added nitrom ethane (0.207 mL, 3.85 mmol) and then TBAF (2.77 mL, 2.77 mmol). The reaction was heated to 70°C for 2 hours after which the mixture was cooled to ambient temperature, concentrated in vacuo and purified via MPLC (0-100% EtO Ac/Hex) to afford the title compound.
- Step D benzyl 6-(l-amino-4-methoxy-4-oxobutan-2-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate: To an ice-cooled acetic acid (7.50 mL) water (7.50 mL) mixture of benzyl 6-(4- methoxy- 1 -nitro-4-oxobutan-2-yl)-3 -azabicycio[3.1.0]hexane-3 -carboxylate (670 mg, 1.85 mmol) was added zinc (3020 mg, 46.2 mmol) in 500mg portions every 30 minutes. At about ⁇ 15 equivalents, the reaction mixture was warmed to ambient temperature and stirred for an additional 30 minutes.
- reaction was complete.
- the reaction mixture was filtered over a pad of celite and washed with -20 mL of ethyl acetate.
- the organics were then rotovapped off and the aqueous layer was made basic by addition of solid sodium bicarbonate.
- the basic aqueous layer was then extracted with 30% IPA/chloroform (3 X 10 mL).
- the combined organic layers were then dried over sodium sulfate, filtered, concentrated in vacuo to afford the title compound which was used without further purification.
- Step E benzyl 6-(5-oxopyrrolidin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate: To methanol (10 mL) solution of benzyl 6-(l-amino-4-methoxy-4-oxobutan-2-yl)-3-azabicyclo[3.1 .Ojjhexane- 3-carboxylate (570 mg, 1.72 mmol) was added potassium carbonate (237 mg, 1.72 mmol). The reaction mixture was allowed to stir at ambient temperature for 3 hours after which the mixture was concentrated in vacuo. Reverse phase Gilson purification afforded the title compound.
- Step F benzyl 6-(5-oxo-l-(5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-3-yl)-3- azabicyclo[3.1.0]hexane-3 -carboxylate: 4-Bromofuran-2(5H)-one (195 mg, 1.20 mmol), bis(dibenzylideneacetone)palladium (28.7 mg, 0.050 mmol), 4,5-Bis(diphenylphosphino)-9,9- dimethylxanthene (87 mg, 0.150 mmol), and cesium carbonate (488 mg, 1.50 mmol) were combined in a microwave vial and benzyl 6-(5-oxopyrrolidin-3-yl)-3-azabicyclo[3.
- Step G 4-(3-azabicyclo[3.1.0]hexan-6-yl)-l-(5-oxo-2,5-dihydrofuran-3-ynpyrrolidin-2-one: To a palladium on carbon (29.0 mg, 0.027 mmol) slurry in DCM (10 ml) was added benzyl 6-(5- oxo- 1 -(5-0X0-2, 5-dihydrofuran-3 -yl)pyrrolidin-3 -yl)-3 -azabicyclo[3.1.0]hexane-3 -carboxvlate (327 mg, 1.089 mmol) as a methanol (5.00 mL) solution.
- Step A l-fert-Butyl 4-ethyl 4-(2-((t g rt-butoxycarbonyl)amino)-l-hydroxyethyl)piperidine-1.4- di carboxylate: To a solution of LDA (prepared by adding «-butyllithium (20 mL, 49.3 mmol) to diisopropylamine (5.16 mg, 51.0 mmol) in THF (40 mL) at 0°C, stir for 30 min) was added 1- tert-butyl 4-ethyl piperidine-l ,4-dicarboxylate (4,00 g, 16.4 mmol) in TMEDA (15 mL, 99 mmol) dropwise via syringe pump at ⁇ 78°C for 10 min.
- LDA prepared by adding «-butyllithium (20 mL, 49.3 mmol) to diisopropylamine (5.16 mg, 51.0 mmol) in THF (40 mL
- Step B 1-tert-Butyl 4-ethyl 4-(2-oxooxazolidin-5-yl)piperidine-1.4-dicarboxylate: To a solution of 1 -tert-butyl 4-ethyl 4-(2-((tert-butoxycarbonyl)amino)- 1 -hydroxy ethyDpiperidine- 1 ,4- dicarboxylate (450 mg, 1.08 mmol) in DCM (10 mL) at -78°C was added tri ethyl amine trihydrofluoride (0.35 mL, 2.16 mmol), tri ethyl amine (0. 15 mL, 1.08 mmol), and
- Step C 1-fert-Butyl 4-ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxooxazolidin-5- yl)piperidine-1.4-dicarboxylate: To a round bottom flask was charged 1 -tert-butyl 4-ethyl 4-(2- oxooxazolidin-5-yl)piperidine- 1 ,4-dicarboxylate (180 mg, 0.526 mmol), 4 ⁇ methyl-5-oxo-2,5 ⁇ dihydrofuran-3-yl trifluoromethanesulfonate (155 mg, 0.631 mmol), Pd 2 (dba) 3 (12.0 mg, 0.013 mmol ), XantPhos (22,8 mg, 0.039 mmol), and cesium carbonate (343 mg, 1.05 mmol).
- Step D ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl -2-oxooxazolidin-5-yl)piperidine-4- carboxylate: 1-tert-Butyl 4-ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxooxazolidin- 5-yl)piperidine-l,4-dicarboxylate (230 mg, 0.525 mmol) in DCM (2.6 mL) was treated with TFA ( 1.2 mL, 15.7 mmol) at 0°C to free Boc and give TFA salt.
- Step B tot-butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-y0pyridin-2- vDpiperazine- 1 -carboxylate: tot-butyl 4-(5-bromo-4-methylpyridin-2-yl)piperazine-l- carboxylate (0.80 g, 2.331 mmol) was mixed with bis(pinacolato)diboron (0.710 g, 2.80 mmol) and potassium acetate (0.686 g, 6.99 mmol) in 1,4-dioxane (18 mL).
- Step C tot-butyl 4-(4-methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperazine- 1 -carboxylate: In a microwave vial, tot-butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)pyridin-2-yl)piperazine-l -carboxylate (0.9 g, 2.231 mmol) was mixed with 4- methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (0.824 g, 3.35 mmol) in tetrahydrofuran (8 ml) and sodiumbicarbonate and water (8 mi).
- Step D 3-methyl-4-(4-methyl-6-(piperazin-l-yl)pyridin-3-yl)f iran-2(5H)-one: ert-butyi 4-(4- methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperazine-l-carboxyk was dissolved in DCM and treated with TFA. The reaction was monitored by LC-MS until completion whereupon the volatiles were removed under vacuum to afford the title compound.
- Step A rert-butyl 4-(5-bromopyridin-2-yl)piperazine-l-carboxylate: To a solution of tert-butyl piperazine-l-carboxylate (1.00 g, 5.37 mmol) in DMF (2ml) and THF (10 mi) in a 20 mL microwave vial was added DIEA (1.125 mL, 6,44 mmol) and the mixture was heated at 160°C for 100 minutes. The solvent was removed after cooling to room temperature, the residue was dissolved in EtOAc (50 ml) and was washed with water (30 mi ) followed by Brine (20 ml).
- Steps B through D 4-(6-(piperazin-l-yl)pyridin-3-yl)furan-2(5i -one: The title compound was prepared in an analogous fashion as described for Intermediate 58 (Steps B-D), immediately above, starting from tert-butyl 4-(5-bromopyridin-2-yl)piperazine-l-carboxylate. LC-MS [M+l] + 246.1
- Step A fert-butyl 5-chloro-5'6'-dihydro- 2,4 l --bipyridine]- (2'H)--carboxylate:
- 2-bromo-5-chloropyridine 0.34 g, 4.85 mmol
- /er/-butyl 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-l(2H)-carboxylate (l .Og, 3.23 mmol) in tetrahydrofuran (8 nil) and sodium bicarbonate (0,543 g, 6.47 mmol) and water (8 n L).
- Step B ferr-butyl 5-(4,4,5,5 etramethyl-l,3,2-dioxaborolan--2-yl)-5',6'-dihydiO-j ' 2,4 l --bipyridine]- l'(2'H)-carboxylate: ieri-huty] 5-chloro-5 , 6'-dihydro-[2,4 , -bipyridine]-r(2'H)-carboxylate (410 mg, 1.391 mmol), bis(pinacolato)diboron (1060 mg, 4.17 mmol), 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl (13.26 mg, 0.028 mmol), potassium acetate (410 mg, 4.17 mmol) and tris(dibenzylideneacetone)dipalladiurn(0) (12,74 mg, 0.014 mmol) were taken up in 1,4
- Step C fe/V-butyl 5-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)-5',6'-dihydro-r2,4'-bip ⁇ i Tidinel- 1 '(2'H)-carboxylate :
- the title compound was prepared from rert-butyl 5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-5 , ,6'-dihydro-[2,4 , -bipyridine]- (2'H)-carboxylate and 4-methyl-5-oxo- 2,5-dihydrofuran-3-yl trifluoromethanesulfonate in an analogous fashion as described for tert- butyl 4-(4-methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran
- Step D fert-butyl 4-(5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperidine-l- carboxylate:
- Step E 3-methyl-4-(6-(piperidin-4-yl)pyridin-3-yl)furan-2(5H)-one:
- the title compound was prepared from fert-butyl 4-(5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperidine-l- carboxylate in an analogous fashion to that described for 3 -methyl -4-(4-methyl-6-(piperazin-l - yl)pyridin-3-yl)furan-2(5H)-one INTERMEDIATE 59 (Step D) using TFA.
- Step A tert-butyl 4-(l H-L2,4-triazol-3-yl)piperidine-l -carboxylate: To a solution of tert-butyl 4-cyanopiperidine-l-carboxylate (32.75 g, 156 rnmol) in MeOH (280 ml.) was added a solution of NaOMe (2.50 g, 47 mmol) in 5 niL of MeOH.
- Step B ferr-butyl 4-(l-(4-memyl-5-oxo-2,5-dihvdrofuran-3-yl)-lH-l,2,4-triazol-3-yl)piperidine- 1-carboxylate: To a solution of fert-butyl 4-(l H-l ,2,4-triazol-3-yl)piperidine-l -carboxylate (1 .00 g, 4.0 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (1.30 g, 5.2 mmol) in 20 mL of toluene was added Pd-1 18 (200 mg) under N 2 atmosphere, followed by Cs 2 C0 3 (2.60 g, 8,0 mmol), the resulting mixture was heated at 90°C overnight under ? atmosphere, then cooled to room temperature, filtered and the solvent was removed under vacuum, the residue was purified by flash chromatography
- Step C 3 -methyl -4-(3 -(piped din-4-yl)- ill- 1.2.4-triazol- 1 -yl)furan-2(5H)-one: To a solution of tert-butyl 4-(l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-lH-l,2,4-triazol-3-yl)piperidine-l- carboxylate (230 mg, 0.66 mmol) in 3 mL of EtOAc was added 3 mL of HCl/EtOAc, the mixture was stirred at room temperature for 3 h, then concentrated to afford the title compound.
- reaction mixture was evaporated for purifcation by ISCO (0-10% MeOH/DCM) to provide the product as a free base which was separated to two single diastereomers by SFC chiral chroraatography: Column AS-H (2 x 25 era), eluent 40% methanol (0.1% DEA)/C02, 100 bar, flow rate 65 mL/min, detection wavelength 254 nm, injection volume. : 1 mL, 13mg mL 1 : 1 DCM:methanol.
- Step A 4-methyl-5-( " prop- 1 -en- 1 -yl)i sobenzofuran- 1 (3H)-one: To a solution of 4-m ethyl -1-oxo- l,3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (1.50 g, 5.1 mmol) in 30 mL of THF was added (E)-prop-l-en- l-ylboronic acid (700 mg, 1.6 mmol) and Pd-1 18 (326 mg, 0.5 mmol) under N 2 atmosphere, followed by K 3 P0 4 (2.15 g, 10 mmol, 1 M in H 2 0).
- Step B 5-(l ,2-dihvdroxypropyl)-4-methylisobenzofuran- 1 (3H)-one: To a solution of 4-methyl-5- (prop-l -en-l -yl)isobenzofuran-l(3H)-one (930 mg, 4.9 mmol) in 40 mL of CH 3 CN and 4 mL of water was added NMO (746 mg, 5.4 mmol), followed by K 2 0s0 5 - 2H 2 0 (91 mg, 0.25 mmol) at 0°C, the resulting mixture was warmed to room temperature and stirred for 2 hrs under N 2 atmosphere. The resulting mixture was diluted with DCM and washed with Na 2 S 2 0 3 solution (25% aq) and water, the organic layer was dried over anhydrous Na 2 S0 4 , filtered and
- Step C 1 -( 1 -( 1 -hydroxy- 1 -(4-methyl- 1 -oxo- 1 , 3 -dihydroi sobenzofuran- 5 -yl )propan-2- yl)piperidin-4-yl )-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one: To a MW vial was charged with 5-(l,2-dihydroxypropyl)-4-methylisobenzofuran- l (3H)-one (170 mg, 0.76 mmol), l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (243 mg, 0.92 mmol), Ru 3 (CO) 12 ( 147 mg, 0.23 mmol ), 2-(dicyclohexylphosphino)-l-phenyl-lH-
- a Thallium Flux Assay was performed on the compounds of the Examples. This assay has been described previously; see, e.g., PCT Published Application WO 2013/062900.
- Kir 1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al . Pfluegers Archives 391 :85-100 (1981 )) using the IonWorks Quattro automated eiectrophysiology platform (Molecular Devices, Sunnyvale, CA). Chinese hamster ovary cells stably expressing KM .1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% C0 2 incubator at 37°C. Prior to an experiment, Kirl . l expression was induced by overnight incubation with 1 mM sodium butyrate.
- the intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl 2 , 3 EGTA, and 5 Hepes, at pH 7.4. Electrical access to the cytoplasm was achieved by perforation in 0.13 mg/mL amphotericin B for 4 min. Amphotericin B (Sigma A- 4888) was prepared as a 40 mg/mL solution in DMSO.
- Voltage protocols and current recordings were performed using the IonWorks HT software/hardware system. Currents were sampled at 1 kHz. There was no correction for liquid junction potentials.
- the test pulse consisting of a 100 ms (millisecond) step to 0 mV (millivolts) from a holding potential of -70 mV, followed by a 100 ms voltage ramp from -70 mV to +70 mV, was applied before and after a 6 min compound incubation period.
- Test compounds were prepared by diluting DMSO stock solutions into the bath solution at 3x the final concentration and placed in the instrument in 96-well polypropylene plates. Current amplitudes were measured using the IonWorks software.
- control compound is typically included to support that the assay is giving consistent results compared to previous measurements.
- the control can be any compound of Formula I of the present invention, preferably with an IC 50 potency of less than I uM in this assay.
- control could be another compound (outside the scope of Formula I) that has an IC 50 potency in this assay of less than 1 ⁇ .
- the spontaneously hypertensive rat exhibits age-dependent hypertension that does not require administration of exogenous agents to elevate blood pressure nor does it require the use of a high salt diet to elevate blood pressure. Thus it resembles human essential hypertension and provides an opportunity to assess the dose-dependence of novel agents for their ability to Iwer blood pressure.
- HCTZ 25 mg/kg/day, PO
- the blood pressure lowering efficacy of compounds of the present invention compared to vehicle control was evaluated following a single oral gavage each day for a typical duration of three to fourteen da . Data were collected as hourly averages, and changes in blood pressure were calculated by subtracting vehicle control baseline data on an hourly basis.
- the Spontaneously Hypertensive Rat Assay is well known and often used in the art as an experimental model simulating human hypertension (see, e.g., Lerman, L.O., et ai., J Lab Clin Med, 2005; 146: 160-173).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides compounds of Formula (I); and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
Description
TITLE OF THE INVENTION
INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL
BACKGROUND OF THE INVENTION
The Renal Outer Medullary Potassium (ROMK) channel (Kirl .1) (see e.g., Ho,
K., et a!.. Cloning and expression of an inwardly rectifying ATI* -regulated potassium channel, Nature, 1993, 362(6415): p. 31-8.1, 2, and Shuck, M.E., et al.. Cloning and characterization of multiple forms of the human kidney ROAd-K potassium channel, J Biol Chem, 1994, 269(39): p. 24261-70) is a member of the inward rectifier family of potassium channels expressed in two regions of the kidney: thick ascending loop of Henle (TALH) and cortical collecting duct (CCD) (see Hebert, S.C., et al., Molecular diversity and regulation of renal potassium channels, Physiol Rev, 2005, 85(1): p. 319-713). At the TALH, ROMK participates in potassium recycling across the luminal membrane which is critical for the function of the Na+/K+/2C1- co-transporter, the rate-determining step for salt reuptake in this part of the nephron. At the CCD, ROMK provides a pathway for potassium secretion that is tightly coupled to sodium uptake through the amiloride-sensitive sodium channel (see Reinalter, S.C., et al., Pharmacotyping o ' hypokalemic salt-losing tubular disorders, Acta Physiol Scand, 2004, 181(4): p. 513-21; and Wang, W., Renal potassium channels: recent developments, Curr Opin Nephrol Hypertens, 2004, 13(5): p. 549- 55). Selective inhibitors of the ROMK channel (also referred to herein as inhibitors of ROMK or ROM K inhibitors) are expected to represent novel diuretics for the treatment of hypertension and other conditions where treatment with a diuretic would be beneficial with potentially reduced liabilities (i.e., hypo- or hyperkalemia, new onset of diabetes, dyslipidemia) over the currently used clinical agents (see Lifton, R.P., A.G. Gharavi, and D. S. Geller, Molecular mechanisms of human hypertension, Cell, 2001, 104(4): p. 545-56). Human genetics (Ji, W., et al., Rare independent mutations in renal salt handling genes contribute to blood pressure variation, Nat Genet, 2008, 40(5): p. 592-9; and Tobin, M.D., et al., Common variants in genes underlying monogenic hypertension and hypotension and blood pressure i the general population.
Hypertension, 2008, 51(6): p. 1658-64) and genetic ablation of ROMK in rodents (see Lorenz, J.N,, et al ., Impaired renal NaCl absorption in mice lacking the ROMK potassium channel, a model for type II Bartter's syndrome, J Biol Chem, 2002, 277(40): p. 37871-80 and Lu, M., et al., Absence of small conductance K channel (SK) activity in apical membranes of thick ascending limb and cortical collecting duct in ROMK (Bartter's) knockout mice, J Biol Chem, 2002, 277(40): p. 37881-7) support these expectations. To our knowledge, the first publicly
disclosed small molecule selective inhibitors of ROMK, including VU590, were reported from work done at Vanderbilt University as described in Lewis, L.M., et al., High-Throughput Screening Reveals a Small-Molecule Inhibitor of the Renal Outer Medullary Potassium Channel andKir .f Mol Pharmacol, 2009, 76(5): p. 1094-1103. The compound VU591 was later reported in Bhave, G. et al., Development of a Selective Small-Molecule Inhibitor of Kir 1.1, the Renal Outer Medullary Potassium Channel, Mol Pharmacol, 2011, 79(1), p.42-50, the text of which states that "ROMK (Kirl . l), is a putative drug target for a novel class of loop diuretics that would lower blood pressure without causing hypokalemia."
Since then, other ROMK inhibitors have been described.
The continued discovery of selective small molecule inhibitors of ROMK is needed for the development of new treatments for hypertension, heart failure, edematous states and related disorders. The compounds of Formula I and salts thereof of this invention are selective inhibitors of the ROMK channel and could be used for the treatment of hypertension, heart failure and other conditions where treatment with a diuretic or natriuretic would be beneficial.
SUMMARY OF THE INVENTION
The present invention rovides compounds of Formula I
and the pharmaceutically acceptable salts thereof The compounds of Formula I are inhibitors of the ROMK (Kirl .1) channel. As a result, the compounds of Formula I could be used in methods of treatment, inhibition or amelioration of one or more disease states that could benefit from inhibition of ROMK. The compounds of this invention could be used in methods of treatment which comprise administering a therapeutically or prophyiactically effective amount of a compound of Formula I to a patient in need of a diuretic and/or natriuretic agent. Therefore, the compounds of Formula I could be valuable pharmaceutically active compounds for the therapy, prophylaxis or both of medical conditions, including, but not limited to, cardiovascular diseases such as hypertension and heart failure as well as chronic kidney disease, and conditions associated with excessive salt and water retention. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not
limited to, other drugs which are useful for the treatment of hypertension, heart failure and conditions associated with excessive salt and water retention. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which compri se compounds of Formula I These and other aspects of the invention wil l be evident from the description contained herein.
DETAILED DESCRIPTION OF THE INVENTION
The resent invention provides compounds of Formula I
atoms which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C1-3 alky] ,
R1 is H, OH or 0(C1-3 alkyl);
R2 is H or C1-3 aikyl;
R4 is H or C1-3 alkyl;
R5 is H or C1-3 alkyl,
R" is H or C]_3 alkyl;
R7 is H, C1.3 alkyl or 0(Ci.3 alkyl),
R:iisll orO,.;alkyi:
Rb is H, OH, <',., alkyl or (C 0)(K , alkyl;
R; is H, halo, C1-3 alkyl or 0(C1-3 alkyl),
n is 0, 1 or 2;
is an optional bond;
or a pharmaceutically acceptable salt thereof.
The resent invention also relates to compounds of F
atoms which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C1-3 alkyl;
R S H, OHorO(C i alkyl),
R is H or C1-3 alkyl;
R4 is H or C1- alkyl;
R" is H or C , alkyl,
R6 is H or C1-3 alkyl;
R:iis Il orO,.;alkyi:
R is H, OH, C1-3 alkyl or (OO C^ alkyl;
R; is H, halo, C1-3 alkyl or 0(C1-3 alkyl);
or a pharmaceutically acceptable salt thereof.
In an embodiment of the invention, X is N. In another embodiment of the invention, N is CR .
In an embodiment of the invention, Z is O. In another embodiment of the invention, Z i CH2.
pyridinyl, pyrazinyl or pyndazinyl, wherein said pyridinyi, pyrazinyi or pyndazinyl are optionally substituted with one or two substituents independently selected from the roup
another class of the embodiment, A is
. In another class of the embodiment, A is pyridinyl, which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C1-3 alkyl. In another class of the embodiment, A is pyrazinyl, which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C ? alkyl. In another class of the embodiment, A is pyridazinyl, which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazolyl and C1-3 alkyl.
In an embodiment of the invention, R1 is I E n another embodiment of the invention, R1 is OH. In another embodiment of the invention, R1 is Ο(01-3 alkyl). In a class of the embodiment, R1 is OCH3. In another class of the embodiment, R1 is OCH2CH3.
In an embodiment of the invention, R is I E In another embodiment of the invention, R is C1-3 alkyl. In a class of the embodiment, R" is CH
In an embodiment of the invention, R4 is H. In another embodiment of the invention, R4 i s C1-3 aikyl. In a class of the embodiment, R4 is CH3.
In an embodiment of the invention, R5 is H. In another embodiment of the invention, R5 is C1-3 alkyl. In a class of the embodiment, R' is CI¾. In another class of the embodiment, R5 is CH2CH3.
In an embodiment of the invention, R6 is H. In another embodiment of the invention, R6 is C1-3 alkyl. In a class of the embodiment, R6 is CH3.
In an embodiment of the invention, R' is H. In another embodiment of the invention, R' is 0(C1 -3 aikyl). In a class of the embodiment, R' is OCH .
In an embodiment of the invention, Rd is H. In another embodiment of the invention, Ra is C1-3 alkyl. In a class of the embodiment, Ra is CH3.
In an embodiment of the invention, R is H. In another embodiment of the invention, Rb is OH. In another embodiment of the invention, Rb is Cf .3 alkyl. In another embodiment of the invention, R is (C=0)OC1-3 alkyl. In a class of the embodiment, R is (C=0)OCH2CH3.
In an embodiment of the in venti on, iV is I E In another embodiment of the invention, Rx is halo. In another embodiment of the invention, R¾ is Q.3 alkyl. In another embodiment of the invention, Rx is 0(C1-3 alkyl).
In an embodiment of the invention, n is 0. In another embodiment of the invention, n is 1. In another embodiment of the invention, n is 2.
Reference to the preferred classes and subclasses set forth above is meant to include ail combinations of particular and preferred groups unless stated otherwise.
Specific embodiments of the present invention include, but are not limited to the compounds identified herein as Examples 1 to 61, or pharmaceutically acceptable salts thereof.
Also included within the scope of the present invention is a pharmaceutical composition which is comprised of a compound of Formula I or Formula la as described above and a pharmaceutically acceptable carrier. The invention is also contemplated to encompass a pharmaceutical composition which is comprised of a pharmaceutically acceptable carrier and any of the compounds specifically disclosed in the present application. These and other aspects of the in vention will be apparent from the teachings contained herein.
It will be understood that, as used herein, the compounds of the instant invention can also include the pharmaceutically acceptable salts, and also salts that are not
pharmaceutically acceptable when they are used as precursors to the free compounds or their pharmaceutically acceptable salts or in other synthetic manipulations.
The compounds of the present invention may be administered in the form of a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts of basic compounds encompassed within the term "pharmaceutically acceptable salt" refer to non-toxic salts of the compounds of this invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts of basic compounds of the present invention include, but are not limited to, the following: acetate, ascorbate, adipate, alginate, aspirate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, eamphorate,
camphorsulfonate, camsyiate, carbonate, chloride, clavulanate, citrate, cyclopentane propionate, diethylacetic, digluconate, dihydrochloride, dodecylsulfanate, edetate, edisylate, estolate, esylate, ethanesulfonate, formic, fumarate, gluceptate, glucoheptanoate, gluconate, glutamate, glycerophosphate, glycollylarsanilate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hy drab amine, hydrobromide, hydrochloride, 2-hydroxyethanesulfonate, hydroxynaphthoate, iodide, isonicotinic, isothionate, lactate, iactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methyl sulfate, methanesulfonate, mucate, 2- naphthalenesulfonate, napsylate, nicotinate, nitrate, N-methylglucamine ammonium salt, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, pectinate, persuifate,
phosphate/di phosphate, pimelic, phenyl propionic, polygalacturonate, propionate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, thiocyanate, tosyiate, triethiodide, trifluoroacetate, undeconate, valerate and the like. Furthermore, where the compounds of the invention earn,' an acidic moiety, suitable pharmaceutically acceptable salts thereof include, but are not limited to, salts derived from inorganic bases including aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic, mangamous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, cyclic amines, dicyclohexyl amines and basic ion-exchange resins, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanoi, 2-dimethylaminoethanol, ethanolamine, ethylamine, ethyl enedi amine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, moipholine,
piperazine, piperidine, polyamine resins, procaine, purines, theobromine, tri ethyl amine, trimethylamine, tripropyi amine, tromethamine, and the like. Also, included are the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; di alkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and steaiyl chlorides, bromides and iodides, aralkyf halides like benzyl and phenethyl bromides and others.
These salts can be obtained by known methods, for example, by mixing a compound of the present invention with an equivalent amount and a solution containing a desired acid, base, or the like, and then collecting the desired salt by filtering the salt or distilling off the solvent. The compounds of the present invention and salts thereof may form solvates with a solvent such as water, ethanol, or glycerol. The compounds of the present invention may form an acid addition salt and a salt with a base at the same time according to the type of substituent of the side chain.
The present invention encompasses all stereoisomer! c forms of the compounds of Formula I or Formula la. Unless a specific stereochemistry is indicated, the present invention is meant to comprehend all such isomeric forms of these compounds. Centers of asymmetry that are present in the compounds of Formula I or Formula la can all independently of one another have (R) configuration or (S) configuration. When bonds to the chiral carbon are depicted as straight lines in the structural Formulas of the invention, it is understood that both the (R) and (S ) configurations of the chiral carbon, and hence both enantiomers and mixtures thereof, are embraced within the Formula. Similarly, when a compound name is recited without a chiral designation for a chiral carbon, it is understood that both the (R) and (S) configurations of the chiral carbon, and hence individual enantiomers and mixtures thereof, are embraced by the name. The production of specific stereoisomers or mixtures thereof may be identified in the Examples where such stereoisomers or mixtures were obtained, but this in no way limits the inclusion of all stereoisomers and mixtures thereof from being within the scope of this invention.
The invention includes all possible enantiomers and diastereomers and mixtures of two or more stereoisomers, for example mixtures of enantiomers and/or diastereomers, in all ratios. Thus, enantiomers are a subject of the invention in enantiomerically pure form, both as levorotatory and as dextrorotatory antipodes, in the form of racemates and in the form of mixtures of the two enantiomers in ail ratios. In the case of a cis/trans isomerism the invention includes both the cis form and the trans form as well as mixtures of these forms in all ratios. The preparation of individual stereoisomers can be carried out, if desired, by separation of a mixture
by customary methods, for example by chromatography or crystallization, by the use of stereochemically uniform starting materials for the synthesis or by stereoselective synthesis. Optionally a derivatization can be carried out before a separation of stereoisomers. The separation of a mixture of stereoisomers can be carried out at an intermediate step during the synthesis of a compound of Formula I or Formula la or it can be done on a final racemic product. Absolute stereochemistry may be determined by X-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing a stereogenic center of known configuration. Where compounds of this invention are capable of tautomerization, all individual tautomers as well as mixtures thereof are included in the scope of this invention. Unless a particular isomer, salt, solvate (including hydrates) or solvated salt of such racemate, enantiomer, diastereomer or tautomer is indicated, the present invention includes ail such isomers, as well as salts, solvates (including hydrates) and solvated salts of such racemates, enantiomers, diastereomers and tautomers and mixtures thereof.
In the compounds of the invention, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the specifically and generically described compounds. For example, different isotopic forms of hydrogen (H) include protium (iH) and deuterium (¾). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the general process schemes and examples herein using appropriate isotopically- enriched reagents and/or intermediates.
When any variable (e.g. IRS, etc.) occurs more than one time in any constituent, its definition on each occurrence is independent at every other occurrence. Also, combinations of substituents and variables are permissible only if such combinations result in stable compounds, Lines drawn into the ring systems from substituents represent that the indicated bond may be attached to any of the substitutable ring atoms. If the ring system is bicyclic, it is intended that the bond be attached to any of the suitable atoms on either ring of the bicyclic moiety.
It is understood that one or more silicon (Si) atoms can be incorporated into the compounds of the instant i nvention in place of one or more carbon atoms by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art from readily available starting materials. Carbon and silicon differ in their covalent radius leading to differences in bond distance and the steric arrangement when comparing analogous C-eiement and Si-element bonds. These differences lead to subtle changes in the size and shape of silicon-containing compounds when compared to carbon. One of ordinary skill in the art would understand that size and shape differences can lead to subtle or dramatic changes in potency, solubility, lack of off -target activity, packaging properties, and so on. (Diass, J. O. et al. Organometallics (2006) 5: 1 188-1198, Showell, G.A. et al. Bioorganic & Medicinal Chemistry Letters (2006) 16:2555-2558).
It is understood that substituents and substitution patterns on the compounds of the instant inventi on can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those methods set forth below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups may be on the same carbon or on different carbons, so long as a stable structure results. The phrase
"optionally substituted" (with one or more substituents) should be understood as meaning that the group in question is either unsubstituted or may be substituted with one or more substituents.
Furthermore, compounds of the present invention may exist in amorphous form and/or one or more crystalline forms, and as such all amorphous and crystalline forms and mixtures thereof of the compounds of Formula I or Formula la are intended to be included within the scope of the present invention. In addition, some of the compounds of the instant invention may form solvates with water (i.e., a hydrate) or common organic solvents. Such solvates and hydrates, particularly the pharmaceutically acceptable solvates and hydrates, of the instant compounds are likewise encompassed within the scope of this invention, along with un-soivated and anhydrous forms.
Reference to the compounds of this invention as those of a specific formula or embodiment, e.g., Formula I or Formula la or any other generic structural formula or specific compound described or claimed herein, i s intended to encompass the specific compound or compounds falling within the scope of the formula or embodiment, including salts thereof, particularly pharmaceutically acceptable salts, solvates of such compounds and solvated salt forms thereof, where such forms are possible unless specified otherwise.
Also, in the case of a carboxylic acid (-COOH) or alcohol group being present in the compounds of the present invention, pharmaceutically acceptable esters of carboxylic acid derivatives, such as methyl, ethyl, or pivaloyloxymethyl, or acyl derivatives of alcohols, such as O-acetyl, O-pivaloyl, O-benzoyl, and O-aminoacyl, can be employed. Included are those esters and acyl groups known in the art for modifying the solubility or hydrolysis characteristics for use as sustained-release or prodrug formulations.
If the compounds of Formula I or Formula la simultaneously contain acidic and basic groups in the molecule the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). Salts can be obtained from the compounds of Formula I or Formula la by customary methods which are known to the person skilled in the art, for example by combination with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange from other salts. The present invention also includes all salts of the compounds of Formula I or Formula la which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, for example, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
Any pharmaceutically acceptable pro-drug modification of a compound of this invention which results in conversion in vivo to a compound within the scope of this invention is also within the scope of this invention. For example, esters can optionally be made by esterification of an available carboxylic acid group or by formation of an ester on an available hydroxy group in a compound. Similarly, labile amides can be made. Pharmaceutically acceptable esters or amides of the compounds of this invention may be prepared to act as prodrugs which can be hydrolyzed back to an acid (or -COO- depending on the pH of the fluid or tissue where conversion takes place) or hydroxy form particularly in vivo and as such are encompassed within the scope of this invention. Examples of pharmaceutically acceptable pro- drug modifications include, but are not limited to, -C1-6alkyi esters and ~C1-6alkyl substituted with phenyl esters.
Accordingly, the compounds within the generic structural formulas, embodiments and specific compounds described and claimed herein encompass salts, ail possible
stereoisomers and tautomers, physical forms (e.g., amorphous and crystalline forms), solvate and hydrate forms thereof and any combination of these forms, as well as the salts thereof pro-drug forms thereof, and salts of pro-drug forms thereof, where such forms are possible unless specified otherwise.
Except where noted herein, the term "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification, e.g. methyl, may be represented by conventional abbreviations including "Me" or CH3 or a symbol that is an extended bond as the terminal group, e.g. ^ , ethyl may be represented by "Et" or CH2.CH3, propyl may be represented by "Pr" or CH2CH2CH3, butyl may be represented by "Bu" or CH2CH2CH2CH3, etc. "C].4 alkyl" (or "C1-C4 alkyl") for example, means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms. For example, the structures
have equivalent meanings, C1-4 alkyl includes n~, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. If no number is specified, 1-4 carbon atoms are intended for linear or branched alkyl groups.
Except where noted herein, "alkanol" is intended to include aliphatic alcohols having the specified number of carbon atoms, such as methanol, ethanol, propanol, etc., where the -OH group is attached at any aliphatic carbon, e.g., propan-l -ol, propan-2-ol, etc.
Except where noted, the term "halogen" or "halo" means fluorine, chlorine, bromine or iodine.
"Celite®" (Fiuka) diatomite is diatomaceous earth, and can be referred to as
Except where noted herein, structures containing substituent variables such as variable "R" below:
Vi
N
11
iii iv
which are depicted as not being attached to any one particular bicyclic ring carbon atom, represent structures in which the variable can be optionally attached to any bicyclic ring carbon atom. For example, variable R shown in the above structure can be attached to any one of 6 bicyclic ring carbon atoms i, ii, iii, iv, v or vi.
Except where noted herein, bi cyclic ring systems include fused ring systems, where two rings share two atoms, and spiro ring systems, where two rings share one atom.
The invention also includes derivatives of the compounds of Formula I or Formula la, acting as prodrugs and solvates. Prodrugs, following administration to the patient, are converted in the body by normal metabolic or chemical processes, such as through hydrolysis in the blood, to the compound of Formula I or Formula la. Such prodrugs include those that demonstrate enhanced bioavailability, tissue specificity, and/or cellular delivery, to improve drag absorption of the compound of Formula I or Formula la. The effect of such prodnigs may result from modification of physicochemical properties such as iipophilicity, molecular weight, charge, and other physicochemical properties that determine the permeation properties of the drug.
The invention also relates to medicaments containing at least one compound of the Formula I or Formula la and/or of a pharmaceutically acceptable salt of the compound of the Formula I or Formula la and/or an optionally stereoisomeric form of the compound of the Formula I or Formula la or a pharmaceutically acceptable salt of the stereoisomeric form of the compound of Formula I or Formula la, together with a pharmaceutically suitable and
pharmaceutically acceptable vehicle, additive and/or other active substances and auxiliaries.
The compounds of Formula I or Formula la according to the invention are inhibitors of ROMK, and therefore could be used as diuretic and/or natriuretic agents. ROMK. inhibitors may be used to help to increase urination and increase urine volume and also to prevent or reduce reabsorption of sodium in the kidneys leading to increased excretion of sodium and water. Therefore, the compounds could be used for treatment or prophylaxis or both of disorders that benefit from increased excretion of water and sodium from the body. Accordingly, the compounds of this invention could be used in a method for inhibiting ROMK comprising administering a compound of Formula I or Formula la in a ROMK-inhibitory effective amount to a patient in need thereof. This also encompasses the use of the compounds for inhibiting ROMK in a patient comprising administering a compound of Formula I or Formula la in a
therapeutically effective amount to a patient in need of diueresis, natriuresis or both. The inhibition of ROMK by the compounds of Formula I or Formula la can be examined, for example, in the Thallium Flux Assay described below. Moreover, this invention also relates to the use of the compounds of Formula I or Formula la or salts thereof to validate in vitro assays, for example but not limited to the Thallium Flux Assay described herein.
The compounds of this invention could be used in a method for causing diuresis, natriuresis or both, comprising administering a compound of Formula I or Formula la in a
therapeutically effective amount to a patient in need thereof. Therefore, the compounds of Fonnual I of this invention could be used in methods for treatment of prevention of or reduction of risk for developing medical conditions that benefit from increased excretion of water and sodium, such as but not limited to one or more of hypertension, such as essential hypertension (also known as primary or idiopathic hypertension) which is a fonn of hypertension for which no cause can be found, heart failure (which includes both acute heart failure and chronic heart failure, the latter also known as congestive heart failure) and/or other conditions associated with excessive salt and water retention. The compounds could also be used to treat hypertension which is associated with any of several primary diseases, such as renal, pulmonary, endocrine, and vascular di seases, including treatment of patients with medical conditions such as heart failure and/or chronic kidney disease. Furthermore, the compounds of Formula I or Formula la could be used in methods for treatment of, prevention of or reduction of risk for developing one or more disorders such as pulmonary hypertension, particularly pulmonary arterial hypertension (PAH), cardiovascular disease, edematous states, diabetes meliitus, diabetes insipidus, post- operative volume overload, endothelial dysfunction, diastolic dysfunction, systolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, preeclampsia, cerebral edema, nephropathy, glomerulonephritis, nephrotic syndrome, acute kidney insufficiency, chronic kidney insufficiency (also referred to as chronic kidney disease, or more generally as renal impairment), acute tubular necrosis, hypercalcemia, idiopathic edema, Dent's disease, Meniere's disease, glaucoma, benign intracranial hypertension, and other conditions for which a diuretic or natriuretic or both would have therapeutic or prophylactic benefit. The compounds of the invention may be administered to a patient having, or at risk of having, one or more conditions for which a diuretic or natriuretic or both would have therapeutic or
prophylactic benefit such as those described herein.
The compounds of Formula I or Formula la may potentially have reduced unintended effects (for example, hypo- or hyperkalemia, new onset of diabetes, dyslipidemia, etc.) over currently used clinical agents. Also the compounds may have reduced risk for diuretic tolerance, which can be a problem with long-term use of loop diuretics,
In general, compounds that are ROMK inhibitors can be identified as those compounds which, when tested, have an IC50 of 5 μ,Μ or less, preferably 1 μΜ or less, and more particularly 0.25 uM or less, in the Thallium Flux Assay, described in more detail further below.
The dosage amount of the compound to be administered depends on the individual case and is, as is customary, to be adapted to the individual circumstances to achieve an optimum effect. Thus, it depends on the nature and the severity of the disorder to be treated, and also on the sex, age, weight and individual responsiveness of the human or animal to be treated, on the efficacy and duration of action of the compounds used, on whether the therapy is acute or chronic or prophylactic, or on whether other active compounds are administered in addition to compounds of Formula I or Formula la. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the therapeutically effective or prophylactically effective dosage amount needed to prevent, counter, or arrest the progress of the condition. It is expected that the compound will be administered chronically on a daily basis for a length of time appropriate to treat or prevent the medical condition relevant to the patient, including a course of therapy lasting days, months, years or the life of the patient.
In general, a daily dose of approximately 0.001 to 100 mg/kg, particularly 0.001 to 30 mg/kg, in particular 0.001 to 10 mg/kg (in each case mg per kg of bodyweight) is appropriate for administration to an adult weighing approximately 75 kg in order to obtain the desired results. The daily dose is particularly administered in a single dose or can be divided into several, for example two, three or four individual doses, and may be, for example but not limited to, 0.1 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.25 mg, 2 mg, 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, etc., on a daily basis. In some cases, depending on the potency of the compound or the individual response, it may be necessary to deviate upwards or downwards from the given daily dose. Furthermore, the compound may be formulated for immediate or modified release such as extended or controlled release.
The term "patient" includes animals, particularly mammals and especially humans, who use the instant active agents for the prophylaxis or treatment of a medical condition. Administering of the daig to the patient includes both self-administration and administration to the patient by another person. The patient may be in need of treatment for an existing disease or medical condition, or may desire prophylactic treatment to prevent or reduce the risk for developing said disease or medical condition or developing long-term complications from a disease or medical condition.
The term "therapeutically effective amount" is intended to mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or
other clinician. A "prophylactically effective amount" is intended to mean that amount of a pharmaceutical drug that will prevent or reduce the risk of occurrence of the biological or medical event that is sought to be prevented in a tissue, a system, animal or human by a researcher, veterinarian, medical doctor or other clinician. The terms "preventing," "prevention," "prophylactic" and deri vatives of these term s as used herein refer to administering a compound to a patient before the onset of clinical symptoms of a condition not yet present in the patient. It is understood that a specific daily dosage amount can simultaneously be both a therapeutically effective amount, e.g., for treatment of hypertension, and a prophylactically effective amount, e.g., for prevention or reduction of risk of myocardial infarction or prevention or reduction of risk for complications related to hypertension.
In the methods of treatment of this invention, the ROMK inhibitors may be administered via any suitable route of administration such as, for example, orally, parenterally, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous (IV), intramuscular, intrasternal inj ection or infusion techniques. Oral formulations are preferred for treatment of chronic indications such as hypertension or chronic heart failure, particularly solid oral dosage units such as pills, tablets or capsules, and more particularly tablets, IV dosing is preferred for acute treatment, for example for the treatment of acute heart failure.
This invention also provides pharmaceutical compositions comprised of a compound of Formula I or Formula la and a pharmaceutically acceptable carrier which is comprised of one or more excipients or additives. An excipient or additive is an inert substance used to formulate the active drug ingredient. For oral use, the pharmaceutical compositions of this invention containing the active ingredient may be in forms such as pills, tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. The excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, mannitol, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc.
Pharmaceutical compositions may also contain other customary additives, for example but not limited to, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. Oral immediate-release and time-controlled release dosage forms may be employed, as well as enterically coated oral dosage forms. Tablets may be uncoated or they may be coated by known techniques for aesthetic purposes, to mask taste or for other reasons.
Coatings can also be used to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water or miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti -oxidant such as ascorbic acid. Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose.
The instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining a compound of Formula I or Formula la with a
pharmaceutically acceptable carrier. Also encompassed is the pharmaceutical composition which is made by combining a compound of Formula I or Formula la with a pharmaceutically acceptable carrier. Furthermore, a therapeutically effective amount of a compound of this invention can be used for the preparation of a medicament useful for inhibiting OMK, for causing diuresis and/or natriuresis, and/or for treating, preventing or reducing the risk for any of the medical conditions described herein, in dosage amounts described herein.
The amount of active compound of Formula I or Formula la and/or its pharmaceutically acceptable salts in the pharmaceutical composition may be, for example but j 7
not limited to, from about 0. 1 mg to 1 g, particularly 0.1 mg to about 200 mg, more particularly from about 0.1 mg to about 100 mg, and even more particularly from about 0.1 to about 50 mg, per dose on a free acid/free base weight basis, but depending on the type of the pharmaceutical composition, potency of the active ingredient and/or the medical condition being treated, it could also be lower or higher. Pharmaceutical compositions usually comprise about 0.5 to about 90 percent by weight of the active compound on a free acid/free base weight basis.
The compounds of Formula I or Formula la inhibit ROMK. Due to this property, apart from use as pharmaceutically active compounds in human medicine and veterinary medicine, they can also be employed as a scientific tool or as aid for biochemical investigations in which such an effect on ROMK is intended, and also for diagnostic purposes, for example in the in vitro diagnosis of cell samples or tissue samples. The compounds of Formula I or Formula la can also be employed as intermediates for the preparation of other pharmaceutically active compounds.
One or more additional pharmacologically active agents may be administered in combination with a compound of Formula I or Formula la. The additional active agent (or agents) is intended to mean a medicinal compound that is different from the compound of Formula I or Formula la, and which is a pharmaceutically active agent (or agents) that is active in the body, including pro-drugs, for example esterified forms, that convert to pharmaceutically active form after administration, and also includes free-acid, free-base and pharmaceutically acceptable salts of said additional active agents when such forms are sold commercially or are otherwise chemically possible. Generally, any suitable additional active agent or agents, including but not limited to anti-hypertensive agents, additional diuretics, anti-atherosclerotic agents such as a lipid modifying compound, anti-diabetic agents and/or anti-obesity agents may be used in any combination with the compound of Formula I or Formula la in a single dosage formulation (a fixed dose drug combination), or may be administered to the patient in one or more separate dosage formulations which allows for concurrent or sequential administration of the active agents (co-administration of the separate active agents). Examples of the one or more additional active agents which may be employed include but are not limited to thiazide-like diuretics, e.g., hydrochlorothiazide (HCTZ or HCT); angiotensin converting enzyme inhibitors (e.g, alacepiil, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, or trandolapril); dual inhibitors of angiotensin converting enzyme (ACE) and neutral
endopeptidase (NEP) such as omapatrilat, sampatrilat and fasidotril; angiotensin II receptor
antagonists, also known as angiotensin receptor blockers or ARBs, which may be in free-base, free-acid, salt or pro-drug form, such as azilsartan, e.g., azilsartan medoxomil potassium
(EDARBI®), candesartan, e.g., candesartan cilexetii (AT AC AND®), eprosartan, e.g., eprosartan mesylate (TEVETAN®), irbesartan (AVAPRO®), losartan, e.g., losartan potassium
(COZAAR®), olmesartan, e.g, olmesartan medoximil (BENICAR®), telmisartan
(MICARDIS®), valsartan (DIOVAN®), and any of these drugs used in combination with a thiazide-like diuretic such as hydrochlorothiazide (e.g., HYZAAR®, DIOVAN HCT®,
ATACAND HCT®), etc.); potassium sparing diuretics such as amiloride HQ, spironolactone, epleranone, triamterene, each with or without HCTZ; carbonic anhydrase inhibitors, such as acetazoiamide; neutral endopeptidase inhibitors (e.g., thi orphan and phosphoramidon);
angiotensin receptor neprilysin inhibitors (e.g., LCZ696); aldosterone antagonists; aldosterone synthase inhibitors; renin inhibitors (e.g., enalkrein; RO 42-5892; A 65317; CP 80794; ES 1005; ES 8891; SQ 34017, aliskiren (2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4- hydroxy-2,7-diisopropyl-8-[4-methoxy-3-(3-methoxypropoxy)-phenyl]-octanamid
hemifumarate), SPP600, SPP630 and SPP635); endothelin receptor antagonists; vasodilators
(e.g, nitroprusside); calcium channel blockers (e.g., ami odi pine, nifedipine, verapamil, diltiazem, felodipine, gallopamil, niludipine, nimodipine, nicardipine, bepridil, nisoldipine); potassium channel activators (e.g., nicorandil, pinacidil, cromakalim, minoxidil, apriikalim, loprazolam); sympatholitics; beta-adrenergic blocking drags (e.g., acebutoiol, atenolol, betaxolol, bisoprolol, carvedilol, metoprolol, metoprolol tartate, nadolol, propranolol, sotalol, timolol); alpha adrenergic blocking drugs (e.g., doxazocin, prazocin or alpha methyidopa); central alpha adrenergic agonists; peripheral vasodilators (e.g. hydralazine); nitrates or nitric oxide donating compounds, e.g. isosorbide mononitrate; lipid lowering agents, e.g., HMG-CoA reductase inhibitors such as simvastatin and lovastatin which are marketed as ZOCOR® and MEVACOR® in lactone pro-drug form and function as inhibitors after administration, and pharmaceutically acceptable salts of dihydroxy open ring acid HMG-CoA reductase inhibitors such as atorvastatin (particularly the calcium salt sold in LIPITOR®), rosuvastatin (particularly the calcium salt sold in CRESTOR®), pravastatin (particularly the sodium salt sold in PRAVACHOL®), and fluvastatin (particularly the sodium salt sold in LESCOL®); a cholesterol absorption inhibitor such as ezetimibe (ZETTA®), and ezetimibe in combination with any other lipid lowering agents such as the HMG-CoA reductase inhibitors noted above and particularly with simvastatin (VYTORIN®) or with atorvastatin calcium; niacin in immediate-release or controlled release
forms, and particularly niacin in combination with a DP antagonist such as laropiprant and/or with an HMG-CoA reductase inhibitor; niacin receptor agonists such as acipimox and acifran, as well as niacin receptor partial agonists; metabolic altering agents including insulin sensitizing agents and related compounds for the treatment of diabetes such as biguanides (e.g., metformin), meglitinides (e.g., repaglinide, nateglinide), sulfonylureas (e.g., chlorpropamide, glimepiride, glipizide, glybunde, tolazamide, tolbutamide), thiazolidinediones also referred to as glitazones (e.g., pioglitazone, rosiglitazone), alpha glucosidase inhibitors (e.g., acarbose, miglitol), SGLT2 inhibitors (e.g., canagliflozin, dapagliflozin, ipragliflozin, empagliflozin, tofogliflozin, luseogliflozin/TS-071, ertugliflozin, and remogliflozin), dipeptidyi peptidase inhibitors, (e.g., sitagliptin (JANUVIA®), omarigliptin, alogliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, gemigliptin), ergot alkaloids (e.g., bromocriptine), combination medications such as JANUMET® (sitagliptin with metformin), and injectable diabetes medications such as exenatide and pramlintide acetate; phosphodiesterase-5 (PDE5) inhibitors such as sildenafil (Revatio, Viagra), tadalafil (Cialis, Adcirca) vardenafil HC1 (Levitra); a stimulator of soluble guanylate cyclase (sGC), such as riociguat, vericiguat; or with other drugs beneficial for the prevention or the treatment of the above-menti oned diseases including but not limited to diazoxide; and including the free-acid, free-base, and pharmaceutically acceptable salt forms, pro-drug forms (including but not limited to esters), and salts of pro-drags of the above medicinal agents where chemically possible. Trademark names of pharmaceutical drugs noted above are provided for exemplification of the marketed form of the active agent(s); such pharmaceutical drugs could be used in a separate dosage form for concurrent or sequential administration with a compound of Formula I or Formula la, or the active agent(s) therein could be used in a fixed dose drug combination including a compound of Formula I or Formula la. EXAMPLES
Several methods for preparing the compounds of this invention are described in the following Schemes and Examples. Starting materials and intermediates are purchased, made from known procedures, or as otherwise illustrated. Some frequently applied routes to the compounds of Formula I or Formula la are also described by the Schemes as follows. In some cases the order of carrying out the the steps of reaction schemes may be varied to facilitate the reaction or to avoid unwanted reaction products. The "R" substituents in the Schemes correspond to the substituents defined in Formula I or Formula la at the same positions on the structures.
Compound 1.3, which is substituted at the benzylic position with an OH group, can be prepared following the sequence detailed in Scheme 1. Coupling of epoxide 1.1 to amines 1.2 at elevated temperatures leads to the formation of alcohols 1.3 (Nomura, Y. et al. Chemical & Pharmaceutical Bulletin, 1995, 43(2), 241-6). The reaction can be carried out with conventional heating, or by heating using a microwave apparatus. A number of solvents can be used in this reaction, for example, ethanol, 2-propanoi and toluene. Amines 1.2 may be free bases, or they may be salts, in which case a base such as triethylamine or N;N-diisopropylethylamine may be added. Note that when enantiomerically pure chirai epoxides are employed (such as (R)-l.l in Scheme 1) epoxide opening occurs with retention of stereochemistry in the benzylic position and individual isomer (R)-1.3 may be obtained (and if the (S)-epoxide is employed the alcohol produced will have the opposite stereochemistry to that shown). Alternatively, chirai HPLC separation of enantiomers or diastereomers of 1.3 may be performed to provide single enantiomers or diastereomers.
Compounds of formula 2,3 can be prepared by the sequence detailed in Scheme 2, Aldehydes or ketones 2.1 may be used in reductive alkylation reactions of amines 1.2 to afford ROMK inhibitors of the formul a 2.3 by using various conditions (for example using sodium cyanoborohydride, sodium triacetoxy borohydride, or titanium tetra-isopropoxide, followed by sodium borohydride or sodium cyanoborohydride). Alternatively, compounds of formula 2.3 can be prepared by addition of amine 1.2 to an olefin of type 2.2 in the presence of a catalyst Rh(COD)2BF4/DPEPhos. Under this condition, the olefins of type 2.2 may be required to be
activated by a nitrogen atom or other electron-withdrawing group at the position ortho to the double bond on the aromatic ring.
Preparation of tetrazol e styrene and tetrazole-epoxide intermediates of types 3.4 and 3.5 may start, from halo-substituted aniline 3 (Scheme 3, X= halo). Thus, formation of the tetrazol e ring can be accomplished by stirring CF3C02TMS, N3TMS and CH(OEt)3 in ethyl acetate or NaN3 and CH(OEt)3 in acetic acid at room temperature. The epoxide ring in intermediate 3.5 can be built by treatment of 3.2 (where X is chloride, bromide, iodide, or trifluoromethane sulfonate) with potassium vinyl trifluoroborate (Molander, G.; Luciana, A. journal of Organic Chemistry, 2005, 70(10), 3950-3956) under palladium catalyzed coupling conditions followed by epoxidation of the formed styrene with NBS/NaOH. The intermediate styrene 3.4 can be used to prepare ROMK inhibitors in place of 2.2 according to Scheme 2. Other methods for formation of styrene may be employed, for example, using vinylstannane reagents and palladium catalysis, and other methods for epoxidation of the styrene may be used, for rexample, mCPBA. The racemic epoxides of formula 3.5 can be resolved under chiral HPLC chromatography conditions to afford its enantiomers (R)-3.5 and (S)-3.5, which can be used in place of 1.1 according to Scheme I .
SCHEME 3
Aldehydes 4.3 can he prepared in numerous ways, including as described in Scheme 4, Aldehyde 4.3 can be prepared by hydrogenation of intermediate epoxides 3.5 followed by oxidation with Dess-Martin peiiodinane. Aldehydes 4.3 can be used in place of intermediates 2.1 in Scheme 2 to prepare ROMK inhibitors.
SCHEME 4
The epoxides 5.3 (and single enatiomers (R)-5.3 and (S)-5.3) can be prepared following the method detailed in Scheme 5, Treatment of 5.1 (where X is chloride, bromide, iodide, or trifluoromethane sulfonate) with commercially available potassium vinyl trifluoroborate (Molander, G.; Luciana, A. Journal of Organic Chemistry, 2005, 70(10), 3950-3956) under palladium catalyzed coupling conditions with an appropriate phosphine ligand gives rise to styrene 5.2 (Molander, G.; Brown, A. journal of Organic Chemistry, 2006, 71(26), 9681-9686).
Alternatively, other methods may be employed, for example, using vinyl stannane reagents and palladium catalysis. The resulting styrenes 5 can be converted to the corresponding epoxides 5.3 under various epoxidation conditions, for example, with mCPBA (Fringuelli, F. et al. Organic Preparations and Procedures International, 1989, 21(6), 757-761). The racemic epoxide 5.3 can be resolved under chiral HPLC chromatography conditions to afford its enantiomers (R)-5.3 and (S)-5.3), which can be used in place of 1.1 according to Scheme 1.
(R)-5.3 (S)-5.3
Alternatively, enantiopure epoxides (J?)-5.3 or (S)-5.3 can be prepared as shown in Scheme 6. Treatment of 5.1 (where X is bromide, iodide, or trifluoromethane sulfonate) with commercially available vinyl butylether 6.1 under palladium catalyzed conditions with a suitable ligand (for example Pd(OAc)2, DPPP) can provide the enol ethers 6.2. Enol ethers may be prepared using other methods known to the chemist. Treatment of the resulting enol ethers 6.2 with NBS or other similar reagents affords the corresponding bromomethyl ketones 6.3. These can be subjected to a variety of asymmetric ketone reduction conditions, for example with an enzyme that can affect such a transformation with high enantioselectivitv. Subsequent treatment with a base such as triethylamine leads to cyclization, affording the enantioenriched epoxides (R)-5.3 or (S)-5.3 (depending upon the asymmetric reducing agent).
Et,N
Aldehydes 7.2 may be prepared in numerous ways, with one approach described in Scheme 7. Treatment of 5.1 (where X is bromide, iodide, or trifluoromethane sulfonate) with allyltnbutylstannane in the presence of palladium catalyst affords the allyl product 7.1.
Oxidation, for example with ozone, followed by reduction of the ozonide with dimethyl sulfide, provides aldehydes 7.2 which can be used in place of 2.1 to prepare ROMK inhibitors according to Scheme 2.
Heterocyclic furanones 8.4 can be prepared as described in Scheme 8. Heterocycles such as 8.1, where an amine is protected as appropriate (Greene, T.; Wuts, P. G. M. protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York, NY 1991), and where Z represents a heterocycle possessing an N-H group, can be coupled to furanone inflates or bromides 8.2 using a palladium catalyst and ligand, for example palladium acetate and 4,5-
Bis(diphenylphosphino)-9,9-dimethylxanthene. Heterocycles such as 8.1, where an amine is protected as appropriate, and where Z represents a heterocycle possessing an N-H group are known or can prepared as described in the experimental section below. One example is represented by 8.1a, wherein Z is an imidazolinone heterocycle, which i s shown to proceed through the steps of SCHEME 8. 4-Bromofuran-2(5H)-one is commercially available; other
furanones 8.2 can be prepared as described in the examples below. Intermediates 8.3 are converted to spirocyclic aminofuranones 8.4 by removal of the protective group, for example, rert-butoxycarbonyl can be removed with TFA or HCl. The heterocyclic furanones 8.4 can be used in place of Intermediate L2 in Schemes 1 and 2 above to afford ROMK inhibitors.
The independent synthesis of diastereomers and enantiomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a
reagent containing an asymmetric center of known absolute stereochemistry, or by vibrational circular dichroism (VCD) spectroscopy.
The subject compounds may be prepared by modification of the procedures disclosed in the Examples as appropriate. Starting materials are commercially available or made by known procedures or as illustrated. The following examples are provided for the purpose of further illustration only and are not intended to be limitations on the disclosed invention.
Reactions sensitive to moisture or air were performed under nitrogen or argon using anhydrous solvents and reagents. The progress of reactions was determined by either analytical thin layer chromatography (TLC) usually performed with E. Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm or liquid chromatography-mass spectrometry (LC-MS).
Typically the analytical LC-MS system used consisted of a Waters ZQ platform with eiectrospray ionization in positive ion detection mode with an Agilent 1 100 series HPLC with autosampler. The column was usually a Water Xterra MS C18, 3.0 χ 50 mm, 5 μπι. The flow rate was 1 mL/min, and the injection volume was 10 «L. UV detection was in the range 210-400 nm. The mobile phase consisted of solvent A (water plus 0,06% TFA) and solvent B (acetonitrile plus 0.05% TFA) with a gradient of 100% solvent A for 0.7 min changing to 100% solvent B over 3.75 min, maintained for 1.1 min, then reverting to 100% solvent A over 0.2 min.
Preparative HPLC purifications were usually performed using a mass spectrometry directed system. Usually they were performed on a Waters Chromatography Workstation configured with LC-MS System Consisting of: Waters ZQ single quad MS system with
Eiectrospray Ionization, Waters 2525 Gradient Pump, Waters 2767 Injector Collector, Waters 996 PDA Detector, the MS Conditions of: 150-750 amu, Positive Eiectrospray, Collection Triggered by MS, and a Waters Sunfire C-18 5 micron, 30 mm (id) x 100 mm column. The mobile phases consisted of mixtures of acetonitrile (10-100%) in water containing 0.1%TFA. Flow rates were maintained at 50 mL/min, the injection volume was 1800 ,«L, and the UV detection range was 210-400 nm. Mobile phase gradients were optimized for the individual compounds.
Reactions performed using microwave irradiation were normally carried out using an Emrys Optimizer manufactured by Personal Chemistry, or an Initiator manufactured by Biotage.
Concentration of solutions was carried out on a rotary evaporator under reduced pressure.
Flash chromatography was usually performed using a Biotage Flash Chromatography apparatus (Dyax Corp.) on silica gel (32-63 niM, 60 A pore size) in pre-packed cartridges of the size noted, Ή NMR spectra were acquired at 500 MHz spectrometers in CDCl, solutions unless otherwise
- / -
noted. Chemical shifts were reported in parts per million (ppm). Tetram ethyl silane (TMS) was used as internal reference in CD3C1 solutions, and residual CH3OH peak or TMS was used as internal reference in CD3OD solutions. Coupling constants (J) were reported in hertz (Hz).
Chiral analytical chromatography was usually performed on one of Chiralpak AS, Chiralpak AD, Chiral eel OD, Chiralcel IA, or Chiralcel OJ columns (250 x 4.6 mm) (Daicel Chemical Industries, Ltd.) with noted percentage of either ethanol in hexane (%Et/Hex) or isopropanol in heptane (%IPA/Hep) as isocratic solvent systems, Chiral preparative
chromatography was sometimes conducted on one of Chiralpak AS, Chiralpak AD, Chiralcel OD, Ciralcel IA, or Chiralcel OJ columns (20 x 250 mm) (Daicel Chemical Industries, Ltd.) with desired isocratic solvent systems identified on chiral analytical chromatography or by
supercritical fluid (SFC) conditions. Alternatively, chiral preparative chromatography was by supercritical fluid (SFC) conditions using one of Chiralpak AS, Chiralpak AD-H, Chiralcel OD- FI, Chiralpak IC, or Chiralcel OJ-H columns (250 x 21.2 mm) (Daicel Chemical Industries, Ltd.). Where retention times are provided in the Examples and Tables, they are not intended to be a definitive characteristic of a particular compound since, as known to those skilled in the art, retention times will vary and the timing and/or order of peak elution may change depending on the chromatographic conditions, such as the column used, the condition of the column, and the solvent system and instruments used.
Flash chromatography was carried out on silica gel (230-400 mesh). NMR spectra were obtained in CDCI3 solution unless otherwise noted. Coupling constants (J) are in hertz (Hz).
Abbreviations used herein include: -C(0)CH3 (Ac), -OC(0)CH3 (OAc);
ethyl acetate (EtOAc), benzyl oxycarbonyl (Cbz); dibenzylideneacetone (dba); 11- chloroethylchioroformate (ACE-Ci); phenyl (Ph); dichloromethane (DCM), starting material (SM), diethyl ether (ether or Et20), trill uoroacetic acid (TFA), triethylamine (TEA), 1,8- Diazabicyclo[5.4.0]undec-7-ene (DBU); Diethanolamine (DEA); N,N-diisopropylethylamine (DIEA, Hunig's base, DIPEA), dimethyl sulfide (DMS), 1 -ethyl -3 -(3 -dimethyl aminopropyl), carbodiimide (EDC, ED AC, or EDO); ethylene glycol tetraacetic acid (EGTA), 2~(7-Aza-L//~ benzotriazole-l-yl)-l, 1,3,3-tetramethyluronium hexafluorophosphate (HATU), (4-(2- hydroxyethyl)- 1 -piperazineethanesulfonic aci d (HEPES); I -Hydroxybenzotriazole hydrate (HOBt), hexane (Flex); methyl ieri-hutyi ether (MTBE), Cyclopentyl methyl ether (CPME), 1 ,3- Bis(diphenylphosphino)propane (DPPP), 2-Dicyclohexylphosphino-2',4 6'-triisopropylbiphenyl (X-Phos), 1 ,2-dichloroethane (DCE), methanol (MeOH), N-bromo succinimide (NBS), N- chlorosuccinimide (NCS); N-iodosuccinimide ( S), lithium diisopropylamide (LDA),
tetrahydrofuran (THF), Diethylaminosulfur trifluoride (DAST); dimethyl sulfoxide (DMSO), isopropanol (IP A), /-butyloxycarbonyl (Boc or BOC), di-t-butyl di carbonate (BOC2O, B0C2O), acetic acid (AcOH; HO Ac), N;N-dimethylformamide (DMF), 4-dimethylaminopyridine
(DMAP), dimethylacetamide (DMA; DMAC); Lithium bis(trimethylsilyl)amide (LiHMDS), 3- chloroperoxybenzoic acid (mCPBA); nicotinamide adenine dinucleotide phosphate (NADP), petroleum ether (PE), lithium aluminum hydride (LAH), di-isopropylamine (DIP A),
Carbonyldiimidazoie (GDI), /Moluenesulfonic acid (TsOH), /Moluene-S02- (tosyl or Ts), methane sulfonyl chloride or mesyl chloride (Ms-Cl), methanesulfonic acid (MsOH), CH3SG2- (mesyl or Ms), dimethoxyethane (DME), l ,l '- s,(diphenylphosphino)ferrocene (dppf , DPPF); Pd(dppf)Cl2 or PdCl2(dppf) is 1, 1 '-Bis(diphenylphosphino)ferrocene]dichloropaliadium(II) which may be complexed with CH2CI2, (Oxydi-2,1 -phenyl ene)bis(diphenylphosphine)
(DPEphos); hexamethylphosphoramide (HMPA); isopropyl acetate (IP Ac); N~
methylmorpholine-N-oxide (NMO); tetrakis(triphenylphosphine)paliadium (Pd(PPh ;) , );
tr 5(dibenzylidineacetone)dipalladium (Pd2(dba)3); Diethylaminodifluorosulfinium
tetrafluorob orate (XtalFluor-E); 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene (Xantphos); iV,iV,A",A"-Tetramethyiethylenediamine (TMEDA); Trimethylsilyl (TMS);[1 ,4- Bis(diphenylphosphino)butane](l.,5-cyclooctadiene)rhodium(I) tetrafluorob orate (Rh(COD)BF4); round-bottom flask (RB or RBF); aqueous (aq); saturated aqueous (sat'd), saturated aqueous sodium chloride solution (brine); medium pressure liquid chromatography (MPLC), high pressure liquid chromatography (HPLC), flash chromatography (FC), liquid chromatography (LC), supercritical fluid chromatography (SFC); thin layer chromatography (TLC), mass spectrum (ms or MS); liquid chromatography-mass spectrometry (LC-MS or LC/MS), microwave (MW), column volume (CV), room temperature (rt, r.t. or RT), hour(s) (h or hr), minute(s) (min), retention time (Rt); gram(s) (g); miiligram(s) (mg); milliliter(s) (mL);
microliter(s) (uL); millimole (mmol), Celite is a trademark name for diatomaceous earth, and Solka Floe is a trademark name for powdered cellulose. X or x may be used to express the number of times an action was repeated (e.g., washed with 2 x 200 mL IN HC1), or to convey a dimension (e.g., the dimension of a column is 30 x 250mm).
The following are representative procedures for the preparation of intermediates used to prepare the final products described in the Examples that follow thereafter. These examples are provided for the purpose of further illustration only and are not intended to be limitati ons on the disclosed invention.
INTERMEDIATE 1
5-bromo-4-methyl-2-benzofuran-I (3H)-one
Step A: (3-bromo-2-methylphenyl)methanol : To a solution of 3-bromo-2-methyl benzoic acid (35 g, 163 mmol) in THF (200 mL) was added Borane THF Complex (1.0 M, 212 mL, 212 mmol). The mixture was allowed to stir for 24 h. TLC showed one single product spot. The reaction was quenched with water. The solvent THF was removed under reduced pressure. The resulting solid was dissolved in ethyl acetate (500 mL), washed with IN HC1, sodium carbonate, and brine. The organic layer was dried over sodium sulfate and concentrated to afford (3-bromo- 2-methylphenyl)methanol. 1H NMR (500 MHz, CDC13) δ 7.76 (d, J = 8.0 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 5.30 (s, 2H), 2.42 (s, 3H).
Step B: 5-bromo-4-methyl-2-benzofuran- l (3H)-one: To a flask charged with (3-bromo~2- methylphenyl)methanol (6.0 g, 30 mmol) was added a 1M TFA solution of Thallium
Trifluoroacetate (16.2 g, 29.8 mmol). The mixture was stirred at RT overnight. Analysis by TLC showed no starting material remaining. The solvent was removed under vacuum, and the residue was pumped under high vacuum for 30 min to ensure complete removal of TFA. To the residue was then added Palladium(II) Chloride (529 mg, 2.98 mmol), Lithium Chloride (2,53 g, 59.7 mmol), Magnesium Oxide (2.41 g, 59.7 mmol), and MeOH (150 mL). The reaction was flushed with CO twice, and kept under CO at room temperature. Analysis by LC showed a big product spot within 2 hours. To this solution was added ethyl acetate to precipitate the salts. The black solution was filtered through a celite pad, washed with EtOAc, adsorbed onto silica and purified by silica gel chromatography to afford title compound. 1H-NMR (500 MHz, CDC13) δ ppm 7.71 (d, ./ 8.0 Hz, l i s ), 7,58 (d, J = 8.0 Hz 1H), 5.25 (s, 2H), 2,37 (s, M l ).
(4-Methyl-l -oxo-l,3-dihydro-2-benzofuran-5-yl acetaldehyde
Step A: 4-Methyl-5-prop-2-en- l -yl-2-benzofuran-l(3H)-one: To a flask charged with 5-bromo- 4-methyl-2-benzofuran-l(3H)-one (320 mg, 1.409 mmol) and a stir bar was added ally! tri-n- butyltin (0.655 mL, 2.1 1 mmol), Pd(PPh3)4 (244 mg, 0.21 mmol), lithium chloride (179 mg, 4.23 mmol), and toluene (1 5 mL). The reaction was purged with nitrogen 2 times then was heated at reflux for 4 hours. The product was separated by silica gel chromatography to give 4- methyl-5-prop-2-en-l -yl-2-benzofuran-l(3H)-one.
Step B: (4-M.ethyl-l -oxo- L3-dihvdro-2-benzofuran-5-yl acetaldehvde: A solution of the above olefin (220 mg, 1.2 mmol) in MeOH (20 mL) was cooled to -78°C. To this solution was bubbled ozone until the reaction turned blue. Nitrogen was bubbled through the reaction to drive off excess ozone, followed by addition of DMS (0.870 mL, 1 1.7 mmol). The reaction was allowed to warm up to RT. The crude product was purified by flash chromatography to afford the title compound, 1H-NMR (500 MHz, CDC13) δ ppm 9.78 (s, I I I ) 7.75 (d, ./ 7.5 Hz, IH), 7,34 (d, J = 7.5 Hz, 1 1 1 ), 5.27 (s, 2H), 3.90 (s, 2H), 2.23 (s, 3H).
4-methyl-5-oxiran-2-yl-2-benzofuran- 1 (3H)-one
Step A: 5-ethenyl-4-methyl-2-benzofuran-l (3H)-one: 5-Bromo-4-methyl-2-benzofuran-l(3H)- one (598 mg, 4.47 mmol), potassium vinyl trifluoroborate (507 mg, 2.23 mmmol), PdCl2(dppf)- CH2Cl2Adduct (182 mg, 0.223 mmmol) , and TEA (0.622 mL, 4.47 mmol) were added to 10 mL ethanol in a 20 mL microwave tube. The tube was sealed and degassed, then heated to 140°C for 20 min. Analysis by LC-MS showed product peak. The reaction mixture was diluted with ethyl acetate, washed with brine twice, dried and evaporated to dryness. The crude product was purified by MPLC chromatography using a 120g Redi-sep column and 0-80% ETOAC/Hexane solvent system to yield 5-ethenyl-4-methyl-2-benzofuran-l(3H)-one. 1H-NMR (500 MHz, CDC13): δ ppm 7.76 ( d, J = 8Hz, 1H), 7.03(dd, J= 1 1, 17 Hz, 1 1 1 ). 5.84 (d, J= 17 Hz, IH), 5.55 (d, .! 1 1 Hz, IH), 5.29 (s, 2H), 2.34 (s, 3H); LC-MS: M · 1 175,
Step B : 4-methyl-5-oxiran-2-yl-2-benzofuran- 1 (3H)-one: 5-ethenyl-4-methyl-2-benzofuran- l(3H)-one (1.46 g, 8.38 mmol) was added to DCM (25 mL) at 0°C then mCPBA (2,89 g, 16.8 mmol) was added and the mixture was stirred at RT overnight. The reaction mixture was washed once each with saturated aqueous Na2S203, NaHC03, and brine. The organic layer was dried
over Na2S0 , filtered, and evaporated to dryness. The crude material was purified by MPLC chromatography through 120g Redi-sep column eluting with 0-80% EtOAc/hexane solvent system to yield target 4-methyl-5-oxiran-2-yl-2-benzofuran-l(3H)-one. 1H-NMR (500 MHz, CDCi3): δ ppm 7 77 ( d, J= 8 Hz, 1H), 7.43 (d, .1 8 Hz, i l l), 5,30 (s, 2 H), 4.12 ( s, 1 H), 3.27 (t, J 4Hz, 1 H), 2.735 ( dd, J = 2.2, 5.5 Hz, 1H) , 2.43 (s, 3H), LC-MS: M l 191 .
INTERMEDIATES 3A AND 3B Method 1)
3 A: 4-methyl-5-[(2S)-oxiran-2-yl]-2-benzofuran-l (3H)-one
3B : 4-methyl-5-|"(2R -oxiran-2-yll-2-benzofuran- 1 (3H)-one
Racemic 4-methyl-5-oxiran-2-yl-2-benzofuran-l(3H)-one was resolved on a ChiralPak® AD-H column (5x25cm)under supercritical fluid chromatography (SFC) conditions on a Berger \!(ΠΠ preparative SFC instrument. The racemate was diluted to 50 mg/mL in 1 : 1 DCM:MeOH. The separation was accomplished using 10% EtOH/CO?, flow rate 200 mL/min, 100 bar, 25°C. 500ul Injections were spaced every 2.12 mins. The fast epoxide (4-methyl-5-[(2R)-oxiran-2-yl]-2- benzofuran-l(3H)-one, 3B) eluted first, and the slow epoxide (4-methyl-5-[(2S)-oxiran-2-yl]-2- benzofuran-l (3H)-one, 3 A) eluted second.
Alternatively, the resolution could also be achieved using a mobile phase of 8%MeOH / 98% C02 with a flow rate of lOOmL/min. In that case the sample was prepared by dissolving in methanol, 20mg/mL, and using a 1 raL volume per injection. After separation, the fractions were dried off via rotary evaporator at bath temperature 40°C,
The absolute stereochemistry of each enantiomer was inferred based on the X-ray crystal structure determination of a final compound made with 3B and by Mosher ester and Trost ester HNMR analysis of esters made starting from 3B. Both epoxide isomers find utility in the present invention.
INTERMEDIATE 3B (Method 2)
4-m ethyl -5 - [(2R)-oxi ran -2-y 1 ] -2-benzofuran- 1 (3H)-one
Step A: 3-hydroxymethyl-2-methyl phenol: To a 5L 3 neck RB equipped with overhead stirrer was charged NaBH4 (87.0 g, 2.30 mol) and THE (3.0 L) and the resulting slurry was cooled to 10°C. To the slurry was then added 3-hydroxy-2-methyl benzoic acid (175 g, 1.15 mol) portionwise over 20 min (Tmax 17°C). A stirrable slurry formed, and was aged for an additional 45 min at 10-15°C after which BF3-OEt2 (321 mL, 2.53 mol) was added slowly over 1.5 hours. The slurry was aged at 10°C-15°C for 2 h then assayed for reaction completion. The slurry was cooled to < 10 °C and quenched with 931 mL MeOH slowly over 1.5 h (gas evolution). The resulting slurry was aged overnight at RT. The batch was cooled to < 10°C then quenched with 1 N HC1 (1.5 L) to get a homogeneous solution (pH solution ~ 1), which was aged for 30 min and then the organic solvents were removed by rotary evaporation to approximately 1.8 L of total reaction volume (bath temperature was set to 50°C; internal temp of concentrate after rotary evaporation was ~ 40°C). The slurry was held at 45°C for 30 min then cooled slowly to 15°C. The solids were filtered and washed with cold (15°C) water (2 x 300 mL), providing 3- hydroxymethyl-2-methyl phenol. ' l !-N X!R (400 MHz, DMSO-d6 ): δ 9.1 1 (s, 1H), 6,95 (t, ,/ 7.8 Hz, I I I ), 6.82 (d, J = 7,4 Hz, 1 1 1), 6.71 (d, J = 7,8 Hz, H I ), 4.93 (t, J= 5.5 Hz, H i), 4,44 (d, J = 5.5 Hz, 2H), 2.06 (s, 3H).
Step B: 4-Bromo-3-hvdroxymethyl-2-methyl phenol: 3 -Hydroxymethyl-2-methyi phenol (1 13.9 g, 824.0 mmol) was dissolved in a mixture of acetonitrile (850 mL) and trifluoroacetic acid (750.0 mL, 9,735 mmol) in a 3 -neck 5-L flask under nitrogen. The reaction mixture was cooled to -33°C. N-bromosuccinimide (141 g, 791 mmol) was added over 15 minutes, with the temperature during addition in the range of -35 to -33°C. The reaction mixture was allowed to stir for an additional 15 min during which time the temperature decreased to -40°C. The cooling bath was removed, and potassium carbonate (741.0 g, 5,358 mmol) diluted with water to a total of 1.0 L was added. Off-gassing was observed, and the temperature increased to 25°C. MTBE (1.5 L) was added, and the reaction mixture was transferred to a separatory funnel . The layers were separated. The aqueous layer was diluted with water (500 mL) and extracted with MTBE (1 L) + EtOAc (500 mL), and then MTBE (500 ml .) + EtOAc (250 mL). The combined organic
layers were washed with water (240 mL) and dried over sodium sulfate. The sodium sulfate was removed by filtration, washed with additional MTBE and concentrated under reduced pressure. MTBE (684 mL, 2 volumes) was added, and the suspension was heated to 40°C to produce a homogeneous solution. The solution was allowed to cool to room temperature. Six volumes of heptane were added, and the supension was stirred overnight. The suspension was filtered, and the crystals were washed with 4: 1 heptane: MTBE (500 mL), followed by heptane (500 mL). The solid was dried under vacuum, providing 4-bromo-3-hydroxymethyl-2-methyl phenol. 1H NMR (400 MHz, DMSO-d6 ): δ 9.52 (s, 1H), 7.21 (d, ./ 8.6 Hz, 1H), 6.71 (d, ./ 8.6 Hz, 1H), 4.88 (t, 5. 1 Hz, 11 1 ). 4.59 (d, ,/ 5.1 Hz, 2H), 2.23 (s, 3H)
Step C: 5-Hydroxy-4-methyl-3H-isobenzofuran-l-one: To a 2 L 3 neck flask equipped with overhead stirrer, N2 inlet, and condenser were charged 4-bromo-3-hydroxymethyl-2-methyl phenol (100 g, 461 mmol), CuCN (83.0 g, 921 mmol), and DMF (500 mL). The solution was sparged with N2 for 15 min then heated to 145°C to obtain a homogeneous solution. The solution was aged at 145°C for 2h, then the reaction mixture was cooled to 95°C. 41.5 mL water was added (sparged with 2), and the reaction aged for 20 h. The reaction was cooled to RT then the solids filtered through solka flok and the cake washed with 50 mL DMF, To a 3 L flask containing 1 L EtOAc was added the DMF filtrate. A precipitate coating formed in bottom of flask. The DMF/EtOAc suspension was filtered through solka flok and the cake was washed with 250 mL EtOAc, The resulting filtrate was washed with 5 % brine solution (3x500 mL). The aqueous layers were extracted with 500 mL EtOAc and the combined organics were dried over MgS04, fitered and evaporated. The solids were slurried in 250 mL MTBE at RT then filtered and washed with 100 mL MTBE. The solids were dried under vaccum at RT, providing 5- hydroxy-4-methyl-3H-isobenzofuran-l-one. 1H NMR (400 MHz, DMSO-d6 ): δ 10.52 (s, 1H), 7.51 (d, J= 8.3 Hz, i l l ). 6,99 (d, J= 8.3 Hz, H i), 5.28 (s, 2H), 2.07 (s, 3H).
Step D: 4-methyl-l-oxo-l,3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate
5-Hydroxy-4-methyl-3H-isobenzofuran-l -one (46.8 g, 285 mmol) was suspended in
dichloromethane (935 mL) in 2-L roundbottom flask equipped with overhead stirrer under nitrogen. Triethylamine (59.5 mL, 427 mmol) was added, and the reaction mixture was cooled in an ice bath to 3.8°C. Trifluoromethanesulfonic anhydride (67.4 mL, 399 mmol) was added via addition funnel over 50 min, keeping the temperature < 10°C. After stirring the recation mixture for an additional 15 min, the reaction mixture was quenched with water (200 mL), then stirred with DARCOfe' KB (activated carbon, 25 g) for 15 min. The biphasic mixture was f ltered over Solka floe, washing with additional dichloromethane, and transferred to a separator}' funnel,
whereupon it was diluted with additional water (300 mL). The layers were separated, and the organic layer was washed with water (500 mL) and 10% brine (200 mL). The dichloromethane solution was dried over sodium sulfate, filtered and evaporated. The solid was adsorbed onto silica gel (27.5 g) and eluted through a pad of silica gel (271 g) with 25% ethyl acetate/hexanes. The resulting solution was concentrated under vacuum with the product crystallizing during concentration. The suspension was filtered, the solid washed with heptane and dried under vacuum and nitrogen, providing trifluoromethanesulfonic acid 4-m ethyl- 1-oxo- 1 ,3 -dihydro- isobenzofuran-5-yl ester. 1H NMR (400 MHz, CDC13 ): δ 7.87 (d, J = 8.4 Hz, IH), 7.47 (d, J = 8.4 Hz, IH), 5.32 (s, 2H), 2.41 (s, 3H)
Step E : 5 -( I -B utoxy-vinylV 4-m ethyl -3H -i sobenzofuran- 1 -one : To a 1 L 3 -neck was charged trifluoromethanesulfonic acid 4-methyl-l-oxo- l,3-dihydro-isobenzofuran-5-yl ester (63.0 g, 213 mmoi), DMF (315 mL), butyl vinyl ether (138 mL, 1063 mmol) )then Et3N (35.6 mL, 255 mmol). The solution was sparged with N2 for 20 min. To the solution was added Pd(OAc)2 (1. 19 g., 5.32 mmol) and DPPP (2.41 g., 5.85 mmoi) and sparged for an additional 10 min then heated to 80°C. After a 1 hr age, the solution was cooled to < 10°C then quenched with 630 mL EtOAc and washed with 5% NH4C1 (2 x 3 15 mL), 10% brine (2 x 315 mL), dried over MgS04, filtered, concentrated by rotary evaporation and flushed with EtOAc (3 x 100 mL) to remove excess butyl vinyl ether, providing crude 5-(l ~butoxy-vinyl)-4-methyl-3H-isobenzofuran- 1 -one. 'H NMR (400 MHz, DMSO-de ): δ 7.67 (d, J = 7.7 Hz, IH), 7.48 (d, J = 7.7 Hz, IH), 5.42 (s, 2H), 4.54 (d, ./ 2,3 Hz, IH), 4.27 (d, ./ 2,3 Hz, I H), 3.85 (t, 6.4 Hz, 2H), 2,27 (s, 3H), 1 ,71 -1 ,64 (m, 2H), 1 ,46-1 ,37 (m, 2H), 0.92 (t, J = 7.4 Hz, 3H)
Step F: 5-(2-Bromo-acetyl)-4-methyl-3H-isobenzofuran-l -one: To a 1 L 3 -neck flask equipped with overhead stirrer was added crude 5-(l-butoxy-vinyl)-4-methyl-3H-isobenzoforan-l-one
(55.8 g) and THF (315 mL). The solution was cooled to < 5°C after which water (79 mL) was added and the solution was maintained at < 5°C. NBS (41 ,6 g) was then added portion-wise while maintaining Tmax = 19°C. The solution was then warmed to RT for 30 minutes. HBr (48 %, 0.241 mL) was added and the reaction was aged at RT for approximately 1 h after which 236 mL water was then added to the batch , A water bath is used to maintain temp at 20°C, Another 315 mL of water was added (solvent composition 1 :2 THF: water) and the slurry was cooled to 15°C. The resulting solids were filtered and washed with cold 1 :2 THF: water ( 5°C): 150 mL displacement wash followed by 100 mL slurry wash. The solids were dried under vacuum at RT to provide 5-(2-bromo-acetyl)-4-methyl-3H-isobenzofuran-l-one. 1H MR (400 MHz, DMSO- d6 ): δ 7.99 (d, J= 7.8 Hz, IH), 7.82 (d, J = 7.8 Hz, IH), 5.49 (s, 2H), 4.92 (s, 2H), 2.33 (s, 3H)
Step G : 4-m ethyl -5 - [(2R)-oxi ran-2-y 1 ] -2-benzofuran- 1 (3H)-one
5-(2-Bromo-acetyl)-4-methyl-3H-isobenzofuran~l-one (48,8 g., 181 mmol) was charged to a 5 L 3 neck round bottom equipped with overhead stirrer, thermocouple, and heating mantle. 2- Propanol (1 ,22 L ) was added, followed by 610 mL of pH 7 0.1 M potassium phosphate buffer. Buffer solution (610 mL) was charged to a 1.0L erlenmeyer, and 2,44 g of NADP was added to the erlenmeyer and swirled to dissolve. A reducing enzyme, KRED MIF-20 (2.44 g) (available from Codexis, Inc., 200 Penobscot Drive, Redwood City, CA 94063, www. codexi s . com , tel . 1 - 650-421-8100) was added to the erlenmeyer flask and the mixture was swirled to dissolve the solids. The resulting solution was added to the 5 L round bottom, which was then heated to 28°C and aged for 6 hours, at which point the reaction was cooled to RT and triethylamine (50,2 mL, 360 mmol) was added. The resulting solution was aged at 40°C for 1 h. The light slurry solution was cooled to RT, after which 122 g NaCl was added. The solution was aged at RT then extracted with 1.22 L isopropyl acetate (IP Ac). The aqueous layer was re-extracted with 400 mL IP Ac and the combined organics were washed with 400 mL 20 % brine solution, dried over MgS04, filtered and concentrated by rotary evaporation. The resulting solids were taken up in 100 mL IP Ac (thick slurry). Hexanes were added (400 mL) and the suspension aged at RT th en filtered and washed w/ 5: 1 HexanesTPAc solution (150 mL). The crystalline solids were dried under vacuum at RT to provide 4-methyl-5-[(2R)-oxiran-2-yl]-2-benzofuran-l(3H)-one. 1H
NMR (400 MHz, CDC13 ): δ 7,75 (d, J= 8.1 Hz, H i), 7.42 (d, J = 8.1 Hz, I I I ), 5.28 (s, 2H), 4.10 (dd, J= 4.0, 2.8, 1H), 3.26 (dd, J= 5.6, 4.0, 1H), 2.72 (dd, J= 5.6, 2.8, 1H), 2.42 (s, 3H).
INTERMEDIATE 4
4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate
Step A: ethyl 4-bromo-2-methyl-3-oxobutanoate: To the solution of ethyl 2-methyl-3- oxobutanoate (5,05 g, 35,0 mmol) in water (10 mL) at 0°C was added bromine (1.805 mL, 35.0 mmol) dropwise over 2h. The resulting solution was stirred at rt for 16h. The reaction mixture was extracted with ethyl acetate, the organic phase was dried over sodium sulfate, and concentrated to give ethyl 4-bromo-2-methyl-3-oxobutanoate. 1HNMR (500 MHz, CDC13), 54.322-4.274 (m, 2H), 2,455(s, 2H), 1.991 (s, 3H), 1.337-1.309 (t, 31 1 )
Step B: 4-hydroxy-3-methylfuran-2(5H)-one: Ethyl 4-bromo-2-methyl-3-oxobutanoate (7.81 g, 35 mmol) was treated with hydrogen bromide (0.040 mL, 48%, 0.35 mmol) and the mixture was
heated at 100°C for 6 h. The precipitate was collected by filtration followed by washing with ethyl acetate to give 4-hydroxy-3-methylfuran-2(5H)-one. XHNMR (500 MHz, CDC13), 64.595 (s, 2H), 3.314 (s. 1H), 1.668 (s, 3H).
Step C : 4-methy 1 - 5 -oxo-2.5 -dihydrofuran-3 -yl trifl uoromethanesul fonate : To the solution of 4- hydroxy-3-methylfuran-2(5H)-one (400 mg, 3.51 mmol) in dichloromethane (10 mL) at -78°C was added 2,6-lutidine (0.612 mL, 5.26 mmol) and triflic anhydride (0.71 mL, 4.21 mmol) dropwise. The reaction temperature was maintained at -78°C for 0.5 h before being warmed to rt for Ih. The mixture was diluted with DCM (100 mL) and washed with 1 N hydrogen chloride (3 times 100 mL), then with diluted sodium bicarbonate solution, then dried over sodium sulfate, and concentrated to give 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifiuoromethanesulfonate.
(R)-5-(Oxiran-2-yl)-2-(lH-tetrazol-l -yl)pyridine (SA) and
(S -S-(Oxiran-2-yl -2-(lH-tetrazol-l-yl pyridine (SB)
Step A: 5-Bromo-2-(lH-tetrazol- 1 -yOpyridine
To a solution of 5-bromopyridin-2-amine (5.0 g, 28.9 mmol) in acetic acid (40 ml, 699 mmol) was added (diethoxymethoxy) ethane (7.70 ml, 46.2 mmol), followed by sodium azide (2.82 g, 43.3 mmol). The mixture was heated at 80°C for 1 h, cooled to room temperature and diluted with water. Precipitate was collected by filtration and dried under high vacuum to provide the title compound.
Step B : 5-Ethenyl-2-(lH-tetrazol-l -yOpyridine
To a stirring solution of 5-bromo-2-(lH-tetrazol- 1 -yl)pyridine (1.0 g, 4.42 mmol), in EtOH (70 mL) was added bis[(diphenylphosphino)ferrocene]dichioropailadium(II), complex with dichloromethane (0.361 g, 0.442 mmol), potassium vinyl trifluoroborate (1.18 g, 8.85 mmol, 2 equiv.), tri ethyl amine (1.23 mL, 8.85 mmol, 2 equiv), and water (0.5 mL). The reaction mixture was heated at reflux (90°C, oil bath) under N2. Upon completion (1-2 h) as determined by- reverse phase HPLC-MS and TLC (eluent: 10% ethyl acetate in hexane), the mixture was cooled to room temperature, and then diluted with water. The organic layer was separated, and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine,
dried over MgS04, and concentrated. The crude material was chromatographed over a column of Si02 (0-20% EtOAc in hexane as eluent). Evaporation of the solvent yielded the title compound. [.{' MS [M+l]+ = 174.0.
Step C: 5-(Oxiran-2-yl)-2-(lH-tetrazol-l -yl)pyridine (5)
To a solution of 5-ethenyl-2-(lH-tetrazol-l-yl)pyridine (0.664 g, 3.83 mmol) in a 2: 1 ratio of 1 !/·(): t-BuOH (30 mL) was added N-bromosuccinimide (0.751 g, 4.22 mmol) in portions over 5 min. The mixture was heated at 40°C for 1 h, cooled to 5°C, made basic with sodium hydroxide aqueous solution (0.46 g in 5 mL of H20, 1 1.50 mmol), stirred for another 1 h at the same temperature, and poured into H20 (10 mL). The product precipitated out. The solid was collected by filtration, washed with water, and dried in vacuo. 1H NMR (500 MHz, DMSO-d6), δ 10.17 (s, 1H), 8.60 (d, 1.4 Hz, 1 1 1). 8.04-7.99 (m, 2H), 4. 14 (dd, J= 2.7 Hz, ,/ 2.8 Hz, 1 1 1 ), 3.23 (t, J = 4,6 Hz, I I I ). 3.02 (dd, J = 25 Hz, H i ): LCMS [M+l]+ - 190. Further chiral separation (AD-H 30x250mm, 50% MeOH/C02, 70 mL/min, lOObar, 46 mg in MeOHZDCM) afforded faster eluted 5A (R)-5-(oxiran-2-yl)-2-l H-tetrazol-l-yl)pyridine and slower eluted SB (S)-5-(oxiran-2-yl)-2-(li -tetrazol-l-yl)pyridine. Absolute chemistry was determined by using Vibrational Circular Dichroism (VCD) spectroscopy with high confidence. Analysis was done comparing experimental data to the calculated VCD and IR spectra of the (K) and (S)
compounds.
INTERMEDIATES 6A and 6B
yI)EyrazjTie
Step A: 2-Bromo-5-(lH-tetrazol-l-yl)pyrazine: To a solution of 5-bromopyrazin-2-amine (10.75 g, 57,5 mmol) in ethyl acetate (150 ml) was added trimethylsilyl 2,2,2-trifluoroacetate (16,88 ml, 98 mmol). After the mixture was stirred for 5 min, triethoxymethane (17.21 ml, 103 mmol) was added. The resulting mixture was stirred for another five min, and this was followed by addition of azidotrim ethyl silane (12,09 ml, 92 mmol). Stirring continued at rt for 2 days, and the mixture
was concentrated under reduced pressure. Recrystallization of the residue from ethyl acetate afforded 2-bromo-5-(lH-tetrazol-l-yl)pyrazine. LCMS [ M 2 · i ] ;=: 228.9.
Step B: 2-( 1 H-Tetrazol - 1 -y 1 )-5 - vinyl pyrazine : A solution of 2-bromo-5-(lH-tetrazol-l- yl)pyrazine (1 1 .2 g, 49.3 mmol), potassium vinyltrifluoroborate (13.22 g, 99.0 mmol), Ι , Γ- bis(diphenylphosphino)ferrocene-palladium(ii)dic-hloride dichloromethane complex (2.01 g, 2.47 mmol), and TEA (13.75 mi, 99.0 mmol) in ethanol (150 mi) was heated at reflux at 82 °C for 4 h. The reaction mixture was cooled to rt, and the precipitate was filtered off The filtrate was concentrated, and the residue was purified by flash chromatography (Biotage, Si , ethyl acetate in hexane: 35 to 45%) affording 2-(lH-tetrazol-l-yl)-5-vinylpyrazine LCMS [M+ l ]"" = 175.10. The filter cake was stirred in DCM (50 mL), and the solid was filtered off. The filtrate was concentrated to afford more 2-(lH-tetrazol-l-yl)-5-vinylpyrazine.
Step C: 2-(Oxiran-2-yl)-5-(lH-tetrazol-l-yl)pyrazine: To a suspension of 2-(lH-tetrazol-l-yl)-5- virryl pyrazine (6.7 g, 38.5 mmol) in t-BuOH: water (96 ml: 190 ml) was added N- bromosuccinimide (7.53 g, 42.3 mmol) in portions at rt. The mixture was heated at 50C'C for 1 h, and cooled to 0°C in an ice bath. NaOH (4,61 g in 30 mL water, 1 15 mmol ) was added dropwise, and the resulting mixture was stirred at the same temperature for 20 min. The product was collected by filtration, washed with water, dried under vacuum to give 2-(lH-tetrazol-l-yl)-5- vinylpyrazine LCMS ( M ! | 191.07. Chiral separation (AD-H 30x250mm, 50% MeOH/C02, 70 mL/min, 100 bar, MeOH/DCM) afforded faster eluted isomer 6A and slower eluted isomer 63B LCMS [M+ 1 ]+ ::= 191.1. Both i somers were useful for the preparation of potent ROMK inhibitors.
The following epoxide intermediates in Table 1 were prepared employing a similar synthetic method as that described for Intermediates 5, 5A, SB or 6, 6A, 6B. Column 2 shows the structure of the starting material followed by the method used (either 1-5 for the procedure described for Intermediate 5, or 1-6 for the procedure described for Intermediate 6). Note that the absolute stereochemistry was not determined unambiguously for these
intermediates. Both isomers were useful for the preparation of potent ROMK inhibitors.
TABLE 1 : Epoxides prepared using the method described for 1-5 or 1-6
2-( 1 H-Tetrazol - 1 -y 1 ) - 5 - vi ny 1 py razin e
Step A: 2-Bromo-5-( lH-tetrazol- 1 -vDpyrazine: To a solution of 5-bromopyrazin-2-amine (10.75 g, 57.5 mmol) in ethyl acetate (150 mL) was added trimethylsilyl 2,2,2-trifluoroacetate (17 mL, 98 mmol). The mixture was stirred for 5 min, and triethoxym ethane (17.21 ml, 103 mmol) was added. After the resulting mixture was stirred for another five min, azidotrimethvlsilane (12.09
ml, 92 mmol) was added. Stirring continued at rt for 2 days, and the mixture was concentrated under reduced pressure. Recrystallization of the residue from ethyl acetate afforded the title compound. LCMS [M+2+l = 228.9.
Step B : 2-(lH-Tetrazol-l -yl)-5-vinylpyrazine: A solution of 2-bromo-5-(lH-tetrazol -l - yl)pyrazine (1 1.2 g, 49.3 mmol), potassium vinyltrifluoroborate (13.2 g, 99.0 mmol), 1, 1 '- bis(diphenylphosphino)ferrocene-palladium(ii)di chloride dichloromethane complex (2.0 1 g, 2.47 mmol ), and TEA (13 ,8 mL, 99.0 mmol) in ethanol (1 50 mL) was heated at reflux at 82°C for 4 h. The reaction mixture was allowed to cool to rt, and the precipitation was filtered off. The filtrate was concentrated, and the residue was purified by flash chromatography (Biotage, Si, ethyl acetate in hexane: 35 to 45%) affording the title compound. The filter cake was stirred in DCM (50 mL), and the solid was filtered off. The filtrate was concentrated to afford more of the title compound. LCMS [M+l]+ = 175.1.
The following arylvinyl intermediates in Table 2 were prepared employing a similar synthetic method as that described for Intermediate 10 using the noted starting material.
TABLE 2: Aryl vinyls prepared according to the method described for INTERMEDIATE 10
7-(oxiran-2-yl)tetrazolo l,5-fllquinoline
Step A: 7-bromotetrazolo[L5-a]quinoline: A solution of 6-bromo-2-chloroquinoline (4.00 g, 16.6 mmol) and sodium azide (2.16 g, 3.32 mmol) in 20 mL DMF was stirred at 130°C for 18 h. Then the solution was poured into cold water (200 mL) and stirred for 30 min, filtered and washed with cold water, dried to afford the title compound, LC MS[M+ 1]+ ;=: 248.9.
Step B : 7-vinyltetrazol oj" 1 ,5-a jquinoline: To a mi ture of 7-bromotetrazolo [ 1 , 5 ~a] qui noline (3.35 g, 13.4 mmol), potassium vinyltrifluoroborate (3.62 g, 8.0 mmol), Pd(dppf)Cl2 (335 mg, 0.44 mmol) in EtOH (100 mL) was added Et3N (1.31 g, 13.2 mmol), the mixture was heated at 80 °C for 2 hours. The mixture was cooled and filtered, rinsed the cake with EtOH, and then concentrated, the residue was purified on silica gel column eluted with petroleum ether/EtOAc from 5/1 to 1/1 as eluting solvents to afford the title compound, LC/'MS [M+l]~ = 197.1 ,
Step C: 7-(oxiran-2-yl)tetrazolo|"1.5-fl"|quinoline: A mixture of 7-vinyltetrazolo[l,5-a]quinoline (1 .64 g, 8.32 mmol) and NBS (1.62 g, 9.15 mmol) in a solution of t-butanol (27.3 mL) and water (54.6 mL) was heated to 40°C, stirred until the solid was mostly dissolved, then stirred for another 2 hours, a solution of NaOH (998 mg, 25.0 mmol) in water (11 mL) was added slowly, cooled to 0°C, then stirred for 1 hour, concentrated, purified on silica gel column eluted with petroleum ether EtOAc = 1/1 as eluting solvents to afford the title compound. LC/MSfM+l]1" = 213.1.
INTERMEDIATE 15
2-(6-(l /-Tetrazol-l-yl pyridin-3-yl )acetaldehvde
Step A: 2-(6-( lH-Tetrazol- 1 -yl pyridin-3 -yOethanol : To a solution of 5-(oxiran-2-yl)-2-(lH- tetrazol-l -yl)pyridine (500 mg, 2.64 mmol) in ethanoi (5.3 mL) were added 10% Pd/C (101 mg, 0.952 mmol) and HCOONH4 (500 mg, 7.93 mmol). The reaction mixture was vigorously stirred for 1.5 h, and filtered through a pad of silica gel. The filtrate was evaporated to give 2-(6-(lH- tetrazol-l-yl)pyridin-3-yl)ethanol. 1H MR (500 MHz, CDC13) δ 9.54 (s, 1 1 1), 8.43 (d, J = 2.0 Hz, H I ), 8.02 (d, J = 8.3 Hz, 1H), 7.90 (dd, J = 8,3, 2,0 Hz, 1 1 1), 3.91 (t, J - 6,3 Hz, 2H), 2.96 (t, J = 6.3 Hz, 2H),
Step S3: 2-(6-( lH-Tetrazol - 1 -yl)pyridin-3 -yPacetal dehy de : To a solution of 2-(6-(lH-tetrazol-l- yl)pyridin-3-yl)ethanol (100 mg, 0.523 mmol) in DCM (2.6 mL) was added Dess-Martin periodinane (333 mg, 0.785 mmol). The mixture was stirred for 1.5 h, diluted with 10%
Na2S702, NaHC03, and stirred for 20 rain. The aqueous layer was extracted with DCM, and the combined organic layers were washed with brine, dried (MgS04), and concentrated to give title compound. LC/MS: [(M+l)]+ = 190
INTERMEDIATE 16
-2-methoxy-2-(4-methyl- 1 -oxo- 1 , 3 -dihydroi sobenzofuran-5 -yPacetal dehyde
Step A : (R -5 -(2-hydroxy- 1 -meth oxyeth vP-4-m ethyl i sobenzofuran- 1 (3H)-one : To a solution of (S)-4-methyl-5-(oxiran-2-yl)isobenzofuran-l(3H)-one (300 mg, 1.58 mol) in MeOH (10 mL) was added TsOH (30 mg, 0.16 mmol). The resulting mixture was stirred at 70 °C for 2 h. The mixture was concentrated and partitioned between EtOAc and water; the organic layer was separated and concentrated to afford the title compound.
Step B: (R)-2-methoxy-2-(4-methyl-l -oxo-1.3-dihydroisobenzofuran-5-yl)acetaldehyde: DMP (405 mg, 0.96 mmol) was added to a solution of (R)-5-(2-hydroxy-l-methoxyethyl)-4- methylisobenzofuran-l(3H)-one (212 mg, 0.96 mmol) in DCM (3 mL) in one portion. The
resulting mixture was stirred at room temperature for 18 h. The mixture was diluted with EtOAc, washed with water; the organic layer was concentrated to afford the title compound.
INTERMEDIATE 17
2-ethoxy-2-(4-methyl-l-oxo-l,3-dihydroisobenzofuran-5-yl)acetaldehyde The title compound was prepared from (S)-4-methyl-5-(oxiran-2-yl)isobenzofuran-l(3H)-one in an analogous fashion as described for (R)-2-methoxy-2-(4-methyl-l-oxo-l,3- dihydroisobenzofuran-5-yl)acetaldehyde (Intermediate 16), but using ethanol in place of methanol.
INTERMEDIATE 18
(/ -2-(6-(lH-tetrazol-l-vnpyridin-3-yl -2-methoxyacetaldehvde The title compound was prepared from (S)-5-(oxiran-2-yl)-2-(lH-tetrazol-l -yl)pyridine
(Intermediate 5B) in an analogous fashion as described for (R)-2-methoxy-2-(4-methyl-l-oxo- l,3-dihydroisobenzofiiran-5-yl)acetaldehyde (Intermediate 16).
fert-butyl 6-(2-oxoimidazolidin-l-yl)-3-azabicyclor3.1.01hexane-3-carboxylate
Step A: tert-butyl 6-(3-(2-chloroethyl)ureido)-3-azabicyclo[3. 1.0]hexane-3-carbox late: To an ice-cooled DCM (10 ml) solution of tert-butyl 6-amino-3-azabicyclo[3.1.0]hexane-3-carboxylate (1.01 g, 5.09 mmol) was added triethylamine (1.775 mL, 12.74 mmol) and then 2-chloroethyl i socyanate (0.591 g, 5.60 mmol). After 1 hour, the reaction mixture was quenched with aqueous
sodium bicarbonate and the aqueous layer was extracted with DCM (3 X 10 niL). The combined organic layers were then dried over sodium sulfate, filtered and concentrated in vacuo to afford tert-butyl 6-(3-(2-chloroethyl)ureido)-3-azabicyclo[3.1.0]hexane-3-carboxylate which was used without further purification,
StepB : fe/7-butyl 6-(2-oxoimidazolidin- 1 -yl)-3-azabicvclo|"3.1.OIhexane-3-carboxylate: To an ice-cooled THF (10 mL) solution of rert-butyl 6-(3-(2-chloroethyl)ureido)-3- azabicyclo[3.1.0]hexane-3-carboxylate (1.50 g, 4.94 mmol) was added Li HMDS (5.93 mL, 5.93 mmoi) dropwise. The reaction was allowed to gradually warm to ambient temperature. Reaction is complete after 1.5 hours. The reaction mixture was quenched with aqueous sodium
bicarbonate and the aqueous layer was extracted with ethyl acetate (3 X 0 mL). The combined organic layers were then dried over sodium sulfate, filtered, concentrated in vacuo and purified v/'a MPLC (0-100% EtO Ac/Hex then 10% methanol/DCM gradient) to afford fcrt-butyl 6-(2- oxoimidazolidin-l-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. LC/MS: [(M+l)]+ =:: 268.
fert-butyl 4-f 2-oxoimidazolidin- 1 -vDpiperidine- 1 -carboxylate Step A: fert-butyl 4-(3-(2-chloroethyl)ureido)piperidine-l-carboxylate: To an ice-cooied solution of te/f-butyl 4-aminopiperi dine- 1 -carboxyl ate (25.00 g, 125 mmol) in DCM (160 mL) was added TEA (31.00 g, 312 mmol) and l-chloro-2-isocyanatoethane (14.50 g, 138 mmol). After 10 min, the mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM (200 mL), washed with aqueous sodium bicarbonate (200 mL X 2), then dried and concentrated to afford the title compound.
Step B: fe/ -butyl 4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate: To a solution of tert-butyl 4-(3-(2-chloroethyl)ureido)piperidine-l-carboxylate (6.87 g, 22.5 mmol) in THF (50 mL) was added LiHMDS (1.0 M, 27 mL, 27 mmol) dropwise at 0°C, then the mixture was allowed to warm to room temperature gradually and stirred for 2 h. The mixture was quenched with aqueous sodium bicarbonate, extracted with EtO Ac (50 mL X 3), the combined organic layers were dried and concentrated. The residue was purified via silica gel to afford the title compound.
"
tert-butyl 3-(2-oxoimidazolidin-l-yl pyrrolidine-l-carboxylate
The title compound was prepared in an analogous fashion to that described for tert-butyl 4-(2- oxoimidazolidin-l-yl)piperidine-l-carboxylate (Intermediate 20) except starting from tert-butyl 3-aminopyrrolidine-l-carboxylate. LC/MS: | (M 1 ) | ::= 256,
feT/-butyl 4-(4-methyl-2-oxoimidazolidin-l-yl piperidine-l -carboxylate Step A: fert-butyl 4-((3-methoxy-2-methyl-3-oxopropyl amino)piperidine-l-carboxylate: To a solution of tert-butyl 4-aminopiperidine-l-carboxylate (8.00 g, 40 mmol) in MeOH (80 mL) was added methyl methacrylate (6,00 g, 60 mmol), the resulting mixture was heated to 65 °C and stirred for 5 days. The mixture was diluted with DCM, washed with water, brine, dried over Na?S04, filtered and concentrated to afford the title compound.
Step B: 3-(( l-(tgrt-butoxycarbonyl)piperidin-4-yl amino)-2-rnethylpropanoic acid: To a solution of ferf-hutyl 4-((3-methoxy-2-methyl-3-oxopropyl)amino)piperidine-l-carboxylate (7.30 g, 24 mmol) in MeOH (40 mL) and water (20 mL) was added NaOH (1.40 g, 35 mmol) at room temperature, the mixture was stirred at room temperature for 16 hours. The mixture was washed by DCM; aqueous phase was acidified with 3 HCl to pH 7, concentrated to afford the title compound.
Step C : fert-butyl 4-(4-methyl-2-oxoimidazolidin- 1 -yl)piperidine- 1 -carboxylate: To a solution of DPPA (14.0 g, 51 mmol), TEA (5.60 g, 55 mmol) in toluene (40 mL) was added 3- {\-(tert- butoxycarbonyl)piperidin-4-yl)amino)-2-methylpropanoic acid (6,60 g, crude), the resulting mixture was heated to reflux and stirred for 16 hours under N2 protection. The mixture was diluted with DCM, washed with water, saturated sodium bicarbonate and concentrated; the residue was washed with a mixture of PE EtOAc (10: 1) to afford the title compound.
"N TERMED I A TE 23
fert-butyl 4-(4-ethyl -2-oxoimi dazolidin- 1 -yOpiperidine- 1 -carboxylate
Step A: ethyl 2-formylbutanoate: Ethyl butyrate (10.00 g, 86.1 mmol) was added slowly to a cooled solution of LDA (130 mL, 2 M in THF, 260 mmol) in 200 mL of diy THF. The resulting mixture was stirred at -78°C for 1 h, then ethyl formate (32.00 g, 432 mmol) was added dropwise and the resulting mixture was allowed to warm to room temperature and stirred for 3 h. The reaction mixture was quenched with 750 mL of water and extracted by PE (200 mL X 3). The aqueous layer was acidified with cone. HCl to pH2 and then extracted by fert-butyi methyl ether (300 mL*3). The ether layer was washed with brine and dried over Na2S04, filtered and concentrated to afford the title compound.
Step B: ferf-butyl 4-((2-('ethoxycarbonyl)butyl)amino piperidine-l -carboxylate: To a solution of ethyl 2-formylbutanoate (14.00 g, 97.2 mmol) and tert-bv&yl 4-aminopiperidine-l -carboxylate (20.00 g, 100 mmol) in DCM (200 mL) was added AcOH (11.50 g, 192 mmol), the mixture was stirred at room temperature for 4 h, then NaBH3CN (18.50 g, 294 mmol) was added, the mixture was stirred at same temperature for 16 h. The mixture was quenched by 100 mL of water, extracted by DCM, washed with water, brine, dried over Na2S04 and concentrated to afford the title compound.
Step C: 2-(((l-(fert-Butoxycarbonyl)piperidin-4-yl)amino)methyl)butanoic acid: To a solution of tert-butyl 4-((2-(ethoxycarbonyl)butyl)amino)piperidine-l -carboxylate (28.00 g, 85.3 mmol) in MeOH (100 mL) and water (40 mL) was added NaOH (4.10 g, 103 mmol) at room temperature, the mixture was stirred at room temperature for 16 hours. The mixture was washed by DCM; aqueous phase was adjusted to pH7 by 3 HC!, concentrated to afford the title compound. i H- NMR (400 MHz, MeOD) δ ppm 3.86-3.83 (m, 2H), 3.16 (s, 2H), 2.82-2.65 (m, 4H), 2.14-2.10 (m, 1 H), 1 .82-1 .75 (m, 3H), 1 ,58-1 ,54 (m, 1 H), 1.37 (s, 9H), 1.27-1.13 (m, 2H), 0.86-0.79 (m, 3H).
Step D: ferf-butyl 4-(4-ethyl-2-oxoimidazolidin-l-yl)piperidine-l -carboxylate: To a solution of 2-(((l-(fert-butoxycarbonyl)piperidin-4-yl)amino)methyl)butanoic acid (17.00 g, crude) and TEA (11.00 g, 109 mmol) in toluene (400 mL) was added DPPA (28.00 g, 102 mmol), the resulting mixture was heated to reflux and stirred for 16 hours under N2 protection. The mixture
was cooled and concentrated, the residue was diluted with DCM, washed with water, saturated sodium bicarbonate, dried and concentrated, the residue was purified on silica gel (25% to 50% EtOAc in PE) to give the title compound.
"N TERMED I A TE 24
fert-hutyl 4-(2-oxotetrahydropyrimidi - 1 (2H)-yl)piperi dine- 1 -carboxy 1 ate
Step A: fenf-butyl 4-(3-(3-chloropropyl )ureido)piperidine-l-carboxylate: 4- Amino- 1-BOC- piperidine ( 1 .00 g, 4.99 mmol), was dissolved in DCM (20 mL). The resulting solution was cooled to 0°C using an ice-water bath and sequentially treated with triethylarnine (1.740 mL, 12.48 mmol) and 3-chloropropyl isocyanate (0.564 mL, 5.49 mmol). The reaction mixture was warmed to ambient temperature and followed by LC/MS. After -1.5 h, LC 'MS indicated formation of the desired product. The reaction mixture was partitioned between DCM and saturated aq. NaHC03. The organic layer was separated, dried (Na2S04), filtered and concentrated to afford the title compound.
Step B : ieri-butyl 4-(2-oxotetrahy dropyrimidin- 1 (2H)-yl)pi peri dine- 1 -carboxylate : fe/7-butyl 4- (3-(3-chloropropyl)ureido)piperidine-l-carboxylate (1.79 g, 5.60 mmol), was diluted in THF (20 mL) and cooled to 0°C using an ice-water bath. A 1M/THF solution of Li HMDS (6.72 mL, 6.72 mmol) was added dropwise over -10 min. The reaction mixture was allowed to gradually warm to ambient temperature. LC/MS analysis after -15 h of stirring at ambient temperature indicated formation of the desired product. The reaction mixture was concentrated; the residue was quenched with saturated aq. NaHC03 and extracted with EtOAc. The combined organic layers were dried (Na2S04), filtered and concentrated. The residue was purified by flash
chromatography using a 40 g ISCO RediSep®Rf silica gel column with gradient elution 0-10% MeOH/DCM (30 min; 40 mL/min). The desired fractions (determined by KMn04 stain) were combined, concentrated and dried in vacuo to afford the title compound. LC/MS: [(M+1)]T =
284,
"N TERMED I A TE 25
tert-butyl tm/?5-3-fluoro-4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate Step A: benzyl 4-oxopiperidine-l -carboxylate: Into a 20 L 4-necked round bottom flask was placed piperidin-4-one hydrochloride ( 1 100 g, 8.1 1 mol, 1 ,00 equiv), THF (5500 mL) and water (5500 mL). To the mixture was added K2C03 (2239 g, 16.20 mol, 2.00 equiv) while the flask was cooled to -5°C. To the above was added benzyl carbonochloridate (1453 g, 8.52 mol, 1.05 equiv) dropwise with stirring at -5UC over 20 minutes. The resulting solution was allowed to react, with stirring, for 2 hours while the temperature was maintained at room temperature. The reaction progress was monitored by LLC (EtOAc/PE = 1 :2). A filtration was performed. The filtrate was extracted three times with 10 L of CH2C12. The organic layers were combined, washed 3 times with 8 L of brine, dried over MgS04 and concentrated under vacuum to afford the title compound.
Step B : benzyl 4-(trimethylsilyloxy )-5,6-dihydropyridine- 1 (2H)-carboxylate: Into a 10L 3 - necked round bottom flask was placed benzyl 4-oxopiperidine-l-carboxylate (1700 g, 7.29 mol, 1 .00 equiv), DMF (8500 ml) and TEA (2590 g, 25.59 mol, 3.51 equiv). To the above was added TMSCl (1587 g, 14,61 mol, 2.01 equiv) dropwise with stirring. The resulting solution was allowed to react, with stirring, overnight while the temperature was maintained at 85 °C. The reaction progress was monitored by TLC (EtOAe/PE = 1 :2). The reaction mixture was then quenched by the addition of ice water. The resulting solution was extracted with PE. The organic layers were combined, washed with brine, dried over MgS04 and concentrated under vacuum to afford the title compound.
Step C: 3-fluoro-4-oxopiperidine-l-carboxylate: Into a 10000 mL 3 -necked round bottom flask was placed benzyl 4-(trimethylsilyloxy)-5,6-dihydropyridine-l(2H)-carboxylate (365 g, 1.19 mol, 1 .00 equiv) and acetonitrile (5000 ml). To the above was added SelectFluor® (321 .5 g, 952.03 mmol, 0.99 equiv) in several batches at 0°C over 20 minutes. The resulting solution was allowed to react, with stirring, overnight while the temperature was maintained at room temperature. The reaction progress was monitored by TLC (EtOAc PE = 1 : 1). The mixture was concentrated under vacuum. The residual solution was diluted with 3 L of EtOAc. A filtration
was performed. The filtrate was concentrated under vacuum. The residue was purified with a silica gel column eluting with a 1 :400 MeOH:DCM solvent system to afford the title compound. Step D: benzyl czs-3-fluoro-4-hydroxypiperidine-l -carboxylate: Into a 5 L 4-neeked round bottom flask was placed a solution of benzyl 3 -fluoro-4-oxopiperidi ne- 1 -carboxyl ate (687 g, 2.73 mol, 1 .00 equiv) in methanol (3500 ml). To the mixture was added NaBH (83.8 g, 2.22 mol, 0.66 equiv) in several batches at 0°C. The resulting solution was stirred for 4 hours at room temperature. The reaction progress was monitored by TLC (EtOAc PE = 1 : 1), The reaction mixture was then quenched by adding 2000 mi of water. The resulting solution was extracted three times with 2000 mi of EtOAc. The organic layers were combined, washed 3 times with 2000 ml of brine, dried over MgS04 and concentrated under vacuum. The residue was purified with a silica gel column eluted with a 1 :8 EtOAc PE solvent system to afford the title compound. Step E: fert-butyl c/'5-3-fluoro-4-hydroxypiperidine-l-carboxylate: A mixture of benzyl cis-3- fluoro-4-hydroxypiperi dine- 1 -carboxyl ate (290 g, 1.15 mol, 1.00 equiv), Boc20 (261 ,3 g, 1 .20 mol, 1.05 equiv) and Pd(OH)2/C (29 g, 10%) in methanol (2300 mi) was hydrogenated (8 atm) for 3 hours at room temperature. A filtration was performed. The filtrate was concentrated under vacuum. The crude product was purified by recrystallization from DCM:PE in the ratio 1 : 10 to afford the title compound. 1H-NMR - (300MHz, COCl3, ppm): δ 1.46(9H,m), 2.0(21 Lm ), 3.4(lH,s), 3.7(iH,s), 3.8(2H,m), 4.5(2! Id )
Step F: fe/f-butyl c/'5-3-fluoro-4-(methylsulfonyloxy)piperi dine- 1 -carboxyl ate: Into a 5000 ml 4- necked round bottom flask was placed a solution of /er/-butyl c/s-3-fluoro-4-hydroxypiperidine- 1-carboxylate (203 g, 925.88 mmol, 1.00 equiv) in DCM (2000 mi) and TEA (121.4 g, 1.20 mol, 1 .30 equiv). To the above was added MsCl (138,3 g, 1 .21 mol, 1 ,49 equiv) dropwise with stirring, at 0°C. The resulting solution was stirred for 2 hours at room temperature. The reaction progress was monitored by TLC (DCM/EtOAc = 2: 1). The resulting solution was diluted with 2000 ml of aq. NH4C1 ( 10%), then extracted three times with 3000 ml of DCM, The organic layers were combined, washed two times with 2000 ml of brine, dried over Na2S04 and concentrated under vacuum to afford the title compound.
Step G: fert-butyl traw5-4-azido-3-fluoropiperidine-l-carboxylate: Into a 5000 mi 4-necked round bottom flask was placed a solution of te/ -butyl 67s-3-fluoro-4- (methylsulfonyloxy)piperidine-l-carboxylate (275 g, 924.87 mmol, 1.00 equiv) in DMF (2100 ml). To the mixture was added NaN3 (180,9 g, 2.78 mol, 3 ,02 equiv). The resulting solution was stirred overnight at 90~100°C in an oil bath. The reaction progress was monitored by TLC (EtOAc/PE = 1 :2). The resulting solution was cooled and diluted with 3000 ml of aq. NaOH
(10%), then extracted three times with 3000 ml of DCM. The organic layers were combined, washed two times with 3000 ml of water and two times with 3000 ml. of brine, dried over Na2S04 and concentrated under vacuum. The residue was purified by eluting through a column with a 1 :20 EtOAc/PE solvent system to afford the title compound.
Step H: tert-butyl tra;?s-4-amino-3-fluoropiperidine-l-carboxylate:
A mixture of tert-butyl tra«s-4-azido-3-fluoropiperidine-l-carboxylate (180 g, 736.89 mmol, 1 .00 equiv) and Pd(OH)2/C (1 8 g, 10%) in CH3OH (2000 ml) was hydrogenated (3 atm) overnight at room temperature. The reaction progress was monitored by TLC (MeOH/DCM = 1 : 10). A filtration was performed. The filtrate was concentrated under vacuum. The residue was purified by eluting through a silica gel column with a 1 : 100 MeOH:DCM solvent system. The collected fraction was concentrated under vacuum. The residue was washed 2 times with 400 ml of hexane to afford the title compound. LC-MS (ES, m/∑): 204 iK i 'i 1 ;C N ! i ]
Step I and J: tert-butyl tm^5-3-fluoro-4-(2-oxoimidazolidin-l -yl)piperidine-l-carboxylate: The title compound was prepared in two steps starting from tert-butyl tra«5-4-amino-3- fluoropiperidine-l-carboxylate and l -chloro-2-isocyanatoethane in an analogous fashion as described for tert-butyl 4-(2-oxoimidazolidin-l-yl)piperidine- l -carboxylate above (Intermediate 20). LC-MS (ES, m/z): 288 [M+H]+
INTERMEDIATE 26
6 -tert-butyl 3 -fluoro-4-f 2-oxoimidazolidin- 1 -yOpiperidine- 1 -carboxylate
Step A: eis-tert-butyl 4-(benzylamino)-3-fluoropiperidine-l-carboxylate: Into a 5000 ml 4- necked round bottom flask purged and maintained with an inert atmosphere of nitrogen was placed tert-butyl 3-fluoro-4-oxopiperidine-l-carboxylate (prepared as described above, 257 g, 1. 18 mol, 1.00 equiv) and THF (1850 ml). To the above was added BnNH2 (143.9 g, 1.34 mol, 1.13 equiv) dropwise with stirring at 0°C. To the mixture was added NaB(AcO)3H (675 g, 3.19 mol, 2,69 equiv). The resulting solution was stirred overnight at room temperature. The reaction progress was monitored by TLC (EtOAc:PE = 1 :2). The resulting mixture was diluted with 2000 ml of aq. 2C03 then extracted 2 times with 2000 mL of EtOAc. The organic layers were combined, dried over MgS04 and concentrated under vacuum. The residue was purified by
eluting through a silica gel column with a 1 :20 EtOAc:PE solvent system to afford the title compound.
Step B: c/s-fert-butyl 4-amino-3-fluoropiperidine-l- carboxylate: A mixture of c/s-tert-butyl 4- (benzylammo)-3-fluoropiperidine-l-carboxylate (128 g, 415.58 mmol, 1 .00 equiv) and
Pd(OH)2/C (13 g) in MeOH (2000 ml) was hydrogenated overnight at room temperature. The reaction progress was monitored by TLC (MeOH/DCM = 1 :20). A filtration was performed. The filtrate was concentrated under vacuum. The residue was purified by eluting through a silica gel column with a 1 : 100 MeOH:DCM solvent system to afford the title compound. LC-MS (ES, m/z): 204 [M-C4H8+CH C +H]+; H- MR (300MHz, C\ , ppm): δ 1.46(9H,s), 1.50(2H,s), 1.67(2H,t), 2 92(31 Km). 4,05(IH,s), 4,30 (lH,s), 4.54(lH,d).
Step C and D: tert-butyl tmw5-3-fluoro-4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate: The title compound was prepared in two steps starting from rert-butyl tra«s-4-amino-3- fluoropiperidine-1 -carboxylate and l-chloro-2-isocyanatoethane in an analogous fashion as described for fert-butyl 4-(2-oxoimidazolidin-l-yl)piperidine-l -carboxylate above (intermediate 20). LC-MS (ES, m/z): 288 [ M i l ) '
INTERMEDIATE 27
c/5-tgrt-butyl 3-methoxy-4-(2 -oxoimidazoli din- l -yl)piperi dine- 1 -carboxylate
The title compound was prepared in an analogous fashion as described for tenf-butyl 4-(2- oxoimidazolidin-l-yl)piperidine-l -carboxylate (Intermediate 20), except starting from commercially available cis-tert-hutyl 4-amino-3-methoxypiperidine-l-carboxylate (available from several sources including Oakwood Chemical, catalog # 040789). LC-MS (ES, m/z): 300 [M+H]+
trans-tert-butyl 3 -methoxy-4-(2-oxoimidazolidin- 1 -yPpiperidine- 1 -carboxylate
The title compound was prepared in an analogous fashion as described for rert-butyl 4-(2· oxoimidazolidin-l-yl)piperidine-l -carboxylate (Intermediate 20), except starting from
commercially available trans-ter t-buty\ 4-amino-3-methoxypiperi dine- 1 -carboxylate (availabl from several sources including Indofine Chemical Company, Inc., catalog # 08-6346). LC-MS (ES, m/z): 300 [M+H]+
fert-butyl 4-(2-oxopyrrolidin-3 -vDpiperazine- 1 -carboxylate Step A: ferf-butyf 3-bromo-2-oxopyrrolidine-l-carboxylate: To a -78°C cooled THF (14 mL) solution of l-(fert-butoxycarbonyl)-2-pyrrolidinone (2.00 g, 10,8 mmol) was add LiHMDS (3.97 g, 23.76 mmol) dropwise. The mixture was stirred for 10 minutes at which time a THF (14 mL) solution of N-bromosuccinimide (1.922 g, 10.80 mmol) was added. The reaction was allowed to stir for another 10 minutes and then quenched by the addition of aqueous ammonium chloride. The aqueous iayer was extracted 3 times with DCM (10 mL). The The combined organic layers were then dried over sodium sulfate, filtered, concentrated in vacuo and purified via MPLC (0- 100% EtO Ac/Hex) to afford fert-butyl 3-bromo-2-oxopyrrolidine-l-carboxylate.
Step B : fer r-butyl 4-( 1 -(fert-butoxycarbonyl)-2-oxopyrrolidin-3 -vDpiperazine- 1 -carboxylate : To an acetonitrile (10 ml) solution of fert-butyl 3-bromo-2-oxopyrrolidine-l-carboxylate ( 1 g, 3.79 mmol) was added potassium carbonate (1.570 g, 1 1.36 mmol) and 1 -BOC-piperazine (0,705 g, 3.79 mmol). The reaction mixture was heated to 40°C for 2 hours, cooled to ambient temperature and solids filtered. The organic layer was concentrated in vacuo and purified via MPLC (0-100% EtOAc/Hex) to afford fert-butyl 4-(l-(/e;V-butoxycarbonyl)-2-oxopyrrolidin-3-yl)piperazine-l - carboxylate.
Step C: 3-(piperazin-l-yl pyrrolidin-2-one: To a DCM (10 ml) solution of fer /-butyl A-{\- tert- butoxycarbonyl)-2-oxopyrrolidin-3-yl)piperazine-l -carboxylate (1.15 g, 3.11 mmol) was added TFA (1.199 mL, 15.56 mmol). The mixture was allowed to stir at ambient temperature for 2 hours after which the solution was concentrated in vacuo. The crude residue was then diluted in methanol and passed through a 10G ion exchange resin. The free base was released using 4M ammonia in methanol to afford 3-(piperazin-l-yl)pyrrolidin-2-one.
Step D : /er/-butyl 4-f 2~oxopyrrolidm-3 -vDpiperazine- 1 -carboxylate : To a THF (20 mL) solution of 3-(piperazin-l-yl)pyrrolidin-2-one (530 nig, 3.13 mmol) was added Hunig'sBase (0.547 mL, 3.13 mmol) and BOC-Anhydride (0.800 mL, 3.45 mmol). The mixture was heated to 40°C for
15 hours. After this time, the reaction mixture was cooled to ambient temperature, quenched with aqueous sodium bicarbonate and the aqueous layer was extracted with ethyl acetate (3 X 10 mL). The combined organic layers were then dried over sodium sulfate, filtered, concentrated in vacuo and purified via MPLC (0-100% EtO Ac/Hex then 10% methanol/DCM gradient) to afford fert-butyl 4-(2-oxopyrrolidin-3-yl)piperazine- 1 -carboxylate.
fert-butyl 2-oxo-[3,4'-bipiperidine]-r-carboxylate
Step A: methyl 4-cyano-2-fpyridin-4-yl)butanoate: To a solution of methyl 2-(pyridin-4- yOaeetate ( 10.0 g, 66 mmoi) in 20 mL of tert-butanol was added Triton B (0.4 mL) and acrylonitrile (7.00 g, 132 mmol) at 0°C. The resultant mixture was stirred at room temperature for 48 h. The mixture was concentrated and diluted with water (150 mL), then extracted with ethyl acetate, the organic layer was washed with brine, dried over anhydrous Na2S04, filtered and concentrated, the residue was purified by column chromatography (EtO Ac: MeOH = 10: 1) to give the title compound. Ή-NMR (400 MHz, CDC13) δ ppm 8.59-8.56 (m, 2H), 7.26-7.20 (m, 2H), 3.78-3.73 (m, 1H), 3,69-3,61 (m, 3H), 2.48-2.31 (m, 2H), 2.28-2.21 (m, H I ). 2.18-2.06 (m, 1H).
Step B: 3-(pyridin-4-yl)piperidin-2-one: A mixture of methyl 4-cyano-2-(pyridin-4-yl)butanoate
(7.80 g, 34.3 mmol), Raney Ni (0,80 g), H4OH (10 mL) in 200 mL of MeOH was stirred at 65C'C for 5 h under 55 Psi of hydrogen. The mixture was then filtered and concentrated. The residue was purified by flash chromatography to afford the title compound. 1H-NMR (400 MHz,CDCl3) δ ppm 8.96-8.77 (m, 2H), 7.52-7.21 (m, 2H), 6.33 (s, 1H), 3.68-3.60 (m, 1H), 3.48- 3.39 (m, 31 ! }. 2,20-2, 18 (m, 2H), 1.98-1 .84 (m, 4H).
Step C: j3,4'-bipiperidin]-2-one: 3-(Pyridin-4-yl)piperidin-2-one (3 ,80 g, 21.5 mmol) and Pt02 (0.38 g) in acetic acid (40 mL) was hydrogenated at 80°C for 37 h under 800 Psi of hydrogen, and then cooled to room temperature, filtered and concentrated to afford the title compound. Step D: /er/-butyl 2-oxo-[3,4'-bipiperidinel-i'-carboxylate: To a solution of [3,4'-bipiperidin]-2- one (400 mg, 2.1 mmol) in 2 mL of THF was added Boc20 (432 mg, 2 mmol ) and 2 mL of TEA, the resulting mixture was stirred at room temperature overnight, the mixture was concentrated, and the residue was purified by chromatography (PE: EtO Ac = 4: 1) to give the title compound.
H-NMR (400 MHz, MeOD) δ ppm 4.19-4.05 (m, 2H), 3.28-3. 17 (m, 2H), 2.83-2.59 (m, 2H), 2.33-2.13 (m, 2H), 1.95-1.81 (m, 2H), 1.75-1.61 (m, 1H), 1.60-1.50 (m, 2H), 1.49-1.39 (m, 9H), 137-1 .28 (m, 2H).
tert-butyl 4-(2-oxopyrrolidin-3-yl piperidine-l -carboxylate
Step A: fert-butyl 4-(2-methoxy-2-oxoethylidene)piperidine-l -carboxylate: A mixture of 60% sodium hydride (1.30 g, 33 mmol) in 145 niL of DMF was cooled to 0°C, methyl 2- (dimethoxyphosphoryl)acetate (4.8 mL, 3 1 mmol) was then added drop wise. After 20 minutes at 0°C, a solution of tert-butyl 4-oxopiperidine-l-carboxylate (5.00 g, 25 mmol) in 13 mL of DMF was added dropwise. The reaction mixture was stirred at r.t. for 3 hours, and then diluted with EtO Ac, washed with water, the organic layer was separated and washed with brine, dried over Na2S04, filtered and concentrated to afford the title compound. 'H-NMR (400 MHz, CDC13) δ ppm 5.70 (s, H I ), 3.67 (s, 3H), 3.40-3.53 (m, 4H), 2.85-2.95 (t, J 6.0 Hz, 2H), 2.20-2.30 (t, J = 5.2 Hz, 2H), 1.45 (s, 9H).
Step B: fe/ -butyl 4-(2-methoxy-2-oxoethyl)piperidine-1 -carboxylate: Crude fert-butyl 4-(2- methoxy-2-oxoethylidene)piperidine-l-carboxylate above was hydrogenated with 0.7 g of 10% Pd/C in EtOAc/MeOH (1 : 1, 50 mL) under 55 Psi overnight, filtered and concentrated. The residue was purified by flash chromatography (PE: EtOAc from 15 : 1 to 8: 1 ) to afford the title compound. *H-NMR (400 MHz, CDC13) δ ppm 4.10 (s, 2H), 3.65 (s, 3H), 2.60-2.75 (t, J= 12 Hz, 2H), 2.19 -2.26 (t, J ------ 7,2 Hz, 2H), 1 .81 -1.95 (m, 1 H), 1.60-1.70 (d. ,/ 13 Hz, 2Ή), 1 .40-
1.45 (m, 9H), 1 .05- 1 . 18 (m,2H).
Step C : fert-butyl 4-(3 -cyano- 1 -methoxy- 1 -oxopropan-2-yl)piperidine- 1 -carboxylate: To a mixture of diisopropylamine (0.78 g, 7.8 mmol) in THF (10 mL) was added dropwi se with n- BuLi (2.7 mL, 6.8 mmol) at -60°C. After being stirred at -60°C for 0.5 hours, fenf-butyl 4-(2- methoxy-2-oxoethyl)piperidine-l -carboxylate ( 1 .00 g, 3.9 mmol) in THF (5 mL) was added dropwise at -60°C. After I hour, bromoacetonitrile (0.93 g, 7.8 mmol) was added dropwise at - 60C'C, the mixture was then stirred at r.t. overnight. The reaction mixture was quenched by water, extracted with EtOAc. The combined organic layers were dried over Na2S04, filtered and concentrated. The residue was purified by column chromatography (PE: EtOAc = 20/1 to 3/1 ) to afford the title compound. *H-NMR (400 MHz, CDC13) δ ppm 5.28 (s, 2H), 3.65 (s, 3H), 2.60-
2,70 (ni, 4H), 2,50-2,60 (m, I I I ), 1.81-1 .90 (m, i l l), 1.62 (t, J - 2.0 Hz, 2H), 1.40-1.45 (m, 9H), 1.15-1.23 (m, 2H).
Step D: tert-butyl 4-(2-oxopyrrolidin-3-yl)piperidine-l-carboxylate: A mixture of Raney Ni (0.70 g), fcrt-butyl 4-(3-cyano-l-methoxy-l-oxopropan-2-yl)piperidine-l.-carboxylate (0.71 g, 2.3 rnrnol), 1.0 mL of ammonia in 40 mL of methanol was hydrogenated at 50 Psi and 80°C overnight. The mixture was filtered and concentrated. The residue was purified by
chromatography (PE: EtOAc = 8: 1 to 1/1) to afford the title compound. ^I- MR (400 MHz, CDC13) δ ppm 5.70 (s, 1H), 4.10 (s, 2H), 3.40-3.45 (m, 4H), 3.25 (t, J= 8.0 Hz, 2H), 2.65 (s, 2H), 1 ,65-1 ,78 {!, ./ 14 Hz, 2H), 1 ,45 (ri, ./ 8.0 Hz, 1H), 1 .36 (s, 10H).
tgrt-butyl 4-(3-methyl-2-oxopyrrolidir!-3-yl)piperidine-l-carboxylate
Step A: rert-butyl 4-( 1 -(fer^-Butoxycarbonyl)-2-oxopyrrolidin-3 -yQpiperidine- 1 -carboxylate: To a solution of ferf-hutyl 4-(2-oxopyrrolidin-3-yl)piperidine-l-carboxylate (1.00 g, 3.73 mmol) in 10 mL of CH3CN was added Boc20 (1 ,20 g, 5.58 mmol), followed by DMAP (42 mg, 0,37 mmol), the resulting mixture was stirred at room temperature overnight and then concentrated, the residue was partitioned between H20 and ethyl acetate, the organic layer was washed with 1 HO solution and brine, dried over anhydrous Na2S04, filtered and concentrated, the residue was purified by flash chromatography eluted with 0 to 30% of ethyl acetate in PE to afford the title compound. ^I-NMR (400 MHz, CDC13) δ ppm 4.23-4.02 (br, 2H), 3.76-3.70 (m, H i), 3.60- 3.51 (m, 1H), 2.75-2.63 (m, 2H), 2,55-2.46 (m, 1H), 2.08-1.96 (m, 2H), 1.88-1.73 (m, 2H), 1.52 (s, 10 H), 1.44 (s, 9H), 1.32-1.20 (m, 2H).
Step B: fer -butyl 4-(l-(tert-butoxycarbonylV3-methyl-2-oxopyrrolidin-3-yl piperidine-l- carboxylate: To a stirred solution of dry diisopropylamine (684 mg, 6.80 mmol) in 10 mL of dry THF was added w-BuLi (2.5 A/ in hexanes, 2,0 mL, 5.1 mmol) under N2 atmosphere at -78°C, the reaction mixture was stirred at - 78C'C for 5 min and then warmed to 0 °C. After 30 min, the reaction was cooled to -78°C. A solution of (R)-fcrt-butyl 4-(l -(tert-butoxycarbonyl)-2- oxopyrrolidin-3-yl)piperidine-l-carboxylate (1 ,00 g, 2.72 mmol) in 8 mL of dry THF was added dropwise at -78°C. After stirring for 30 min at the same temperature, a solution of Mel (1.90 g, 13.6 mmol) in 1 mL of THF was added dropwise, the mixture was then stirred overnight while the temperature rose to room temperature. The mixture was quenched with saturated NH4CI
solution, extracted with ethyl acetate, the aqueous layer was extracted with ethyl acetate, the combine organic layer was dried over anhydrous Na2S04, filtered and concentrated, the residue was purified by flash chromatography eluted with 0 to 25% of ethyl acetate in PE to afford the title compound. ^I-NM (400 MHz, CDC13) δ ppm 4.25-4.05 (br, 2H), 3.72-3.55 (m, 2H), 2.65 (t, J= 11 Hz, 2H), 2.04-1.94 (m, IH), 1.81-1.75 (m, 2H), 1.62-1.54 (m, 4H), 1.53 (s, 9H), 1.45 (s, 9H), 1 .26-1 .10 (m, 2H).
Step C : 3 -methyl -3 - piperi din-4-yl pyrrolidin-2-one : To a solution of t rt-butyl 4-(l-(tert- butoxycarbonyl)-3 -methyl -2-oxopyrrolidin-3 -yl )piperi dine- 1-carboxylate (2.75 g, 7.20 mmol) in EtOAc (25 mL) was added HCl/EtOAc (4 M, 28 mL) at room temperature, the resulting mixture was stirred at room temperature for 3 h. The mixture was concentrated to afford the title compound as hydrochloride.
Step D: tert-butyl 4-(3-methyl-2-oxopyrrolidin-3-vnpiperidine-l-carboxylate: To a solution of 3- methyl-3-(piperidin-4-yl)pyrrolidin-2-one (2.10 g, 11.5 mmol) and TEA (3.50 g, 34.6 mmol) in MeCN (25 mL) was added (Boe)?0 (3.80 g, 17.4 mmol) at room temperature, the resulting mixture was heated to 80°C and stirred for 6 hours. The reaction mixture was diluted with DCM, washed with water, brine, dried over Na2S04, filtered and concentrated; the residue was purified on silica gel eluted with 25% to 50% of EtOAc in PE to afford the title compound. iH-NMR (400 MHz, CDC13) δ ppm 5.89 (s, IH), 4.12-4.1 1 (m, 2H), 3.32-3.24 (m, 2H), 2.66 (s, 2H), 2.14- 2.09 (m, I H), 1 .78-1 .55 (m, 5H), 1 ,45 (s, 9H), 1 ,27-1 ,22 (m, I H), 1.16 (s, 3H),
tert-butyl 4-hydroxy-4-(2-oxopyrrolidin-3-yl piperidine-l -carboxylate
To a stirred solution of anhydrous diisopropvlamine (4.50 g, 44 mmol) in 50 mL of dry THF was added a 2.5 M olution of «-BuLi in hexane (13.6 mL, 34 mmol ) under N2 atmosphere at -78°C. The solution was stirred for 15 min, and then a solution of l-(trimethylsilyl)pyrrolidin-2-one (5.50 g, 35 mmol) in 20 mL of dry THF was added dropwise at -78C'C. After stirring for 50 min at the same temperature, a solution of tert-butyl 4-oxopiperidine- 1 -carboxylate (4.40 g, 22 mmol) in 20 mL of dry THF was added dropwise, the mixture was warmed slowly to room temperature and stirred overnight under N2 atmosphere. The mixture was acidified with 5%> HC1 solution under ice cooling, extracted with ethyl acetate, the organic layer was washed with 5%
HC1 solution, water, brine, dried over anhydrous Na2S04, filtered and concentrated to afford the title compound. 1H-NMR (400 MHz, CDC13) δ ppm 6.08 (s, IH), 4.53 (br, IH), 3.94 (br, 2H), 3.33 (q, 4.8 Hz, 2H), 3, 15 (br, 2H), 2,55 (t, J 10 Hz, 1H), 2,20-2, 15 (m, IH), 1 ,95-1 ,80 (m, 1H), 1.65-1.58 (m, 2H), 1 ,48 (s, 10H).
fert-butyl 4-(5-methyl-2-oxopyrrolidin-3-yl)piperidine-l-carboxylate
Step A: ferf-butyl 4-(l-methoxy-4-methyl- l -oxopent-4-en-2-yl)piperidine-l-carboxylate:
LiHMDS (1 .2 M in THF, 25 mL, 30 mL) was added dropwise to a solution of fert-butyl 4-(2- methoxy-2-oxoethyl)piperidine-l-carboxylate (5.00 g, 1.9 mmol) in THF (50 mL ) at -78°C.
After being stirred at same temperature for 1 h, 3-bromo-2-methylprop-l-ene (2.60 g, 1 .9 mmol) was added; the reaction mixture was stirred at this temperature for 0.5 h, and then stirred at room temperature overnight. The reaction was quenched with saturated aqueous NH4Ci and extracted with EtOAc; the combined organic extracts were dried over Na2S04, filtered and concentrated to give the title compound.
Step B: ferr-butyl 4-(l-methoxy-l,4-dioxopentan-2-yl)piperidine-l-carboxylate: To a solution of tert-butyl 4-(l -methoxy-4-methyl-l-oxopent-4-en-2-yl)piperidine-l -carboxylate (300 mg, 0.96 mmol) in MeOH (3 mL) was added Os04 (2 mg, 0,01 mmol), followed by NaI04 (800 mg, 4.0 mmol ) in H20 (3 mL), the resulting mixture was stirred at room temperature for 12 h. After removing the solvent and partitioned between with H?() and EtOAc, the organic layer was separated and concentrated to get the title compound.
Step C: ferf-butyl 4-(5-methyl-2-oxopyrrolidin-3-yl)piperidine-l-carboxylate: To a solution of fert-butyl 4-(l -methoxy-l ,4-dioxopentan-2-yl)piperidine-l-carboxylate ( 100 mg, 0.32 mmol) in MeOH (3 mL) was added NH4QAc (100 mg, 6.4 mmol), NaBH3CN (77 mg, 6.4 mmol) and MgS0 (160 mg, 6.4 mmol), and then the reaction mixture was heated under reflux overnight. The reaction mixture was cooled and partitioned between water and EtOAc, the organic layer was separated and concentrated, the residue was purified by column chromatography on silica eluted with EtOAc/PE and MeOHZDCM to get the title compound. H-MR (400 Hz, CDC13) δ ppm 4.13-4.08 (m, 2H), 3.71-3.63 (m, 1H), 2.68 (d, J = 4.0 Hz, 2H), 2.44 (t, J= 5.2 Hz, 2H), 2.11-1.62 (m, 2H), 1.73-1.66 (m, 2H), 1.43 (s, 9H), 1.28-1.21 (m, 4H).
tert-butyl 4-(5-oxopyrrolidin-3-yl)piperidine-l-carboxylate Step A: (E)-tert-buty\ 4-(3-methoxy-3-oxoprop-l -en-l -yl)piperidine-l-carboxylate: To a mixture of methyl 2-(diethoxyphosphoryl)acetate (5.90 g, 28 mmol) in THF (100 ml.) was added DBU (4.30 g, 28 mmol) and Li CI (1.20 g, 28 mmol), the mixture was stirred at room temperature for 30 min, then fert-butyl 4-formylpiperidine-l-carboxylate (5,00 g, 23 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The mixture was quenched by saturated NH4C1 (aq.), then extracted with ethyl acetate, the organic layers were washed by brine, dried over anhydrous Na2S04, filtered and concentrated, the crude product was purified by column chromatography (PE: EtOAc = 20: 1 ~ 3 : 1) to afford the title compound.
Step B : ferf-butyl 4-(4-methoxy- 1 -nitro-4-oxobutan-2-yl)piperidine- 1 -carboxylate : To a mixture of (E tert-butyl 4-(3 -methoxy-3 -oxoprop- 1 -en- 1 -yl)piperidine- 1 -carboxylate (2.00 g, 7.4 mmol), in CH3NO2 (20 mL) was added DBU (1.10 g, 7.4 mmol). The mixture was heated to reflux and stirred for 16 hours. The mixture was cooled, diluted with ethyl acetate, washed by brine, dried over anhydrous Na2S04, filtered and concentrated, the residue was purified by column chromatography (PE: EtOAc = 20: 1 ~ 3 : 1) to afford the title compound.
Step C: fert-butyl 4-(5-oxopyrrolidin-3-yl)piperidine-l -carboxylate: To a mixture of tert-buiyl 4- (4-methoxy-l-nitro-4-oxobutan-2-yl)piperidine-l -carboxylate (1.50 g, 4.5 mmol) in MeOH (20 mL) was added Raney Ni (200 mg). The mixture was stirred under H2 atmosphere (balloon) at room temperature for 24 hours, then filtered and concentrated to afford the title compound.
l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-ynimidazolidin-2-one
Step A: fert-butyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxoimidazolidin-l - yOpiperidi ne- 1 -carboxyl ate: A mixture of fers-butyl 4-(2-oxoimidazolidin-l-yl)piperidine-l - carboxylate (5.38 g, 20 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate
(4.92 g, 20 mmol), Pd(OAc)2 (0.22 g, 1 ,0 mmol), Cs2C03 (13.04 g, 40 mmol) and Xantphos (1.16 g, 2,0 mmol) in toluene (100 mL) and H20 (1.08 g, 60 mmol) was stirred at 60°C for 12 h under N2. After cooling, the mixture was diluted with EtOAc ( 50 mL) and washed with water (100 mL). The organic layer was separated and concentrated. The residue was purified via silica gel to afford the title compound.
!H- M (400 MHz, CDC13) δ ppm 5,20 (s, 2H), 4,22 (s, 1H), 4, 16 (t, J ------- 7,8 Hz, 2H), 3.83-3.95
(m, 1 1 1), 3.55 (t, J= 7.8 Hz, 2H), 2,72-2,82 (rn, 2H), 2.00 (s, 3H), 1.50-1.78 (m, 4H), 1.42 (s,
9H).
Step B: l-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one: tert- Butyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxoimidazolidin-l-yl)piperidine-l- carboxylate (1.3 g, 3,6 mmol) was dissolved in HCl/EtOAc (4 M, 20 mL), then the mixture was stirred at room temperature for 30 min. After removing the solvent, the residue was purified via SCX (Ion exchange column) to afford the title compound. LC/MS: [(M+l)]+ = 266.
INTERMEDIATE 37
l-(4-methyl-5-oxo-2.5-dihydrof\iran-3-yl)-3-(piperidin-4-yl)tetrahydropyrimidi
The title compound was prepared in an analogous fashion as described for l -(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one above (Intermediate 36) starting from fert-butyl 4-(2-oxotetrahydropyrimidin-l(2H)-yl)piperidine-l-carboxylate and 4-methyl-5- oxo-2, 5-dihydrofuran-3-yl trifluoromethanesulfonate. LC/MS: [(M+l)]+ = 280.
l-(3-azabicyclo[3.1.0]hexan-6-ylV3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl imidazoli
The title compound was prepared in an analogous fashion as described for l-(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one above (Intermediate 36) starting from e/ -butyl 6-(2-oxoimidazolidin-l-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate and 4- methyl-5 -oxo-2, 5-dihydrofuran-3 -yl trifluoromethanesulfonate. LC/MS: [(M+l)]"r ~ 264.
3 -Oxocvclopent- 1 -enyl trifluoromethanesulfonate
To a solution of 1,3 cyclopentadione (2.5 g, 25.5 mmol) in DCM (50mL) at -78°C was added 2,6-lutidine (4.45 ml, 38 mmol), followed by triflic anhydride (5.14 mL, 30.6 mmol) dropwise. The reaction temperature was maintained at -78°C for 0.5 h before warming to RT for l h. The mixture was washed with 1 N HCi (10 mL), and NaHC03 (5 mL - diluted solution), dried over Na?S04, concentrated to give the title compound. LC-MS (IE, m/z): 231 [M +1 ]+
1 -(3 -azabi cvclo|"3. 1 .0 ljhexan-6-yl)-3 -(3 -oxocvclopent- 1 -en- 1 -yl imidazolidin-2-one
The title compound was prepared in an analogous fashion as described for l-(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one above (Intermediate 36) starting from fe/7-butyl 6-(2-oxoimidazolidin-l-yl)-3-azabicyclo[3. 1.0]hexane-3-carboxylate and 3- oxocyclopent- l-en-l-yl methanesulfonate. LC MS: [(M+l)]† = 248.
l-(4-methyl-5-oxo-2.5-dihvdrofuran-3-yl -3-(pyrrolidin-3-yl)imidazolidin-2-one
The title compound was prepared in an analogous fashion as described for l-(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (Intermediate 36) starting from tert- butyl 3-(2-oxoimidazolidin-l-yl)pyrrolidine-l-carboxylate and 4-methyl-5-oxo-2,5- dihydrofuran-3-yi trifluoromethanesulfonate. LC/MS: [(M+l)]† = 252.
INTERMEDI enantiomers)
(7x!)-4-methyl-3-{4-methy
AND (S)-4~m ethyl -3 -(4-methyl -5 -oxo-2, 5 -dihydrofuran-3 -yl )- 1 -(piperi di n-4-yl)i m i dazol i di n-2- one
Step A: fert-butyl 4-(4-methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yn-2-oxoimidazolidin-l- vDpiperidi ne- 1 -carboxyl ate: A mixture of fers-butyl 4-(4-methyl-2-oxoimidazolidin-l - yl)piperidine-l-carboxylate (2.50 g, 8.8 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (2.80 g, 1 1 mmol), Pd2(dba)3 (0.50 g, 0.55 mmol) and Xantphos (1.00 g, 1.7 mmol) in toluene (30 mL) was added Cs2C03 (8,60 g, 26 mmol), the mixture was heated to reflux, and stirred for 16 hours under N2 protection. The mixture was concentrated, purified on silica gel (PE/EtOAc from 10/1 to 2/1), then separated by SFC chirai chromatography (Column: Chiralcel OD-3 150x4.6 mm ID,, 3 urn; Mobile phase: iso-propanol (0.05% DEA) in C02 from 5% to 40%; Flow rate: 2.5 mL/min; Wavelength: 220 nm) to afford the title compounds (faster eluting and slower eluting enantiomers).
Faster eluting peak: 1H- MR (400 MHz, CDC13) δ ppm 5.38-5.30 (m, IH), 5.1 1-5.06 (m, IH), 4.53-4.50 (m, I H), 4.23-4.21 (m, 2H), 3 ,94-3 ,91 (m, I H), 3.67-3.63 (m, IH), 3 ,07 (d, ./ 8.0 Hz, IH), 2.09-2.76 (m, 2H), 1 ,96 (s, 3H), 1 ,83-1 ,54 (m, 2H), 1.60- 1.58 (m, 2H), 1.46 (s, 9H), 1.34 (d, J= 6.4 Hz, 31 ! )
Slower eluting peak:1!! NMR (400 MHz, CDC13) δ ppm 5.38-5.30 (m, IH), 5, 10-5,06 (m, I H), 4.53-4.50 (m, IH), 4.22 (s, 2H), 3.93-3.89 (m, IH), 3.67-3.63 (m, IH), 3.07 (d, J= 8.8 Hz, IH), 2,78 (s, 2H), 1 .96 (s, 3H), 1 .83-1 .54 (m, 2H), 1 ,59-1 ,55 (m, 2Ή), 1 .46 (s, 9H), 1.35- 1.33 id, J 6,4 Hz, 3H).
Step E: 4-methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-l -(piperi din-4-yl)imidazolidin-2- one: To a solution of tert-butyl 4-(4-methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2- oxoimidazolidin- l-yl)piperidine-l-carboxylate (faster eluting peak from Step A, 470 mg, 1 .24 mmol) in 4 mL of EtOAc was added 5 mL of HCl / EtOAc, the mixture was stirred at room temperature for 3 h and then concentrated to afford the title compound as a single enantiomer (42A). Similarly, the slower eluting product from Step A could be converted to the enantiomeric
title compound (42B) using HC1. The absolute stereochemistry of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
INTERMEDI enantiomers)
(R)-4-ethyl-3-(4-methyl-5-oxo-2,5-dihvdroto
AND (,S -4-ethyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-l-(piperid
Step E: fenf-butyl 4-("4-ethyl-3-("4-methyl-5-oxo-2,5-dihvdrofuran-3-yl -2-oxoimidazolidin-l- yOpiperidine- 1 -carboxylate: To a mixture of tert -butyl 4-(4-ethyl-2-oxoimidazolidin-l- yl)piperidine-l-carboxylate (2,50 g, 8.41 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (2.70 g, 1 1.0 mmol), Pd2(dba)3 (0.425 g, 0.436 mmol) and Xantphos (1.00 g, 1.73 mmol) in a toluene (100 mL) was added Cs2C03 (8.30 g, 25.5 mmol), then heated to reflux, stirred for 16 hours under N2 protection. The mixture was cooled and filtered, concentrated in vacuum, purified on silica gel eluted with PE/EtOAc from 10/1 to 1/1, then separated by SFC chiral chromatography (Column: Chiralcel OD-3 150x4.6 mm I.D., 3 um; Mobile phase: iso-propanol (0,05% DEA) in C02 from 5% to 40%, Flow rate: 2.5 mL/min;
Wavelength: 254 nm) to afford the title compounds as single enantiomers. !H-NMR (400 MHz, CDC13) δ ppm 5.42-5.37 (m, IH), 5,09-5,05 (m, 1 1 1), 4.34-4.06 (m, 4H), 3,62-3,57 (m, 1H), 3.20-3.18 (m, 1 1 1 ). 2.78 (s, 2H), 2.04 (s, 1 1 1). 1.93 (s, 3H), 1.71-1.64 (m, 3H), 1.62 (s, IH), 1.46 (s, 9H), 1.27-1.24 (m, IH), 0.96-0.91 (m, 3H).
Step F: 4-ethyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl )-l-(piperidin-4-yl)imidazolidin-2-one: ert-butyi 4-(4-ethyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxoimidazolidin-l- yl)piperidine-l -carboxylate (faster eluting isomer from Step A, 1 ,30 g, 3.3 mmol) in EtOAc (15 mL) was treated with HCl/EtOAc (4 M, 10 mL) and the resulting mixture was stirred at 25 °C for 18 h. The mixture was concentrated to afford the title compound as a single enantiomer 43A. Similarly, the slower eluting product from Step A could be converted to the enantiomeric title compound (43B) using HC1. The absolute stereochemistry of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
INTERMEDI enantiomers)
(R -4-methyl-3-(5-oxo-2,5-dihvdrof iran-3-yl)-l-(piperidin-4-yl)irnidazolidin-2-one AND (S)-4- methyl-3-(5-oxo-2.5-dihydrofuran-3-yl)-l-(piperidin-4-yl)imidazolidin^
Step A: fert-butyl 4-(4-methyl-2-oxo-3-(5-oxo-2,5-dihydrofuran-3-yl )imidazolidin-l- yl piperidine-l-carboxylate: To a mixture of ferf-hutyl 4-(4-methyl-2-oxoimidazolidin-l- yl)piperidine-l -carboxylate (2.80 g, 9.88 mmol), 5-oxo-2,5-dihydrofuran-3-yl
trifluoromethanesulfonate (2.90 g, 12.5 mmol), Pd2(dba)3 (453 mg, 0.495 mmol) and Xantphos (1.15 g, 1.98 mmol) in a toluene (30 mL) was added Cs2C03 (9.66 g, 29.6 mmol ), the resulting mixture was heated under reflux for 16 hours under N2 protection . The mixture was
concentrated, the residue was purified by flash chromatography (PE/EtOAc from 5/1 to 1/1), and then separated by SFC chiral chromatography (Column: Chiralcel OD-3 150x4.6 mm ID., 3um; Mobile phase: iso-propanol (0.05% DEA) in C02 from 5% to 40%; Flow rate: 2.5 mL/min; Wavelength: 220 nm to get two single enantiomers (faster eluting A and slower eluting B).
Step B : 4-methyl-3-(5-oxo-2,5-dihydrofuran-3-yl)-l-{piperidin-4-yl )imidazolidin-2- To a solution of (e (-butyl 4-(4-methyl-2-oxo-3-(5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-l - yl)piperidine-l -carboxylate (first eluting in Step A under SFC chromatography, 220 mg, 0.60 mmol ) in EtOAc (2.5 mL) was added HCI/EtOAc (4,5 mL), the mixture was then stirred at room temperature for 24 hours, and then concentrated to afford the title compound as a single enantiomer 44A. Similarly, the sl ower eluting product from Step A can be converted to the enantiomeric title compound (44B) using HCl. The absolute stereochemistry of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
tm;¾5-l-(3-fluoropiperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidi
The title compound was prepared in two steps in an analogous fasion as described for 1 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (Intermediate 36)
e starting from 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate and tert- butyl /ram-3-fluoro~4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate. LC MS: [(M+l)]~ = 284.
INTERMEDIATE 46
c 5-l-(3-fluoropiperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-ynimidaz
The title compound was prepared in two steps in an analogous fasion as described for 1 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (Intermediate 36) above starting from 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate and cis- tert-butyl 3-fluoro-4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate. LC MS: [(M+l)]~ := 284.
tra/w-l-(n-methoxypiperidin-4-vn-3-(4-methyl-5-oxo-2,5-dihvdrofuran-3-vni
The title compound was prepared in two steps in an analogous fasion as described for I -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (Intermediate 36) above starting from 4-methyI-5-oxo~2,5-dihydrofuran-3-yl trifluoromethanesulfonate and trans- ert-butyi 3-methoxy-4-(2-oxoimidazolidin-l-yl)piperidine-l-carboxylate. LC/MS: [(M+l)]* = 296.
c/5- l-((3-methoxypiperidin-4-yl)-3-(4-melhyl-5-oxo-2,5-dihydrofuran-3-yl)i
The title compound was prepared in two steps in an analogous fasion as described for 1 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (Intermediate 36) above starting from 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate and cis-
tert-butyl 3-methoxy-4-(2-oxoimidazolidin-l -yl)piperidine-l-carboxylate. LC/MS: [(M+l)]~ =
296.
INTERMEDI single isomers)
(R)-l-(4-methyl-5-oxo-2,5-dihydrofuran-3^ AND (S)-l-(4- methyl-5-oxo-2,5-dihydrof iran-3-yl)-3-(piperidin-4-yl)pyrrolidin-2-one Step E: tert-butyl 4-(l- 4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxopyrrolidin-3-yl)piperidine- 1-carboxylate: A mixture of tert-butyl 4-(2-oxopyrrolidin-3-yl)piperi dine- l-carboxylate (100 mg, 0.94 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (106 mg, 0.43 mmol), Pd2(dba)3 (9 mg, 0.01 mmol), Xantphos (17 mg, 0.03 mmol), Cs -CO, (192 mg, 0.59 mmol ) in 6 mL of toluene was heated at 90°C overnight. The mixture was filtered through Celite, evaporated, the residue was purified by flash chromatography (PE: EtOAc = 8: 1. to 2: 1) to give a mixture of two enantiomers which were separated by SFC: Column: Chiralcel OJ-H 250x4.6 mm I.D., 5 um; Mobile phase: methanol (0.05% DEA) in CO? from 5% to 40%; Flow rate: 2.35 mL/min, Wavelength: 220 nm; 5H-NMR (400 MHz, CDC13) δ ppm 5.30 (d, J = 1.6 Hz , 1H), 5.20 (d, ,/ 1.2 Hz, I H), 4.10-4.20 (m, 2H), 3.95-4.05 (m, IH), 3.92 (s, IH), 2.67 (s, 2H), 2,50 (s, 1H), 2.15-2.25 (m, IH), 1 ,90-2,05 (m, 5H), 1 .80 i x. 3.2 Hz, IH), 1 ,53 (s, 3H), 1.40- 1.45 (s, 9H).
Step F: l -(4-methyl-5-oxo-2,5-dihydrof iran-3-yl)-3-(piperidin-4-yl)pyrrolidin-2-one: 4-(l-(4- M€thyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxopyrrolidin-3-yl)piperidine-l-carboxylate (first peak in SFC, 100 mg, 0.28 mmol) was dissolved in 4 mL of EtOAc and treated with 6 mL of 4 M HCl/EtOAc. The mixture was then stirred at r.t. over night, and then concentrated to afford the title compound (49A) as a single enantiomer. Similarly, the opposite enantiomer (49B) was obtained from the second peak coming from SFC separation of the precursor using 4 M
HCl/EtOAc. The absolute stereochemistry of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
INTERMEDI enantiomers)
( V3-methyl-l-(4-methyl-5-oxo-2,5-dihydro^
Step E : tert-butyl 4-(3 -methyl - 1 -( 4-methyl-5 -oxo-2, 5 -di hydrofuran-3 -yl)-2-oxopyrrolidin-3 - yl )pi peri dine- 1 -carboxylate : A mixture of tert-butyl 4-(3-methyl-2-oxopyrrolidin-3- yl)piperidine-l -carboxylate (920 mg, 3.26 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (1.04 g, 4.22 mmol), Pd2(dba)3 (159 mg, 0.163 mmol) and Xantphos (377 mg, 0.652 mmol) in toluene (30 mL) was added Cs2C03 (3 , 19 g, 9.79 mmol), the resulting mixture was heated to reflux and stirred for 16 hours under N2 protection. The mixture was cooled, filtered and concentrated; the residue was purified on silica gel, eluted with PE/EtOAc from 8/1 to 2/1 to get the target products which were separated by SFC chiral chromatography: Column: Chiraipak AD-H 250x4.6 mm ID., 5 um; Mobile phase: methanol (0.05% DEA) in C02 from 5% to 40%; Flow rate: 2.35 mL/min; Wavelength: 220 ran. !H-NMR (400 MHz, CDC13) δ ppm 5.32-5.18 (m, 2H), 4.15-4.09 (m, 2H), 3.98-3.94 (m, 2H), 2.67 (s, 2H), 2.21-2.20 (m, 1 1 1). 2.04 (s, 3H), 1.84-1.71 (m, 4H), 1.59 (s, 9H), 1.50 (s, 1H), 1.27-1.13 (m, 4H).
Step F: 3-methyl-l-(4-memyl-5-oxo-2.5-dihydrofuran-3-ylV3-(piperidin-4-yl)pyrroli
To a suspension of tert-butyl 4-(3-methyl-l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2- oxopyrrolidin-3-yl)piperidine-l -carboxylate (second eluting in SFC chiral chromatography from Step A, 190 mg, 0.50 mmol) in EtOAc (2 mL) was added HCl/EtOAc (4 , 2.5 ml,), the resulting mixture was stirred at room temperature for 1 h. The mixture was concentrated to afford the title compound 50B. Similarly, the opposite enantiomer (50A) was obtained from the second peak coming from SFC separation of the precursor using 4 M HCl EtOAc. The absolute stereochemistry of each product was not established; however, both enantioniers were useful for preparing ROMK inhibitors.
TNTERMEDLATES 51 A and 5 IB (two single enantioniers)
(R -l-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)-r3,4'-bipiperidin1-2-one AND (6* -l -(4-methyl-5- oxo-2,5-dihydrofuran-3-yl)- 3,4l-bipiperidin]-2-one
Step A: tert-butyl l-(4-methyl-5-oxo-2,5-dihvdrofuran-3-vn-2-oxo-[3.4'-bipiperidine1-l '- carboxylate: To a solution of tert-butyl 2-oxo-[3,4!-bipiperidine]-r-earboxylate (270 mg, 0.96 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (351 mg, 1.43 mmol) in
1 8 mL of toluene was added Pd2(dba)3 (46 mg, 0.05 mmol) and Xantphos (56 mg, 0.10 mmol) under N2 atmosphere, followed by Cs2C03 (624 mg, 1.92 mmol), the resulting mixture was heated at 100°C overnight, then cooled to room temperature, filtered and concentrated, the residue was purified by flash chromatography (60% ethyl acetate in PE) to afford the title compound. The two enantiomers were separated by SFC chiral chromatography (faster eluting and slower eluting enantiomers were obtained): Column: Chiralpak AD-3 150x4.6 mm ID., 3 um; Mobi l ephase: methanol (0.05% DBA) in C02 from 5% to 40%; Flow rate: 2.5 mL/min; Wavelength: 254 nm. ¾- MR (400 MHz, CDC13) δ ppm 5.20 (d, J = 17 Hz, 1H), 5.00 (d, J = 17 Hz, 1 H), 4.25-4.05 (br, 2H), 3 ,80-3 ,65 (m, 2H), 2.77-2.62 (m, 2H), 2.50-2.42 (m, 1 H), 2.35- 2.22 (m, 1H), 2.08-2.03 (m, 1H), 1.95 (s, 3H), 1.94- 1.80 (m, 2H), 1.68-1.52 (m, 3H), 1.41-1.22 (m, 2H).
Step F: 1 -(4-methyl-5-oxo-2.5-dihvdrofuran-3-yl)-|"3,4'-bipiperidin1-2-one: To a solution of tert- butyl l-(4-methyi-5-oxo-2,5-dihydrofuran-3-yl)-2-oxo-[3,4!-bipiperidine]-r-carboxylate (first eluting in SFC chromatography in Step A, 1 50 mg, 0.4 mmol) in 2 mL of EtOAc was added 2 mL of HCl/ EtOAc, the mixture was stirred at room temperature for 3 h, and then concentrated to afford the title compound as a single enantiomer 51A. Similarly, the slower eluting product from Step A could be converted to the enantiomeric title compound (51B) using HCl. The absolute stereochemistry of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
INTERMEDIATES 52A and 52B (two single enantiomers)
(R)-3-(4-hvdroxypiperidin-4-yl)-l-(4-meth^ AND
(R)-3-(4-hydroxypiperidin-4-yl)-l -(4-methyl-5-ox
Step A: /er -butyl 4-hvdroxy-4-( l-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)-2-oxopyrrolidin-3- yl)piperidine-l -carboxylate: To a solution of tert-butyl 4-hydroxy-4-(2-oxopyrrolidin-3- yl)piperidine-l-carboxylate (2,00 g, 7.0 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (2.25 g, 9.2 mmol) in 40 mL of toluene was added Pd2(dba)3 (322 mg, 0.35 mmol) and Xantphos (404 mg, 0.7 mmol) under N2 atmosphere, followed by Cs2C03 (4.58 g, 14 mmol), the resulting mixture was heated at 100°C overnight, then cooled to room
temperature, filtered and concentrated, the residue was purified by flash chromatography
(PE:EtOAc from I : I to 1 :4) to afford the product which was separated to provide two single enantiomers (faster and slower eluting) by SFC chiral chromatiography: Column: Chiralpak AD- 3 150x4.6 mm ID., 3 um; Mobile phase: iso-propanol (0.05% DEA) in CO . from 5% to 40%; Flow rate: 2.5 mL/min; Wavelength: 254 nm. ]H- MR (400 MHz, CDC13) δ ppm 5.32-5.12 (m, 2H), 4,05-3,88 (m, 3H), 3.50 (s, 1 H), 3.16 (br, 2H), 2,72-2,51 (m, 1 H), 2.32-2.22 (m, 1H), 2,04 (s, 4H), 1 ,78-1.45 (m, 13 I f )
Step B: 3-(4-hydroxypiperidin-4-yl)-l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidi
To a solution of fcrt-butyl 4-hydroxy-4-(l.-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2- oxopyrrolidin-3-yl)piperidine-l-carboxylate (single enantiomer faster eluting from Step A, 100 mg, 0.26 mmol) in 1 mL of EtOAc was added 1 mL of HCl / EtOAc, the mixture was stirred at room temperature for 3 h, and then oncentrated to afford the title compound as a single enantiomer S2A. Similarly, the slower eluting product from Step A could be converted to the enantiomeric title compound (52B) using HCl, The absolute stereocheraistn,' of each product was not established; however, both enantiomers were useful for preparing ROMK inhibitors.
1 -(4-m ethyl -5-oxo-2.5-dihydrofuran-3-yl)-4-(piperidin-4-yl)pyrrolidin-2-one Step A: fert-butyl 4-(l -(4-methyl-5-oxo-2.5-dihydrofuran-3-yl)-5-oxopyrrolidin-3-yl)piperidine- 1-carboxylate: The mixture of fert-butyl 4-(5-oxopyrrolidin-3-yl)piperidine-l-carboxylate (500 mg, 1.87 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (504 mg, 2.04 mmol), Xantphos (108 mg, 0, 187 mraol), Pd2(dba)3 (86 rng, 0.094 mmol) and Cs2C03 (909,5 mg, 2.8 mmol) in toluene (5 mL) was stirred at 110 °C overnight under N2. The mixture was filtered through celite, concentrated and purified on silica gel eluted with PE/EA = 1/3 to afford the title compound.
Step B: l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-4-(piperidin-4-yl)pyrrolidin-2-one: The mixture of tert-bu y] 4-(l -(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-5-oxopyrrolidin-3- yl)piperi dine- 1-carboxylate (160 mg, 0,44 mmol) in DCM: TFA (1 : 1, 4 mL) was stirred at ambient temperature for 1 hour. The mixture was concentrated to give the title compound.
"N TERMED I A TE 54
l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperazin-l-ynpyrrolidin-2-one The title compound, as a mixture of two enantiomers, was prepared in two steps in an analogous fashion to that described for l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-4-(piperidin-4- yl)pyrrolidin-2-one Intermediate 54, immediately above) starting from fe/f-butyl 4-(2- oxopyrrolidin-3-yl)piperazine-l-carboxylate and 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate. LC/MS: [(M+l)]+ = 266.
4-{3 -azabi cyclo[3.1.0] hexan-6-yl)- 1 -{5 -oxo-2, 5 -di hydrofuran-3 -yl)pyrrol idin-2-one Step A: benzyl 6-formyl-3-azabicyclo[3.1.0]hexane-3-carboxylate: To an ice-cooled (X'M (10 ml) solution of benzyl 6-(hydroxymethyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (890 mg, 3.60 mmol) was added Dess-Martin Periodinane (1679 mg, 3.96 mmol) portionwise over a period of 20 minutes. After addition was completed, the reaction mixture was allowed to warm to ambient temperature. At the 2 hour point, another 0.5 equivalents of Dess-Martin was added. After 30 minutes, the reaction was complete. The mixture was quenched by addition of 1 : 1 solution of aqueous sodium bicarbonate and aqueous sodium thiosulfate (allow biphasic mixture to sit for -30 minutes). The aqueous layer was extracted with DCM (3 X 10 mL). The combined organic layers were then dried over sodium sulfate, filtered, concentrated in vacuo and purified via MPLC (0-100% EtO Ac/Hex) to afford benzyl 6-formyl-3-azabicyclo[3.1.0]hexane-3- carboxylate.
Step B: (EVbenzyl 6-(3-methoxy-3-oxoprop-l-en-l-yl)-3-azabicyclo[3.1 ,0]hexane-3- carboxylate: In a microwave vial a toluene (10 mL) solution of benzyl 6-formyl-3~
azabicyclo[3.1.0]hexane-3-carboxylate (690 mg, 2.81 mmol) and methyl
(triphenylphosphoranylidene)acetate ( 1223 mg, 3.66 mmol) was heated to 100 °C for 1 .5 hours.
The reaction mixture was cooled to ambient temperature, concentrated in vacuo and purified via MPLC (0-100% EtO Ac/Hex) to afford the title compound.
Step C : benzyl 6-(4-methoxy- 1 -nitro-4-oxobutan-2-yl)-3 -azabicyclo[3.1.0]hexane-3 -carboxylate : To a THF (6 mL) solution of (Til-benzyl 6-(3-methoxy-3-oxoprop-l-en-l-yl)-3- azabicyclo[3.1.0]hexane-3 -carboxylate (773 mg, 2.57 mmol) was added nitrom ethane (0.207 mL, 3.85 mmol) and then TBAF (2.77 mL, 2.77 mmol). The reaction was heated to 70°C for 2 hours after which the mixture was cooled to ambient temperature, concentrated in vacuo and purified via MPLC (0-100% EtO Ac/Hex) to afford the title compound.
Step D: benzyl 6-(l-amino-4-methoxy-4-oxobutan-2-yl)-3-azabicyclo[3.1.0]hexane-3- carboxylate: To an ice-cooled acetic acid (7.50 mL) water (7.50 mL) mixture of benzyl 6-(4- methoxy- 1 -nitro-4-oxobutan-2-yl)-3 -azabicycio[3.1.0]hexane-3 -carboxylate (670 mg, 1.85 mmol) was added zinc (3020 mg, 46.2 mmol) in 500mg portions every 30 minutes. At about ~15 equivalents, the reaction mixture was warmed to ambient temperature and stirred for an additional 30 minutes. The reaction was complete. The reaction mixture was filtered over a pad of celite and washed with -20 mL of ethyl acetate. The organics were then rotovapped off and the aqueous layer was made basic by addition of solid sodium bicarbonate. The basic aqueous layer was then extracted with 30% IPA/chloroform (3 X 10 mL). The combined organic layers were then dried over sodium sulfate, filtered, concentrated in vacuo to afford the title compound which was used without further purification.
Step E: benzyl 6-(5-oxopyrrolidin-3-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate: To methanol (10 mL) solution of benzyl 6-(l-amino-4-methoxy-4-oxobutan-2-yl)-3-azabicyclo[3.1 .Ojjhexane- 3-carboxylate (570 mg, 1.72 mmol) was added potassium carbonate (237 mg, 1.72 mmol). The reaction mixture was allowed to stir at ambient temperature for 3 hours after which the mixture was concentrated in vacuo. Reverse phase Gilson purification afforded the title compound.
Step F: benzyl 6-(5-oxo-l-(5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-3-yl)-3- azabicyclo[3.1.0]hexane-3 -carboxylate: 4-Bromofuran-2(5H)-one (195 mg, 1.20 mmol), bis(dibenzylideneacetone)palladium (28.7 mg, 0.050 mmol), 4,5-Bis(diphenylphosphino)-9,9- dimethylxanthene (87 mg, 0.150 mmol), and cesium carbonate (488 mg, 1.50 mmol) were combined in a microwave vial and benzyl 6-(5-oxopyrrolidin-3-yl)-3-azabicyclo[3. 1.()]hexane-3- carboxylate (300 mg, 1.00 mmol) was added as a solution in toluene (8 mL). The vessel was purged with nitrogen and degassed for 10 minutes. Then the mixture was heated at 90°C, monitoring by LC/MS. When the reaction was judged to be complete by LC/MS, the mixture was filtered through celite, washing with ethyl acetate. The filtrate was concentrated and the
crude product was purified by MPLC using a gradient of ethyl acetate/hexanes (40 g silica column). The title compound was obtained.
Step G: 4-(3-azabicyclo[3.1.0]hexan-6-yl)-l-(5-oxo-2,5-dihydrofuran-3-ynpyrrolidin-2-one: To a palladium on carbon (29.0 mg, 0.027 mmol) slurry in DCM (10 ml) was added benzyl 6-(5- oxo- 1 -(5-0X0-2, 5-dihydrofuran-3 -yl)pyrrolidin-3 -yl)-3 -azabicyclo[3.1.0]hexane-3 -carboxvlate (327 mg, 1.089 mmol) as a methanol (5.00 mL) solution. The reaction was placed under balloon pressure hydrogen (vac purge 3 times) for 15 hours at ambient temperature. After 15 hours, the reaction mixture was filtered over a pad of celite, washed ~20mL of DCM, concentrated in vacuo and purified via MPLC (0-100% EtO Ac/Hex, 0% methanol/DCM then 100% methanol) to afford the title compound. LC/MS: [(M+l)]+ = 249.
4-(3-aza.bicyclo[3.1.0]hexan-6-yi )-l-(4-met.hyl-5-oxo-2,5-dihydrofuran-3-yl)
The title compound was prepared in an analogous fashion to that described for 4-(3- azabicyclo[3.1.0]hexan-6-yl)-l -(5-0X0-2, 5-dihydrofuran-3-yl)pyrrolidin-2-one (Intermediate 56, immediately above) except 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate was used in place of 4-bromofuran-2(5H)-one in Step F. LC/MS: [(M+l)]+ = 263.
ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yn-2-oxooxazolidin-5-yl jpiperidine-4- carboxylate
Step A: l-fert-Butyl 4-ethyl 4-(2-((tgrt-butoxycarbonyl)amino)-l-hydroxyethyl)piperidine-1.4- di carboxylate: To a solution of LDA (prepared by adding «-butyllithium (20 mL, 49.3 mmol) to diisopropylamine (5.16 mg, 51.0 mmol) in THF (40 mL) at 0°C, stir for 30 min) was added 1- tert-butyl 4-ethyl piperidine-l ,4-dicarboxylate (4,00 g, 16.4 mmol) in TMEDA (15 mL, 99 mmol) dropwise via syringe pump at ~78°C for 10 min. The mixture was stirred at the same temperature for 30 min, tert-butyl (2-oxoethyl)carbamate (8.1 1 g, 51.0 mmol) in THF (20 mL)
was added slowly by syringe pump for 15 min. The mixture was stirred at -78°C for 30 min, quenched with saturated NH4C1 at -78°C, wanned up to rt and diluted with EtOAc (200 mL). The organic layer was separated, the aqueous layer was extracted with EtOAc (100 mL). The combined organic layers were washed with brine, dried (MgS04), and concentrated. The residue was purified by column chromatography (80 g, silical gel, MeOH/DCM, gradien 0-10%, monitor at 210 nM) to afford the title compound.
Step B: 1-tert-Butyl 4-ethyl 4-(2-oxooxazolidin-5-yl)piperidine-1.4-dicarboxylate: To a solution of 1 -tert-butyl 4-ethyl 4-(2-((tert-butoxycarbonyl)amino)- 1 -hydroxy ethyDpiperidine- 1 ,4- dicarboxylate (450 mg, 1.08 mmol) in DCM (10 mL) at -78°C was added tri ethyl amine trihydrofluoride (0.35 mL, 2.16 mmol), tri ethyl amine (0. 15 mL, 1.08 mmol), and
(diethylamino)difluorosulfonium tetrafluoroborate (371 mg, 1.62 mmol). The mixture was stirred overnight while warming up to rt, and quenched with aqueous NaHC()3 , The organic layer was separated and the aqeous layer was extracted with DCM (30 mL). The combined organic layers were dried (MgSO-i) and purified by preparative TLC (5% MeOH/DCM as eluent) to give the title compound. I .(VMS: [(M+23)]÷ = 365.
Step C: 1-fert-Butyl 4-ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxooxazolidin-5- yl)piperidine-1.4-dicarboxylate: To a round bottom flask was charged 1 -tert-butyl 4-ethyl 4-(2- oxooxazolidin-5-yl)piperidine- 1 ,4-dicarboxylate (180 mg, 0.526 mmol), 4~methyl-5-oxo-2,5~ dihydrofuran-3-yl trifluoromethanesulfonate (155 mg, 0.631 mmol), Pd2(dba)3 (12.0 mg, 0.013 mmol ), XantPhos (22,8 mg, 0.039 mmol), and cesium carbonate (343 mg, 1.05 mmol). The flask was equipped with condenser, vacuumed and back filled with N2 and filled with Dioxane (2, 1 mL). The reaction mixture was heated at 90°C overnight, and filtered through celite. The filtrate was evaporated to give the crude product, which was purified by column chromatography (0- 10% MeOH/DCM as eluent) to give the title compound. LC/MS: [(M+l-56)]+ = 383.
Step D: ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl -2-oxooxazolidin-5-yl)piperidine-4- carboxylate: 1-tert-Butyl 4-ethyl 4-(3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-2-oxooxazolidin- 5-yl)piperidine-l,4-dicarboxylate (230 mg, 0.525 mmol) in DCM (2.6 mL) was treated with TFA ( 1.2 mL, 15.7 mmol) at 0°C to free Boc and give TFA salt. Then a 2 g Bond Elut SCX (ion exchange) column was first rinsed with MeOH, load sample with MeOH, washed with MeOH dropwise to remove TFA, finally rinsed with 2N H3/MeOH to get the title compound as a free amine. LC/MS: [(M+l)]÷ = 339
3-methyl-4-(4-methyl-6-(piperazin-l-yl pyridin-3-yl)furan-2(5H)-one Step A: tot-butyl 4-(5-bromo-4-methylpyridin-2-vnpiperazine-l -carboxylate: 2,5-dibromo-3- methylpyridine (998 mg, 3.98 mmol), 1-boc-piperazine (570 mg, 3.06 mmol) were combined in a microwave vial, dry toluene (10 ml) was added to that followed by sodium tot-butoxide (441 mg, 4.59 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (106 mg, 0.184 mmol) and tris(dibenzylideneacetone)dipalladium(0) (56.0 mg, 0.061 mmol). The resulting mixture was purged with nitrogen and then heated at 100°C for 3 hours. After cooling to room temperature, the reaction mixture was diluted with EtOAc and washed with water. Organic layer was dried over anhydrous Na2S04, filtererd, concentrated and purified by silica gel column
chromatography using (0-30)% EtOAc/Hexanes as mobile phase and the product, tor-butyl 4-(5- bromo-4-methylpyridin-2-yl)piperazine- 1 -carboxylate, was isolated.
Step B: tot-butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-y0pyridin-2- vDpiperazine- 1 -carboxylate: tot-butyl 4-(5-bromo-4-methylpyridin-2-yl)piperazine-l- carboxylate (0.80 g, 2.331 mmol) was mixed with bis(pinacolato)diboron (0.710 g, 2.80 mmol) and potassium acetate (0.686 g, 6.99 mmol) in 1,4-dioxane (18 mL). After degassing with N2 for 10 minutes, [l , -bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.085 g, 0.117 mmol) was added and the resulting reaction mixture was heated overnight at 80°C. The reaction mixture was then cooled to room temperature, filtered over celite and concentrated to get the crude product, tot-butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2- yl)piperazine-l -carboxylate, which was taken to the next step without purification.
Step C: tot-butyl 4-(4-methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperazine- 1 -carboxylate: In a microwave vial, tot-butyl 4-(4-methyl-5-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)pyridin-2-yl)piperazine-l -carboxylate (0.9 g, 2.231 mmol) was mixed with 4- methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (0.824 g, 3.35 mmol) in tetrahydrofuran (8 ml) and sodiumbicarbonate and water (8 mi). [Ι, - bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.082 g, 0.112 mmol) was added to the
mixture and the resulting reaction mixture was heated for 10 minutes at 120°C under microwave condition at high absorption. After cooling down to rt, reaction was diluted by adding EtOAc and water. After separation, aqueous layer was extracted with EtOAc (2X). Combined organic layers were dried over MgS04, filtered, concentrated to get the crude product that was purified by silica gel column chromatography using (20-80)%EtOAc/Hexanes as mobile phase and the product, ferf-hutyl 4-(4-methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2- yl)piperazine-l-carboxylate, was isolated.
Step D: 3-methyl-4-(4-methyl-6-(piperazin-l-yl)pyridin-3-yl)f iran-2(5H)-one: ert-butyi 4-(4- methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperazine-l-carboxyk was dissolved in DCM and treated with TFA. The reaction was monitored by LC-MS until completion whereupon the volatiles were removed under vacuum to afford the title compound.
4-(6-(piperazin-l-vi )pyridii -3-yl)furan-2(5H)-one
Step A: rert-butyl 4-(5-bromopyridin-2-yl)piperazine-l-carboxylate: To a solution of tert-butyl piperazine-l-carboxylate (1.00 g, 5.37 mmol) in DMF (2ml) and THF (10 mi) in a 20 mL microwave vial was added DIEA (1.125 mL, 6,44 mmol) and the mixture was heated at 160°C for 100 minutes. The solvent was removed after cooling to room temperature, the residue was dissolved in EtOAc (50 ml) and was washed with water (30 mi ) followed by Brine (20 ml). The organic layer was dried over anhydrous Na2S04, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (125g pre packed column) using (0-100)% EtOAc/Hexanes as mobile phase and the title compound was isolated
Steps B through D: 4-(6-(piperazin-l-yl)pyridin-3-yl)furan-2(5i -one: The title compound was prepared in an analogous fashion as described for Intermediate 58 (Steps B-D), immediately above, starting from tert-butyl 4-(5-bromopyridin-2-yl)piperazine-l-carboxylate. LC-MS [M+l]+ 246.1
The Intermediates in Table 3 were prepared in an analogous fashion to the methods described for 3-methyl-4-(4-methyl-6-(piperazin-l -yl)pyridin-3-yl)furan-2(5H)-one (INTERMEDIATE 58)
and 4-(6-(piperazin-l-yl)pyridin-3-yl)furan-2(5H)-one (INTERMEDIATE 59) using either 4- methyl-5-oxo-2,5-dihydrofuran-3-yl irifluoromethanesulfonate or commercially available 4- bromofuran-2(5H)-one and the commercially available starting materials shown.
3-memyl-4-(6-(piperidin-4-yl)pyridin-3-yl)furan-2(5i )-one
Step A: fert-butyl 5-chloro-5'6'-dihydro- 2,4l--bipyridine]- (2'H)--carboxylate: In a microwave vial, 2-bromo-5-chloropyridine (0.934 g, 4.85 mmol) was mixed with /er/-butyl 4-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-l(2H)-carboxylate (l .Og, 3.23 mmol)
in tetrahydrofuran (8 nil) and sodium bicarbonate (0,543 g, 6.47 mmol) and water (8 n L). [Ι, Γ- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.1 18 g, 0. 162 mmol) was added. The reaction was heated for 10 minutes at 120°C in a microwave at high absorption. After cooling down to rt, reaction was diluted by adding EtOAc and water. After separation, aqueous layer was extracted with EtOAc (2X). Combined organic layers were dried over MgSQ j, filtered, concentrated to get the crude product that was purified by silica gel column chromatography using (20-80)%EtOAc- Hexanes as mobile phase and the title compound was isolated.
Step B: ferr-butyl 5-(4,4,5,5 etramethyl-l,3,2-dioxaborolan--2-yl)-5',6'-dihydiO-j'2,4l--bipyridine]- l'(2'H)-carboxylate: ieri-huty] 5-chloro-5,6'-dihydro-[2,4,-bipyridine]-r(2'H)-carboxylate (410 mg, 1.391 mmol), bis(pinacolato)diboron (1060 mg, 4.17 mmol), 2-dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl (13.26 mg, 0.028 mmol), potassium acetate (410 mg, 4.17 mmol) and tris(dibenzylideneacetone)dipalladiurn(0) (12,74 mg, 0.014 mmol) were taken up in 1,4- dioxane (8 mL) in a microwave vial and the resulting mixture was degassed in for 10 minutes and then heated at 1 10°C for 4 hours. The reaction mixture was then cooled to room
temperature, filtered over celite, concentrated and the crade material was taken to the next step. Step C: fe/V-butyl 5-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)-5',6'-dihydro-r2,4'-bip\iTidinel- 1 '(2'H)-carboxylate : The title compound was prepared from rert-butyl 5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)-5,,6'-dihydro-[2,4,-bipyridine]- (2'H)-carboxylate and 4-methyl-5-oxo- 2,5-dihydrofuran-3-yl trifluoromethanesulfonate in an analogous fashion as described for tert- butyl 4-(4-methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperazine-l- carboxylate INTERMEDIATE 58 (Step C).
Step D: fert-butyl 4-(5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperidine-l- carboxylate:
fert-butyl 5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-5',6'-dihydro-[2,4'-bipyridine]- (2'H)- carboxylate (190 mg, 0.533 mmol) was dissolved in methanol (7 mL) and hydrogenated at room temperature at 1 atm. pressure. The reaction mixture was filtered through celite, washed with methanol , concentrated to get the title product.
Step E: 3-methyl-4-(6-(piperidin-4-yl)pyridin-3-yl)furan-2(5H)-one: The title compound was prepared from fert-butyl 4-(5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperidine-l- carboxylate in an analogous fashion to that described for 3 -methyl -4-(4-methyl-6-(piperazin-l - yl)pyridin-3-yl)furan-2(5H)-one INTERMEDIATE 59 (Step D) using TFA.
3 -m ethyl -4-(3 -(piped din-4-yl)- 1H- 1 ,2,4-triazol- 1 -yl)furan-2(5H)-one Step A: tert-butyl 4-(l H-L2,4-triazol-3-yl)piperidine-l -carboxylate: To a solution of tert-butyl 4-cyanopiperidine-l-carboxylate (32.75 g, 156 rnmol) in MeOH (280 ml.) was added a solution of NaOMe (2.50 g, 47 mmol) in 5 niL of MeOH. The resulting mixture was stirred at room temperature for 30 min, and then formohydrazi de (9.40 g, 156 mmol) was added. The reaction mixture was heated under reflux for 16 hrs, another batch of NaOMe (2.50 g, 47 mmol) in 5 mL of MeOH and formohydrazi de (9.40 g, 56 mmol) were added to the above reaction. The reaction mixture was heated under reflux for 48 hrs. The mixture was cooled and adjusted to pH 6 with AcOH, added water and EtOAc, the organic layer was separated and dried over anhydrous Na?SQ4, filtered and concentrated, the crude product was purified by flash chromatography (DCM : MeOH = 60 : 1 to 10 : 1) to afford the title compound.
Step B: ferr-butyl 4-(l-(4-memyl-5-oxo-2,5-dihvdrofuran-3-yl)-lH-l,2,4-triazol-3-yl)piperidine- 1-carboxylate: To a solution of fert-butyl 4-(l H-l ,2,4-triazol-3-yl)piperidine-l -carboxylate (1 .00 g, 4.0 mmol), 4-methyl-5-oxo-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (1.30 g, 5.2 mmol) in 20 mL of toluene was added Pd-1 18 (200 mg) under N2 atmosphere, followed by Cs2C03 (2.60 g, 8,0 mmol), the resulting mixture was heated at 90°C overnight under ? atmosphere, then cooled to room temperature, filtered and the solvent was removed under vacuum, the residue was purified by flash chromatography (PE : EtOAc from 2: 1 to 1 :2) to afford the title compound.
Step C : 3 -methyl -4-(3 -(piped din-4-yl)- ill- 1.2.4-triazol- 1 -yl)furan-2(5H)-one: To a solution of tert-butyl 4-(l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-lH-l,2,4-triazol-3-yl)piperidine-l- carboxylate (230 mg, 0.66 mmol) in 3 mL of EtOAc was added 3 mL of HCl/EtOAc, the mixture was stirred at room temperature for 3 h, then concentrated to afford the title compound.
3 -( 1 -( R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 ,3 -dihydroisobenzofuran-5-yl)ethyl piperidin-4-yl - 1 - (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one
A mixture of (R)-4-methyl-5-(oxiran-2-yl)isobenzofuran-l(3H)-one (190 mg, 1.0 mmol), l-(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)pyrrolidin-2-one (49A single enantiomer from faster eiuting Boc precursor SFC separation) (220 mg, 0.83 mmol) and TEA (0.25 mL, 1.8 mmol) in 10 mL of EtOH was heated at 80°C for 6 h. The reaction mixture was concentrated and purified by preparative TLC (EtOAc/MeOH =:: 3 : 1) to afford the title compound as a single enantiomer. 5H- MR (400 MHz, MeOD) δ ppm 7,80 (d, 8.0 Hz, 1H), 7.73 (d, J= 8.0 Hz, 1H), 5.47 (m, 3H), 5.27 (d, J = 16 Hz, 1H), 5.19 (d, J= 16 Hz, 1H), 4.15 (m, H i ), 4.01 (m, H I ). 3.57 (m, 1H), 3.46 (m, IH), 2.94 (m, 2H), 2.75 (m, 2H), 2.62 (m, 1H), 2.35 (s, 3H), 2.28 (m, 1H), 2, 15 (s, 3H), 1. 98 (m, 4H), 1.82 (m, 2H),
EXAMPLE 2A and 2B
1 -(( .-·>.. I S )- 1 -{(R)-2-(6~{ lH-tetrazol - 1 -vnpyridin-3 -vD-2-hvdiOxyethyl )-3 -fluoropiperidin-4-ylV3 - (4-methyl-5-oxo-2.5-dihvdrofuran-3-vnimidazolidin-2-one AND l-((3R.4RVl-((R -2-(6-(lH- tetrazol-l-yl pyridin-3-yl)-2-hvdroxyethyl)-3-fl
dihydrofuran-3-yl)imidazolidin-2-one
To trans- l-(3-fluoropiperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one (70 mg, 0,247 mmol) in Ethanol (1235 μΐ) was added (R)-5-(oxiran-2-yl)-2-( IH-tetrazol- 1 - yl)pyridine (70.1 mg, 0.371 mmol). The reaction mixture was heated at 90°C overnight. The reaction mixture was evaporated for purifcation by ISCO (0-10% MeOH/DCM) to provide the product as a free base which was separated to two single diastereomers by SFC chiral
chroraatography: Column AS-H (2 x 25 era), eluent 40% methanol (0.1% DEA)/C02, 100 bar, flow rate 65 mL/min, detection wavelength 254 nm, injection volume. : 1 mL, 13mg mL 1 : 1 DCM:methanol.
Faster eluting isomer 2A: LC-MS (ESI, m/z): [M+l] + 473.
Slower eluting isomer 2B: LC-MS (ESI, m/z); [M+l ] + 473,
The Examples in the table below were prepared in an analogous fashion as that described for 3- ( 1 -((R)-2-hy droxy~2-( 4-m ethyl- 1 -oxo- 1 , 3 -di hy droi sobenzofuran -5 -y 1 )ethyl)piperi di n-4-yl )- 1 ~(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one (EXAMPLE 1) and l-((3S,4S)-l -((R)-2-(6- (lH-tetrazol-l-yl)pyridin-3-yl)-2-hydroxyethyl)-3-fluoropiperidin-4-yl)-3-(4-methyl-5-oxo-2 dihy drofuran-3 -y l)imidazolidin-2-one AND 1 -((3R,4R)- 1 -((R)-2-(6-( lH-tetrazol - 1 -yl )pyridi n-3 - yl)-2-hydroxyethyl)-3-fluoropiperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3- yl)imidazolidin-2-one (EXAMPLES 2A and 2B) from the amine and epoxide Intermediates indicated, which were all prepared as described above. In some cases (as in EXAMPLES 2A and 2B) a chirai SFC separation of diastereomers was performed to provide single isomer products.
l-(l-(2-(5-(lH-Tetrazol-l-yl pyridin-2-yl ethyl)piperidin-4-yl)-3-(4-methy
dihydrofuran-3-yl)imidazolidin-2-one
l-(4-Methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (Intermediate 36, 72 mg, 0.27 mmol), 5-(lH-tetrazol-l -yl)-2-vinylpyridine (Intermediate 13, 188 mg, 1 .1 mmol), DPEphos (15 mg, 0.027 mmol) and Rh(COD)BF4 (11 mg, 0.027 mmol) in toluene (1.5 mL) was stirred at 70°C for 24 h under N2. The mixture was concentrated and purified by preparative HPLC to afford the title compound. ^I-NMR (400 MHz, DMSO) 6 pprn 10.42 (s, 1H), 10.12 (s, 1H), 9.06 (d, J= 2.3 Hz, 1H), 8.30-8.38 (m, 1H), 7.65 (d, J= 8.6 Hz, 1H), 5.10 (s, 2H), 4.13 (t, J--- 7.8 Hz, 2H), 3, 10-3,65 (m, 10H), 2.00-2.18 (m, 2H), 1 ,80-1 ,90 (m, 5H), LC- MS (ESI, m/z): 439 [M+l] +.
The following compounds were prepared in an analagous fashion to that described for l-(l-(2~ (5-(lH-Tetrazol-l-yl)pyridin-2-yl)ethyl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3- yl)imidazolidin-2-one (immediately above, Example 44) using styrenes and amines prepared as described previously.
N-sN 1- (1-(2-(6-(1 H-tetrazol-1-yl)pyridazin-3- if y i ) ethy I )p I peri di n - 4 -y ! ) -3- (4 - methyl -5-
45 11 , 36 440
kA oxo-2,5-dihydrofuran-3-yl)imidazolidin-
2- one
1- (1-(2-(5-(1 H-tetrazol-1-yl)pyrazin-2- yl)ethyl)piperidin-4-yl)-3-(4-methyl-5-
46 10, 36 440
oxo-2,5-dihydrofuran-3-yl)imidazolidin-
2- one
(R)~ 1 -( 1 -(2-methoxy-2-(4-m ethyl- 1 -oxo- 1.3 -dihydroi sobenzofuran-5-y OethyDpiperi din-4-yl )-3 - (4-methyl-5-oxo-2,5-dihvdrofuran-3-yl )imidazolidin-2-one
NaBH(OAc)3 (633 mg, 3.00 mmol) was added to a solution of (R)-2-methoxy-2-(4-methyl-l- oxo-1 , 3-di hydroisobenzofuran-5-yl)acetaldehyde (222 mg, 1 .00 mmol) and l -(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (240 mg, 0.80 mmol) in DCM (5 mL) and AcOH (0.1 mL). The resulting mixture was stirred at room temperature for 0.5 h. The mixture was partitioned between water and DCM, The organic layer was separated and concentrated, the residue was purified by column chromatography eluted with EtOAc: MEOH = 5 : 1 to afford the title compound. 1H-NMR (400 MHz, MeOD) δ ppm 7.75 (m, I H), 7.64 (m, IH), 5.38 (s, 2H), 5.21 (s, 2H), 4.22 (m, 2H), 3.63 (m, 1 H), 3.59 (m, 1H), 3.32 (s, 3H), 3.3 1 (m, 2H), 2.78 (m, I H), 2.46 (m, IH), 2.37 (s, 3H), 2.33 (m, IH), 1.98 (s, 3H), 1.88 (m, 2Ή), 1 .74 (m, 2H); LC-MS (ESI, m/z) 470 [M+ 1 ] +.
The following compounds were prepared in an anaiagous fashion to that described for 1 -(1 - (2-methoxy-2-(4-methyl-l-oxo-l,3-dihydroisobenzofuran-5-yl)ethyl)piperidi
methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one (Example 47) using aldehydes and amines prepared as described previously.
EXAMPLES 52A 52B, 52C, 52D (four individual diastereomers)
1 -(1 -(l-hydroxy-l-(4-methyl-l -oxo-1 ,3-dihydroisobenzofuran-5-yl)propan-2-yl)piperidin-4-yl)- 3-(4-methyl-5-oxo-2,5-dihvdrofuran-3-yl)imidazolidin-2-one (individual isomers are: 1 -C1-
(( 1 R.2R)- 1 -hydroxy- 1 -(4-m ethyl - 1 -oxo- 1.3 -di hy droi sobenzofuran -5 -y 1 )propan-2-yl)piperi di n-4- ylV3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl )imidazolidin-2-one; 1 -(. !-(( IR,2S)- 1 -hydroxy- 1 -(4- methyl-1 -oxo-1 -dihydroisobenzofuran-5-yl)propan-2-yl piperidin-4-yl)-3-(4-methyl-5-oxo-2,5- dihydrofuran-3 -yl)imi dazolidin-2-one; 1 -( 1 -(( IS,2R)~ 1 -hydroxy- -(4-m ethyl- 1 -oxo- 1 ,3- dihvdroisobenzofuran-5-vOpropan-2-yl)piperidin^
yl)imidazolidin-2-one; l -(l-((lS,2S)-l-hydroxy-l -(4-methyl-l -oxo-1, 3-dihydroisobenzofuran-5- yl propan-2-yl )pi eridin-4-ylV3-(4-methyl-5-oxo-2.5-dihvdrofuran-3-yl imid
Step A: 4-methyl-5-("prop- 1 -en- 1 -yl)i sobenzofuran- 1 (3H)-one: To a solution of 4-m ethyl -1-oxo- l,3-dihydroisobenzofuran-5-yl trifluoromethanesulfonate (1.50 g, 5.1 mmol) in 30 mL of THF was added (E)-prop-l-en- l-ylboronic acid (700 mg, 1.6 mmol) and Pd-1 18 (326 mg, 0.5 mmol) under N2 atmosphere, followed by K3P04 (2.15 g, 10 mmol, 1 M in H20). The resulting mixture was stirred at 75°C overnight under N2, cooled and concentrated, the residue was diluted with ethyl acetate and H20, filtered, aqueous layer was extracted with EtOAc, the combined organic layers were washed with brine, dried over anhydrous Na2S04, filtered and concentrated, the residue was purified by flash chromatography (0-20% EtOAc in petroleum ether) to afford the title compound. 1H-NMR (400 MHz, CDC13) δ ppm 7.67 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 8.0 Hz, 1H), 6.63 (dd, J = 13 Hz, 1 .2 Hz, IH), 6,34-6,26 (m, I H), 5.23 (s, 2H), 2.27 (s. M i l 1.95 (dd, J = 6 ,8 Hz, 1.6 Hz, 3H),
Step B : 5-(l ,2-dihvdroxypropyl)-4-methylisobenzofuran- 1 (3H)-one: To a solution of 4-methyl-5- (prop-l -en-l -yl)isobenzofuran-l(3H)-one (930 mg, 4.9 mmol) in 40 mL of CH3CN and 4 mL of water was added NMO (746 mg, 5.4 mmol), followed by K20s05- 2H20 (91 mg, 0.25 mmol) at 0°C, the resulting mixture was warmed to room temperature and stirred for 2 hrs under N2 atmosphere. The resulting mixture was diluted with DCM and washed with Na2S203 solution (25% aq) and water, the organic layer was dried over anhydrous Na2S04, filtered and
concentrated, the residue was purified by flash chromatography (0 to 65% EtOAc in petroleum ether) to afford the title compound. 1H-NMR (400 MHz, CDC13) δ ppm 7.77 (d, J= 8.0 Hz, IH), 7.64 (d, ,/ 8.0 Hz, I H), 5.25 (s, 2H), 4.82 (dd, ,/ 7.2 Hz, 3.6 Hz, 1 1 1 ), 3.98-3.90 (m, 1 1 1 ). 2.78 (d, ./ 3 ,2 Hz, I H), 2.39 (d, ,/ 4.0 Hz, I H), 2.34 (s, 3H), 1.12 (d, ,/ 6.4 Hz, 3H).
Step C : 1 -( 1 -( 1 -hydroxy- 1 -(4-methyl- 1 -oxo- 1 , 3 -dihydroi sobenzofuran- 5 -yl )propan-2- yl)piperidin-4-yl )-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one: To a MW vial was charged with 5-(l,2-dihydroxypropyl)-4-methylisobenzofuran- l (3H)-one (170 mg, 0.76 mmol), l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-3-(piperidin-4-yl)imidazolidin-2-one (243 mg, 0.92 mmol), Ru3(CO)12 ( 147 mg, 0.23 mmol ), 2-(dicyclohexylphosphino)-l-phenyl-lH-pyrrole
(156 rag, 0.46 nimol) and 1 ,7 mL of tert-amyl alcohol, the MW vial was degassed, sealed, and heated at 145°C over weekend, then filtered and washed with DCM, concentrated, the residue was purified by flash chromatography (from 0 to 15 of MeOH in EtOAc) to afford the title compounds separated into syn products as a pair of enantiomers and anti products as a pair of enantiomers); the syn and anti enantiomer pairs were individually separated by chiral SFC
[eiuting with 40% MeOH (0.05% DEA)/C02 on Chiralpak AS-! I column] to afford the four single diastereomer products.
52A: less polar on TLC fast eiuting on SFC. Ή-NMR (400 MHz, CDCi3) δ ppm 7.74 (d, J= 8.0 Hz, I N ), 7.60 (d, J 8.4 Hz, 1 1 1 ), 5.24 (s, 21 1). 5,20 (s, 2H), 4,66 (d, J= 9.6 Hz, i l l), 4, 16 (t, ,/ 8.0 Hz, 2H), 3.84-3.74 (m, 1H), 3.62-3.55 (m, 2H), 2.96 (d, J= 12 Hz, 1H), 2.85-2.68 (m, 3H), 2.60-2.50 (br, IH), 2.31 (s, 3H), 1.98 (s, 3H), 1.85-1.78 (m, 3H), 1 .75- 1 .63 (m, IH), 0.76 (d, ,/ 6.4 Hz, 3H). LC-MS (ESI, m/z): 470 [M+I] +.
S2B: less polar on TLC. slow eiuting on SFC. Ή-NMR (400 MHz, CDC13) δ ppm 7,75 (d, J = 8.4 Hz, I I I ). 7.62 (d, ./ 8.0 Hz, IH), 5,25 (s, 2H), 5.21 (s, 2H), 4,70 (d, J= 9.6 Hz, IH), 4 1 7 (t, J= 8.0 Hz, 2H), 3.88-3.77 (m, IH), 3.60 (t, J= 9.2 Hz, 2H), 3.06-3.00 (br, IH), 2.90-2.73 (m, 3H), 2,44-2,35 (m, I H), 2.32 (s, 3H), 2.01 (s, 3H), 1.83 (d, J 8.8 Hz, 3H), 1.23 (s, I H), 0,79 (d, 6.4 Hz, 3H). LC-MS (ESI, m/z): 470 [ M I j ' ,
52C: more polar on TLC. fast eiuting on SFC. 1H-NMR (400 MHz, CDC13) δ ppm 7.78 (s, 2H), 2.25-5.21 (m, 5H), 4.19 (t, J= 8.0 Hz, 2H), 3.86-3.78 (m, IH), 3.58 (t, J= 8.0 Hz, 2H), 3.35 (d, J = 12 Hz, I H), 3.10 (d, ,/ 1 1 Hz, 2.80-2.70 (ni, IH), 2,45-2,30 (m, 2H), 2.28 (s, 3H), 2.02 (s,
3H), 1.80-1.60 (m, 4H), 1.25 (s, IH), 0.82 (d, 6.4 Hz, 3H). LC-MS (ESI, m/z): 470 [M+l] +. 52D: more polar on TLC. slow eiuting on SFC. 5H-NMR (400 MHz, CDC13) δ ppm 7.80-7.70 (m, 2H), 5.23 (s, 2H), 5.17 (s, 2H), 4.14 (t, J 8.4 Hz, 2H), 3.95-3.85 (br, IH), 3.70-3.58 (m, 2H), 2,33 (s, 3H), 1.97 (s, 3H), 1.90-1.80 (br, 2H), 1 .75-1 .38 (m, 4H), 1 ,30-1 , 18 (m, 5H), 1.15- 1.00 (m, 3H). LC-MS (ESI, m/z): 470 [M+ 1 ] +.
The Examples in the table below were prepared in an analogous fashion as that described for 3- ( 1 -((i?)-2-hydroxy-2-(4-m ethyl - 1 -oxo- 1 ,3 -dihydroisobenzofuran-5-yl)ethyl )piperidin-4-yl)- 1 -(4- raethyl-5-oxo-2,5-dihydrofuran-3-yl )pyrrolidin-2-one (EXAMPLE 1) from the amine and epoxide Intermediates indicated, which were, in turn, prepared as described above.
The following Thallium Flux Assay and/or the Eiectrophysiology Assays were performed on each of the final product compounds in the Examples unless otherwise noted.
Thallium Flux Assay
A Thallium Flux Assay was performed on the compounds of the Examples. This assay has been described previously; see, e.g., PCT Published Application WO 2013/062900.
Data collected for compounds in the Examples of the present invention using the Thallium Flux Assay are shown in Table 9 below. All of the tested final product compounds in the Examples (diastereomenc mixtures and individual diastereomers) had IC50 potencies less than 1 uM in the Thallium Flux Assay.
Eiectrophysiology Assay
Blocking of Kir 1.1 (ROMK1) currents was examined by whole cell voltage clamp (Hamill et. al . Pfluegers Archives 391 :85-100 (1981 )) using the IonWorks Quattro automated eiectrophysiology platform (Molecular Devices, Sunnyvale, CA). Chinese hamster ovary cells stably expressing KM .1 channels were maintained in T-75 flasks in cell culture media in a humidified 10% C02 incubator at 37°C. Prior to an experiment, Kirl . l expression was induced by overnight incubation with 1 mM sodium butyrate. On the day of the experiment, cells were dissociated with 2.5 mL of Versene (Invitrogen 15040-066), a non-enzymatic ceil dissociation reagent, for approximately 6 rain at 37°C and suspended in 10 mL of bath solution containing (in mM): 150 NaCl, 10 KCl, 2.7 CaCl2, 0.5 MgCl2, and 5 HEPES, at pH 7.4. After centrifugation, the ceil pellet was resuspended in approximately 4.0 mL of bath solution and placed in the IonWorks instrument. The intracellular solution consisted of (in mM): 80 K gluconate, 40 KCl, 20 KF, 3.2 MgCl2, 3 EGTA, and 5 Hepes, at pH 7.4. Electrical access to the cytoplasm was
achieved by perforation in 0.13 mg/mL amphotericin B for 4 min. Amphotericin B (Sigma A- 4888) was prepared as a 40 mg/mL solution in DMSO.
Voltage protocols and current recordings were performed using the IonWorks HT software/hardware system. Currents were sampled at 1 kHz. There was no correction for liquid junction potentials. The test pulse, consisting of a 100 ms (millisecond) step to 0 mV (millivolts) from a holding potential of -70 mV, followed by a 100 ms voltage ramp from -70 mV to +70 mV, was applied before and after a 6 min compound incubation period. Test compounds were prepared by diluting DMSO stock solutions into the bath solution at 3x the final concentration and placed in the instrument in 96-well polypropylene plates. Current amplitudes were measured using the IonWorks software. To assess compound potency, the fractional block during the voltage step to 0 mV was calculated in Microsoft Excel (Microsoft, Redmond, CA), and dose- response curves were fitted with Igor Pro 4.0 (WaveMetrics, Lake Oswego, OR). Although not required, a control compound is typically included to support that the assay is giving consistent results compared to previous measurements. The control can be any compound of Formula I of the present invention, preferably with an IC50 potency of less than I uM in this assay.
Alternatively, the control could be another compound (outside the scope of Formula I) that has an IC50 potency in this assay of less than 1 μΜ.
Data collected for compounds in the Examples of the present invention using the Thallium Flux Assay and the Electrophysiology Assay are shown in Table 4 below. All of the tested final product compounds in the Examples (diastereomeric mixtures and individual diastereomers) had IC50 potencies less thanl μΜ in one or both of the Thallium Flux Assay and the Electrophysiology Assay.
TABLE in vitro potency
4B 0.12
5A 0.069
5B 0.060 0.027
0.091
6B 0.023
7A 0.16
7B 0.36
8 0.018 0.022
9A 0.036
9B 0.11
10A 0.035 0.058
10B 0.20
11 0.060
12 0.037 0.026
13A 0.23
13B 0.14
14 0.14
15 0.040 0.075
16 0.046 0.056
17 0.20
18A 0.046
18B 0.27
18C 0.062 0.067
18D 0.078
19A 0.081
19B 0.081 0.07
20A 0.16
20B 0.33
21A 0.23
21 B 0.32
22A 0.36
22B 0.21
23A 0.085
23B 0.42
24A 0.15 -
EXAMPLE # Tha!!ium Flux !C50 (M) Electrophysiology IC50 (M)
24B 0.30
25A 0.015
25B 0.020 0.049
26A 0.27
26B 0.061
27A 0.039 0,02
27B 0.40
28 0.084
29A 0.019 0.013
29B 0.031 0.012
30A 0.26
30B 0.10
30C 0.46
30D 0.33
31 0.44
32A 0.032 0.017
32B 0.038 0,02
33A 0.057 0.013
33B 0.22
33C 0.12
33D 0.42
34 0.34
35 0.17
36A 0.073 0.04
36B 0.049
37A 0.15
37B 0.26
38A 0.041
38B 0.071
39 0.066 0.015
40 0.27
41A 0.29
41 B 0.18
42A 0.087 0.061
42B 0.089 0.084
EXAMPLE # Tha!!ium Flux !C50 (M) Electrophysiology IC50 (M)
43 0.40
44 0.049
45 0.11
46 0.11
47 0.053 0.018
48 0.15
49 0.19
50 0.050
51 0.013 0.017
52A 0.070 0.05
52B 0.042
52C 0.042
52D 0.15
53 0.57
54 0.024
55 0.087 0.090
56 0.047 0.068
57 0.16
58 0.067
59 0.010 0.0026
60 0.16
61 0.53 -
Spontaneously Hypertensive Rat (SHR) Assay
The spontaneously hypertensive rat (SHR) exhibits age-dependent hypertension that does not require administration of exogenous agents to elevate blood pressure nor does it require the use of a high salt diet to elevate blood pressure. Thus it resembles human essential hypertension and provides an opportunity to assess the dose-dependence of novel agents for their ability to Iwer blood pressure.
Experimental protocols for evaluating blood pressure lowering efficacy of compounds of the present invention in spontaneously hypertensive rats (SHR): Spontaneously hypertensive rats (SHR, male, 6 months, Charles River) were implanted with DSI TA.1 1 PA-C40 telemetry device (Data Sciences, Inc., St. Paul, MN) under isoflurane or ketamine/rnetomidine anesthesia. The telemetry unit catheter was inserted into the descending aorta via the femoral artery and the
telemetry device was implanted subcutaneously in the left flank area. Animals were allowed to recover from surgery for 14 days before the start of any studies. Blood pressure, heart rate, and activity signals from conscious, freely moving rats were recorded continuously for 30 seconds every 10 minutes. HCTZ (25 mg/kg/day, PO) was included as a reference diuretic at a dose giving approximately maximal efficacy in SHR. The blood pressure lowering efficacy of compounds of the present invention compared to vehicle control was evaluated following a single oral gavage each day for a typical duration of three to fourteen da . Data were collected as hourly averages, and changes in blood pressure were calculated by subtracting vehicle control baseline data on an hourly basis.
The Spontaneously Hypertensive Rat Assay is well known and often used in the art as an experimental model simulating human hypertension (see, e.g., Lerman, L.O., et ai., J Lab Clin Med, 2005; 146: 160-173).
While the invention has been described with reference to certain particular embodiments thereof, numerous alternative embodiments will be apparent to those skilled in the art from the teachings described herein. The scope of the claims should not be limited by the preferred embodiments set forth in the examples, but should be given the broadest interpretation consistent with the description as a whole. Recitation or depiction of a specific compound in the claims (i.e., a species) without a specific stereoconfiguration designation, or with such a designation for less than all chiral centers, is intended to encompass the racemate, racemic mixtures, each individual enantiomer, a diastereoisomeric mixture and each individual diastereomer of the compound where such forms are possible due to the presence of one or more asymmetric centers. All patents, patent applications and publications cited herein are incorporated by reference in their entirety.
Claims
1. A compound of the formula:
wherein X is N or CRS;
Z is O or CH2;
nitrogen atoms which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazoiyl and C j .3 alkyl;
R1 is H, OH or 0(C1-3 alkyl),
R2 is H or C1-3 alkyl;
R4 is H or C I.., alkyl;
R5 is H or d.3 alkyl,
R6 is H or C1-3 alkyl;
R7 is H, Cj .3 alkyl or 0(C ,„3 alkyl),
Ra i H or C I., alkyl ;
R is H, OH, Ci.3 alkyl or (C=0)OCi.3 al kyl;
Rx is H, halo, Cs. alkyl or ( ){{ · ,., alkyl);
n is 0, 1 or 2;
is an optional bond;
or a pharmaceutically acceptable salt thereof.
or a pharmaceutically acceptable salt thereof.
3. The compound of Claim 1 or 2 of the formula
A
or a six-membered aromatic ring containing one or two nitrogen atoms which is optionally substituted with one or two substituents independently selected from the group consisting of tetrazoiyl and C1-3 alkyl;
R! is H, OH or OfO , .< alkyl);
R2 is H or C;,3 alkyl,
R4 is H or C 1.3 alkyl;
R5 is H or C . ; alkyl;
R6 is H or C,,3 alkyl,
R7 is H or 0(Ci,3 alkyl);
Ra i s H or C|.3 alkyl;
R is H, OH, i : alkyl or (C 0) K , alkyl;
Rx is H, halo, C1-3 alkyl or 0(Ci.3 alkyl);
or a pharmaceutically acceptable salt thereof
4. The com ound of any of Claims I to 3 wherein A is
6. The compound of any of Claims 1 to 5 wherein R1 is OH, or a pharmaceutically acceptable salt thereof.
The compound of any of Claims 1 to 6 wherein is H or methyl; or a pharmaceutically acceptable salt thereof.
7. The compound of any of Claims 1 to 7 wherein R4 is H or methyl; or a pharmaceutically acceptable salt thereof.
8. The compound of Claim 1 selected from :
3 ~( J -((R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 , 3 -dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)- 1 - (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
1 -((3 S,4S)- 1 -((R)-2-(6-( 1 //-!eira/oi - 1 -y 1 )pyri din-3 -y l)-2-hydroxyethyl)-3 -fluoropiperidin-4-yl)-3 - (4-methyl - 5 -oxo-2, 5 -dihydrofuran-3 -yl)i midazoli din-2-one;
l-((3R,4R)-l-((R)-2-(6-(lH-tetrazol-l-yl)pyridin-3-yl)-2-hydroxyethyl)-3-fluoropiperidin-4-yl)- 3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one,
3-(l-((R)-2-(6-(lH-tetrazol-l -yl)pyridin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-l-(4-methyl-5- oxo-2, 5-dihydrofuran-3-yl)pyrrolidin-2-one;
3 -( 1 -((S)-2-(6-( 1 H-tetrazol - 1 -y 1 )pyri di n-3 -y 1 )-2-hydroxyethyl)piperi di n-4-yl )- 1 -(4-m ethyl -5 -oxo- 2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
3 -( 1 -((R)-2-(6-( lH-tetrazol - -yl)pyridi n-3 -yl)-2-hydroxyethyl)piperidin-4-yl)- 1 -(4-methyl - 5 - oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
3 -( 1 -((S)-2-(6-( IH -tetrazol - 1 -yl)pyri din-3 -yl)-2-hydroxyethyl)piperidin-4-yl)- 1 -(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
(R)- 1 -( 1 -(2-(6-( l/J-tetrazol- J -yl)pyridin-3 -yl)-2-hy droxyethyl)piperidin-4-yl)-3-(4-methyl-5- oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
(S)-l -(l -(2-(6-(lH-tetrazol-l -yl)pyridin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-3-(4-meth
2,5-dihydrofuran-3-yl)imidazolidin-2-one;
4-(3-((R)-2-hydroxy-2-(4-methyl-l -oxo-l,3-dihydroisobenzofuran-5-yl)ethyl)-3- azabicyclo[3.1.0]hexan-6-yl)-l-(5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
4-(3-((R)-2-hydroxy-2-(4-methyl-l-oxo-l ,3-dihydroisobenzofuran-5-yl)ethyl)-3- azabicyclo[3. 1 .0]hexan-6-yl)-l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
4- (3 -((R)-2-(6-( lH-tetrazol - 1 -yl)pyridin-3 -yl)-2-hydroxyethyl)-3 -azabicycl o[3.1.0]hexan-6-yl)- 1 - (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
l-(3-((R)-2-hydroxy-2-(4-methyl- 1 -oxo-l, 3-dihydroisobenzofuran-5-yl)ethyl)-3- azabicyclo[3.1 .0]hexan-6-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -(3-((R)-2-(6-(lH-tetrazol-l -yl)pyridin-3-yl)-2-hydroxyethyl)-3-azabicyclo[3 , 1 .0]hexan-6-yl)-3-
(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -(3 -((S)-2-(6-( lH-tetrazol - 1 -yl)pyri din-3 -yl)-2-hydroxyethyl)-3 -azabi cyclo[3.1.0] hexan-6-yl)-3 - (4-methyl - 5 -oxo-2, 5 -dihydrofuran-3 -yl)i midazoli din-2-one;
l-(3-(2-hydroxy-2-(2-methyl-6-(lH-tetrazol-l-yl)pyridin-3-yl)ethyl)-3-azabicyclo[3.1.0]hexan-
6-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 ~(3 -((R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 , 3 -dihydroi sobenzofuran- 5 -yl )ethyl)-3 - azabicyclo[3.1.0]hexan-6-yl)-3-(3-oxocyclopent-l-en-l-yl)imidazolidin-2-one;
(R)-l-(l -(2-hydroxy-2-(4-methyl- 1 -oxo-l, 3-dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)-3-
(4-methyl - 5 -oxo-2, 5 -dihydrofuran-3 -yl)i midazoli din-2-one;
1 -( 1 -(2-hydroxy-2-(2 -methyl -6-( lH-tetrazol - 1 -yl)pyri din-3 -yl)ethyl)pyrrolidi n-3 -yl)-3 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 ~( J -((R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 , 3 -dihydroisobenzofuran-5-yl)ethyl)pyrrolidin-3 -yl)-3 - (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
(R)-l-(l -(2-hydroxy-2-(4-methyl-l -oxo-l,3-dihydroisobenzofliran-5-yl)ethyl)piperidin-4-yl)-3- (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)tetrahydropyrimidin-2(lH)-one;
1 -( 1 -(2-hydroxy-2-(2 -methyl -6-( lH-tetrazol - 1 -yl)pyridin-3 -yl)ethyl)piperi din-4-yl)-3 -(4-methyl -
5- oxo-2,5-dihydrofuran-3-yl)tetrahydropyrimidin-2(lH)-one;
l-(3-fluoro- l-(2-hydroxy-2-(2-methyl-6-(lH-tetrazol- l-yl)pyridin-3-yl)ethyl)piperidin-4-yl)-3- (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -(3 -fiuoro- 1 -((R)-2-hydroxy-2-(4-methyl - 1 -oxo- 1 , 3 -dihydroi sobenzofuran-5 -yl)ethyl)piperidin- 4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -(3 -fluoro- 1 -((R)-2-hydroxy-2-(4-m ethyl - 1 -oxo- 1 ,3 -dihydroi sobenzofuran-5-yl)ethyl )pi peri din- 4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l -((R)-2-hydroxy-2-(4-methyl- 1 -oxo-l, 3 -dihydroi sobenzofuran-5-yl)ethyl)-3- methoxypiperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l -(l-(2-(5-(l.H-tetrazol-l -yl)pyrazin-2-yl)-2-hydroxyethyl)-3-methoxypiperidin-4-yl)-3-(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l -(2-(5-(lH-tetrazol-l -yl)pyrazin-2-yl)-2-hydroxyethyl)-3-fluoropiperidin-4-yl)-3-(4-methyl- 5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -( ί -(2-(5-( lH-tetrazol- 1 -yl)pyrazin-2-yl)-2-hydroxyethyl)piperidin-4-yl)-3-(4-methyl-5-oxo- 2, 5-dihydrofuran-3 -yl)tetrahydropyrimidin-2( lH)-one;
l -(l-(2-(6-(l.H-tetrazol- l -yl)pyridazin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-3-(4-methyl -5-oxo- 2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l -(2-(5-(lH-tetrazol-l-yl)pyrazin-2-yl)-2-hydroxyethyl)piperidin-4-yl)-3-(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)imidazolidin-2-one;
3 -(4-((R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 ,3 -dihydroi sobenzofuran-5-yl)ethyl)piperazin- 1 -yl)- 1 - (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
3-(4-(2-hydroxy-2-(2-methyl-6-(lH-tetrazol-l-yl)pyridin-3-yl)ethyl)piperazin-l-yl)-l-(4-methyl- 5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
(R)-l-(l -(2-(6-(lH-tetrazol-l-yl)pyridin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-3-(4-methyl-5- oxo-2,5-dihydrofuran-3-yl)tetrahydropyrimidin-2(lH)-one;
(S)- 1 -( 1 -(2-(6-( lH-tetrazol - 1 -yl)pyridin-3 -yl)-2-hydroxyethyl)piperidin-4-yl)-3 -(4-methyl-5-oxo- 2,5-dihydrofuran-3-yl)tetrahydropyrimidin-2(lH)-one;
3-(l-(2-(5-(lH-tetrazol-l -yl)pyridin-2-yl)-2-hydroxyethyl)piperidin-4-yl)-l-(4-methyl-5-oxo-2,5- dihydrofuran-3-yl)pyrrolidin-2-one;
1 -( 1 -((R)-2-hydroxy-2-(4-methyl - 1 -oxo-1 ,3-dihydroi sobenzofuran-5-yl)ethyl)piperidin-4-yl)-4- methyl-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -( 1 -((R)-2-(6-( lH-tetrazol - -yl)pyridin-3 -yl)-2-hydroxyethyl)piperidin-4-yl)-4-methyl-3 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l-((0>2-(6-(lH-tetrazol-l -yl)pyridin^
methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
3 -( 1 -((R)-2-(6-( lH-tetrazol- 1 -yl)pyridin-3 -yl)-2-hy droxyethyl)-4-hydroxypiperidin-4-yl)- 1 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
l -(l-((R)-2-hydroxy-2-(4-methyl-l-oxo-l ,3-dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)-^ methyl-3-(5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l -((R)-2-(6-(lH-tetrazol-l-yl)pyridin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-4-methyl-3-(5- oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -( -((R)-2-(6-( lH-tetrazol - 1 -yl )pyri c!in-3 -yl)-2-hydroxyethyl)piperidin-4-yl)-4-m ethyl -3 -(5- oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l -((S)-2-(6-(lH-tetrazol-l-yl)pyridin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-4-methyl-3-(5-oxo- 2,5-di hydrofuran-3-yl)imidazolidin-2-one;
ethyl l-((R)-2-(6-(lH-tetrazol-l-yl)pyridin-3-yl)-2-hydroxyethyl)-4-(3-(4-methyl-5-oxo-2,5- dihydrofuran-3-yl)-2-oxooxazolidin-5-yl)piperidine-4-carboxylate;
ethyl l -((R)-2-hydroxy-2-(4-methyl-l-oxo-l ,3-dihydroi sobenzofuran-5-yl)ethyl)-4-(3-(4-methyl- 5-oxo-2,5-dihydrofuran-3-yl)-2-oxooxazolidin-5-yl)piperidine-4-carboxylate;
3 -(4-hydroxy- 1 -((R)-2-hydroxy-2-(4-methyl - -oxo- 1 , 3 -dihydroi sobenzofuran- 5 - yl)ethyl)piperidin-4-yl)-l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
1 '-((R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 ,3-dihydroisobenzofuran-5-yl)ethyl)- 1 -(4-methyl-5-oxo- 2, 5 -dihydrofuran-3 -yl)-[3 ,4' -bi piperi din] -2-one;
4~( I -((R)-2-hydroxy-2-(4-methyl- 1 -oxo- 1 , 3 -dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)- 1 - (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
3-(l -((R)-2-hydroxy-2-(4-niethyl -1 -oxo-l, 3-dihydroi sobenzofuran-5-yl)ethyl )piperi din-4-yl)-3- methyl-l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
3 -( 1 -((R)-2-(6-( lH-tetrazol - -yl)pyridin-3 -yl)-2-hydroxyethyl)piperidin-4-yl)-3 -methyl - -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrrolidin-2-one;
1 ~( I -((R)-2-(6-( lH-tetrazol - 1 -yl )pyiidin-3 -yl)-2-hydroxy ethyl)piperidin-4-yl)-4-ethyl-3 -(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
4-ethyl-l-(l-((R)-2-hydroxy-2-(4-methyl-l -oxo-1, 3-dihydroisobenzofuran-5-yl)ethyl)piperidin- 4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
l-(l-(2-hydroxy-2-(tetrazolo[l ,5-a]quinolin-7-yl)ethyl)piperidin-4-yl)-3-(4-methyl -5-oxo-2,5- dihydrofuran-3-yl)imidazolidin-2-one;
l-(l-(2-(5-(l//-Tetrazol- l-yl)pyridin-2-yl)ethyl)piperidin-4-yl)-3
dihydrofuran-3-yl)imidazolidin-2-one;
l-(l -(2-(6-(lH-tetrazol-l-yl)pyridazin-3-yl)ethyl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5- dihydrofuran-3-yl)imidazolidin-2-one;
l -(l-(2-(5-(l.H-tetrazol- l -yl)pyrazin-2-yl)ethyl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5- dihydrofuran-3-yl)imidazolidin-2-one;
(R)-l-(l -(2-methoxy-2-(4-methyl-l -oxo-1 , 3-dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)-3- (4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
(/?)-! -(l-(2-ethoxy-2-(4-methyl- 1 -oxo-l, 3-dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)-3-(4- methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
(R)-l-(l -(2-(6-(lH-tetrazol-l-yl)pyridin-3-yl)-2-methoxyethyl)piperidin-4-yl)-3-(4-methyl-5- oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -( 1 -(2-(6-( lH-Tetrazol- J -yl)pyridin-3-yl)ethyl)piperidin-4-yl)-3 -(4-methyl-5-oxo-2,5- dihydrofuran-3-yl)imidazolidin-2-one;
l -(l-(2-(4-melhyl-l-oxo-l,3-dihydroisobenzofuran-5-yl)ethyl)piperidin-4-yl)-3-(4-methyl-5 oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -(1 -(1 -hydroxy- 1 -(4-methyl -1 -oxo- 1 ,3-dihydroisobenzofuran-5-yl)propan-2-yl)piperidin-4-yl)- 3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -( 1 -(( 1R,2R)- 1 -hydroxy- 1 -(4-methyl - 1 -oxo- 1 ,3 -dihydroisobenzofuran-5-yl)propan-2- yl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 ~( J -(( 1 .2S)- 1 -hydroxy- 1 -(4-methyl- 1 -oxo- 1 , 3 -dihy droisobenzofuran-5-yl)propan-2- yl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1-(1 -((L5',2/?)-l -hydroxy- 1 -(4-methyl -1 -oxo-l,3-dihydroisobenzofuran-5-yl)propan-2- yl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
1 -( 1 -(( 1 S,2S)- 1 -hydroxy- 1 -(4-methyl - 1 -oxo- 1 , 3 -dihydroi sobenzofuran-5 -yl)propan-2- yl)piperidin-4-yl)-3-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)imidazolidin-2-one;
(R)-5-(l-hydroxy-2-(4-(4-methyl-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2- yl)piperazin-l-yl)ethyl)-4-methylisobenzofuran-l (3H)-one;
(R)-5-(l -hydroxy-2-(4-(5-(4-memyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperidin-l- yl)ethyl)-4-methylisobenzofuran- 1 (3H)-one;
(R)-5-(l-hydroxy-2-(4-(5-(4-memyl-5-oxo-2,5-dihydrofuran-3-yl)pyrimidin-2-yl)piperazin-l- yl)ethyl)-4-methylisobenzofuran- 1 (3H)-one;
(R)-5-(l-hydroxy-2-(4-(5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2-yl)piperazin-l- yl)ethyl)-4-methyli sobenzofuran- 1 (3H)-one;
(R)-5-(l -hydroxy-2-(4-(4-methoxy-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyrimidin-2- yl)piperazin- 1 -yl)ethyl)-4-methylisobenzofuran- 1 (3H)-one;
(R)-5-(l-hydroxy-2-(4-(3-methoxy-5-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)pyridin-2- yl)piperazin- 1 -yl)ethyl)-4-methyli sobenzofuran- 1 ( //)~onc:
(R)-5-(l -hydroxy-2-(4-(l-(4-methyl-5-oxo-2,5-dihydrofuran-3-yl)-lH-l,2,4-triazol-3- yl)piperidin- 1 -yl)ethyl)-4-methylisobenzofuran- 1 (3H)-one;
(R)-4-(3-( ;i-(2-(6-(lH-tetrazol-l -yl)pyriclin-3-yl)-2-hydroxyethyl)piperidin-4-yl)-li -l,2,4- triazol-l-yl)-3-methylfuran-2(5H)-one
(S)-4-(3 -( 1 -(2-(6-( lH-tetrazol- 1 -yl)pyridin-3 -yl)-2-hydroxyethyl)piperidin-4-yl)- \H- 1 ,2,4- triazol-l -yl)-3-methylfuran-2(5H)-one;
or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of any of Claims 1 to 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier,
10. The pharmaceutical composition of Claim 9 further comprising an additional active agent selected from losartan, valsartan, candesartan, olmesartan, telmesartan, eprosartan, irbesartan, amlodipine, alacepril, benazepril, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, imidapril, lisinopril, moveltipril, perindopril, quinapril, ramipril, spirapril, temocapril, trandolapril, amiloride, spironolactone, epleranone, triamterene, riociguat or vericiguat, or a pro-drug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
1 1. A method for inhibiting ROMK comprising administering a compound of any of Claims 1 to 8 or a pharmaceutically acceptable salt thereof in a ROMK -inhibitory effective amount to a patient in need thereof.
12. A method for causing diueresis, natri uresis or both, comprising
administering a compound of any of Claims 1 to 8 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a patient in need thereof.
13. A method for the treatment of one or more disorders selected from hypertension, acute heart failure, chronic heart failure, pulmonary arterial hypertension, cardiovascular disease, diabetes, endothelial dysfunction, diastolic dysfunction, stable and unstable angina pectoris, thromboses, restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, pre-eciampsia, cerebral edema, nephropathy, nephrotic syndrome, acute kidney insufficiency, chronic kidney disease, hypercalcemia, Dent's disease, Meniere's disease, or edematous states comprising administering a compound of any of Claims 1 to 8 or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to a patient in need thereof.
14. The use of a compound of any of Claims J to 8, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating hypertension, acute heart failure, chronic heart failure, pulmonary arterial hypertension, cardiovascular disease, diabetes, endothelial dysfunction, diastolic dysfunction, stable and unstable angina pectoris, thromboses,
restenosis, myocardial infarction, stroke, cardiac insufficiency, pulmonary hypertonia, atherosclerosis, hepatic cirrhosis, ascitis, pre-eclampsia, cerebral edema, nephropathy, nephrotic syndrome, acute kidney insufficiency, chronic kidney disease, hypercalcemia, Dent's disease, Meniere's disease, or edematous states in a patient in need thereof.
15. A compound according to any of Claims 1 to 8 for use in therapy.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/545,891 US10160751B2 (en) | 2015-02-12 | 2016-02-08 | Inhibitors of the renal outer medullary potassium channel |
EP16749643.9A EP3255993B1 (en) | 2015-02-12 | 2016-02-08 | Inhibitors of the renal outer medullary potassium channel |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2015/072865 WO2016127358A1 (en) | 2015-02-12 | 2015-02-12 | Inhibitors of renal outer medullary potassium channel |
CNPCT/CN2015/072865 | 2015-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016130444A1 true WO2016130444A1 (en) | 2016-08-18 |
Family
ID=56614013
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/072865 WO2016127358A1 (en) | 2015-02-12 | 2015-02-12 | Inhibitors of renal outer medullary potassium channel |
PCT/US2016/016918 WO2016130444A1 (en) | 2015-02-12 | 2016-02-08 | Inhibitors of the renal outer medullary potassium channel |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2015/072865 WO2016127358A1 (en) | 2015-02-12 | 2015-02-12 | Inhibitors of renal outer medullary potassium channel |
Country Status (3)
Country | Link |
---|---|
US (1) | US10160751B2 (en) |
EP (1) | EP3255993B1 (en) |
WO (2) | WO2016127358A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
WO2018222795A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
US10160751B2 (en) | 2015-02-12 | 2018-12-25 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US10208064B2 (en) | 2014-07-14 | 2019-02-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066717A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US20140031349A1 (en) * | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2014085210A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1000484A (en) | 1909-12-11 | 1911-08-15 | Carter S Ink Co | Paste-jar. |
US2988551A (en) | 1954-07-30 | 1961-06-13 | Union Chimique Belge Sa | Piperazine derivatives |
GB949088A (en) | 1961-06-26 | 1964-02-12 | Lepetit Spa | Diazabicyclo-octane derivatives |
US3435002A (en) | 1967-05-15 | 1969-03-25 | Gen Electric | Polyamide acid resins and polyimides therefrom |
GB1575310A (en) | 1976-11-16 | 1980-09-17 | Anphar Sa | Piperidine derivatives |
FR2522325B1 (en) | 1982-02-26 | 1985-08-09 | Delalande Sa | NOVEL ARYLIC DERIVATIVES OF PIPERAZINE, HOMOPIPERAZINE AND N, N'-DIALKYL DIAMINO-1,2 ETHANE, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION |
DE3471486D1 (en) | 1983-08-15 | 1988-06-30 | Ciba Geigy Ag | PHOTOCURABLE COMPOSITIONS |
US5145885A (en) | 1983-08-15 | 1992-09-08 | Ciba-Geigy Corporation | Photopolymerizable compositions containing aminoaryl ketone photoinitiators |
GB8603120D0 (en) | 1986-02-07 | 1986-03-12 | Pfizer Ltd | Anti-dysrhythmia agents |
US5215989A (en) | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
FR2673182A1 (en) | 1991-02-22 | 1992-08-28 | Univ Caen | N,N'-Disubstituted piperazines, process for their preparation and their application in therapeutics |
DE69426157T2 (en) | 1993-07-28 | 2001-05-17 | Santen Pharmaceutical Co., Ltd | 1,4-DI (PHENYLALKYL) PIPERAZINE DERIVATIVES |
US5614526A (en) | 1995-06-09 | 1997-03-25 | Hoffmann-La Roche Inc. | Use of phenoxy-piperzine derivatives |
WO1997044329A1 (en) | 1996-05-20 | 1997-11-27 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
DE19637237A1 (en) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazine derivatives |
US6358956B1 (en) | 1999-03-03 | 2002-03-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
CN1172919C (en) | 2002-06-03 | 2004-10-27 | 上海医药工业研究院 | Alkyl alcohol piperazine derivative and its application in preparing medicine for treating depression |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
WO2004037817A1 (en) | 2002-10-25 | 2004-05-06 | Mitsubishi Pharma Corporation | N-oxide compounds |
AU2003284402A1 (en) | 2002-11-15 | 2004-06-15 | Yamanouchi Pharmaceutical Co., Ltd. | Antagonist to melanin-concentrating hormone receptor |
BRPI0408420A (en) | 2003-04-03 | 2006-03-21 | Merck Patent Gmbh | carbonyl compounds |
ATE337000T1 (en) | 2003-06-18 | 2006-09-15 | Merck Patent Gmbh | PYRROLIDINE-1,2-DICARBONONIC ACID-1-(4-ETHINYL-PHENYL)-AMIDO-2-(PHENYL)-AMIDO DERIVATIVES AS INHIBITORS OF THE COAGULATION FACTORS XA AND VIIA FOR THE TREATMENT OF THROMBOSIS |
AU2004266233A1 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
US7795267B2 (en) | 2003-08-29 | 2010-09-14 | Takeda Pharmaceutical Company Limited | Bicyclic piperazine compound having TGR23 antagonistic activity |
CN1897950A (en) | 2003-10-14 | 2007-01-17 | 惠氏公司 | Fused-aryl and heteroaryl derivatives and methods of their use |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
EP1683797A1 (en) | 2003-11-13 | 2006-07-26 | Ono Pharmaceutical Co., Ltd. | Heterocyclic spiro compound |
CA2575003C (en) | 2004-07-29 | 2010-02-16 | Merck & Co., Inc. | Potassium channel inhibitors |
CN101083992A (en) | 2004-09-20 | 2007-12-05 | 泽农医药公司 | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
DE102004045796A1 (en) | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Medicaments containing carbonyl compounds and their use |
DE102004047254A1 (en) | 2004-09-29 | 2006-04-13 | Merck Patent Gmbh | carbonyl |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
JP5114202B2 (en) | 2005-09-27 | 2013-01-09 | 塩野義製薬株式会社 | Sulfonamide derivatives having PGD2 receptor antagonist activity |
CA2634250A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
CN102112453A (en) | 2008-06-13 | 2011-06-29 | 生态有限公司 | Novel potassium channel blockers and uses thereof |
US8673920B2 (en) | 2009-05-06 | 2014-03-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US8742110B2 (en) | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
EP2632465B1 (en) | 2010-10-27 | 2015-12-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2632464B1 (en) | 2010-10-29 | 2015-04-29 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
BR112014003801A2 (en) | 2011-08-19 | 2017-03-07 | Merck Sharp & Dohme | compound, pharmaceutical composition, and methods for inhibiting romk, causing diuresis, natriuresis or both, and treating or prophylaxis of one or more disorders |
WO2013039802A1 (en) | 2011-09-16 | 2013-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013062900A1 (en) | 2011-10-25 | 2013-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2771005B1 (en) | 2011-10-25 | 2016-05-18 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013066718A2 (en) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013066714A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2790511B1 (en) | 2011-12-16 | 2016-09-14 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2014015495A1 (en) * | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9573961B2 (en) | 2012-12-19 | 2017-02-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2956142B1 (en) | 2013-02-18 | 2017-09-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2014150132A1 (en) * | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9751881B2 (en) | 2013-07-31 | 2017-09-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2015065866A1 (en) | 2013-10-31 | 2015-05-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2015096035A1 (en) | 2013-12-24 | 2015-07-02 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
WO2015103756A1 (en) | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
CA2950784A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016008064A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
WO2016060941A1 (en) | 2014-10-14 | 2016-04-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016065582A1 (en) | 2014-10-30 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016069428A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016065602A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
WO2016065603A1 (en) | 2014-10-31 | 2016-05-06 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016122994A1 (en) | 2015-01-29 | 2016-08-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
-
2015
- 2015-02-12 WO PCT/CN2015/072865 patent/WO2016127358A1/en active Application Filing
-
2016
- 2016-02-08 EP EP16749643.9A patent/EP3255993B1/en active Active
- 2016-02-08 US US15/545,891 patent/US10160751B2/en active Active
- 2016-02-08 WO PCT/US2016/016918 patent/WO2016130444A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013066717A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US20140031349A1 (en) * | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2014085210A1 (en) * | 2012-11-29 | 2014-06-05 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
Non-Patent Citations (1)
Title |
---|
DATABASE PubChem 3 March 2014 (2014-03-03), Database accession no. 72950246 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10208064B2 (en) | 2014-07-14 | 2019-02-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US10160751B2 (en) | 2015-02-12 | 2018-12-25 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2017184662A1 (en) | 2016-04-20 | 2017-10-26 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
WO2018222795A1 (en) | 2017-06-01 | 2018-12-06 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
EP3929194A1 (en) | 2017-06-01 | 2021-12-29 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
USRE49700E1 (en) | 2017-06-01 | 2023-10-17 | Bristol-Myers Squibb Company | Substituted nitrogen containing compounds |
Also Published As
Publication number | Publication date |
---|---|
EP3255993B1 (en) | 2021-01-27 |
WO2016127358A1 (en) | 2016-08-18 |
EP3255993A1 (en) | 2017-12-20 |
US20180016263A1 (en) | 2018-01-18 |
EP3255993A4 (en) | 2018-08-22 |
US10160751B2 (en) | 2018-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3027625B1 (en) | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure | |
EP2925322B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3087077B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP2968288B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212618B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3255993B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212619B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
KR20150036142A (en) | Spiro - fused piperidine derivatives for use as inhibitors of the renal outer medullary potassium channel | |
EP3250204B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3063142B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212616A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3169673B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
EP3212617A1 (en) | Inhibitors of the renal outer medullary potassium channel | |
WO2022197761A1 (en) | Plasma kallikrein inhibitors | |
WO2024173196A1 (en) | Plasma kallikrein inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16749643 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016749643 Country of ref document: EP |